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1
HeARt FAIluRe
Heart failure is described as the inability of the heart to pump sufficient oxygenated blood 
to meet the body’s needs. Heart failure is one of the most common, costly, disabling, 
and potential lethal pathologies worldwide.1, 2 Clinical manifestations of heart failure 
can be characterized by hemodynamic, autonomic, neurohumoral, and immunological 
abnormalities (Figure 1).3, 4 Not all of these mechanisms activated in heart failure are 
deleterious. Various beneficial counter-regulatory mechanisms are activated to oppose 
sodium- and water retention, like the natriuretic peptide system. However, when the 
syndrome of heart failure progresses, the potent negative effects of the renin-angiotensin-
aldosterone system and sympathetic nervous system outweigh these counter-regulatory 
mechanisms. As a result, patients experience symptoms of dyspnea – often orthopnea –, 
exercise intolerance with concomitant fatigue, and edema. 
Aging of the population and improved survival of patients with acute myocardial 
infarction has led to an increased incidence and prevalence of heart failure. Of note, there 
is concern heart failure will become an important burden on the health care system the 
next decades. The magnitude of the problem can not be assessed precisely since consistent 
population-based estimates of its epidemiology and prognosis are lacking.5, 6 According to 
data of the Dutch Heart Foundation, 180,000 patients out of a population of 16,5 million are 
diagnosed with heart failure with an incidence rate of 35,000 patients per year. 
Drug therapies can be regarded as the cornerstone of treatment in patients with heart 
failure. In some patients this can be combined with resynchronisation and/or implantable 
cardioverter defibrillator (ICD) therapy. However, this approach is eventually insufficient 
for many patients, resulting in an important need for alternatives. Nowadays the annual 
mortality rate for patients with heart failure is approximately 10%, depending on the stage 
of the disease.2 Due to the limited availability of donor organs, heart transplantation is an 
option for very few patients. Therefore, one of the aims of alternative surgical therapies is 
to improve the systolic pump function. Examples are: 1) revascularisation for the relief of 
objectively proven ischemia; 2) restrictive mitral valve annuloplasty for the treatment of 
functional mitral regurgitation; 3) surgical ventricular reconstruction after a large myocardial 
infarction; 4) external constraint devices for dilated cardiomyopathy; and 5) left ventricular 








































12  •  Chapter 1
Figure 1. overview of the pathophysiology of heart failure. 
The syndrome of heart failure is characterized by hemodynamic, autonomic, neurohumoral, and 
immunological abnormalities. 
Abbreviations: ACE, Angiotensin Converting Enzyme; AT I/II, Angiotensin I/II; CO, Cardiac Output; LV, 
Left Ventricular; LVEDP, Left Ventricular End-Diastolic Pressure; PCWP, Pulmonary Capillary Wedge 
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1
Although the benefits of several surgical interventions have been established for patients 
with heart failure7-9, perioperative morbidity and mortality remain significant and limit the 
widespread use of surgical interventions. Frequent observed complications in patients 
with heart failure undergoing cardiac surgery are ventilator-assisted pneumonias, kidney 
damage, therapy-resistant vasoplegia, stroke, bleeding, and infections. These complications 
in patients with preexisting heart failure seem to occur at a much higher frequency than 
after complex cardiac (valve) surgery in patients without heart failure. Furthermore, these 
complications appear to be largely independent from the high preoperative risk or the 
impaired cardiac function. Hence, these observations suggest that patients with preexisting 
heart failure have a different response to the surgical injury in general, and may reflect a 
different response of the failing heart to cardioplegic arrest and reperfusion. The purpose of 
this thesis was to study this response in more detail. 
ISCHeMIA/RePeRFuSIon InjuRy
Well-timed re-establishment of blood flow is essential to rescue ischemic tissues, preventing 
cell necrosis, and infarction.10-12 However, reperfusion of ischemic myocardium is inevitably 
associated with ischemia/reperfusion (I/R) injury. This is the paradoxical increase of tissue 
damage upon re-oxygenation of previously hypoxic tissue. I/R is considered the major cause 
of tissue damage encountered during a variety of standard medical and surgical procedures, 
like revascularization therapy, organ transplantation, and cardiac surgery with use of 
cardiopulmonary bypass. 
The pathophysiology of I/R injury is complex and not fully elucidated yet. Free radicals, 
thrombocytes, neutrophils, inflammatory mediators, complement components, and 
endothelial cell activation markers have frequently been suggested to play a role in the 
initiation of the complex cascade following I/R (Figure 2).10-12 I/R injury can lead in its 
severest form to multiorgan dysfunction or even death. However, understanding of the 
pathophysiological mechanisms is mainly based on experimentally derived concepts obtained 
from pre-clinical, mainly murine, I/R experiments (Figure 3). Clinical studies concerning 
these mechanisms are sparingly performed, and interventions aimed at attenuating human 
I/R-induced damage fail to show a substantial benefit yet. Identification of the underlying 
mechanisms is difficult as a result of the large variation between different organ systems in 
their sensitivity and response to clinical I/R. 
Myocardial I/R injury is an inevitable consequence of cardiac surgery with use of 
cardiopulmonary bypass. A period of ischemia (i.e. aortic cross-clamping with cardioplegic 
arrest) is followed by restoration of the blood flow during reperfusion (i.e. unclamping 








































14  •  Chapter 1
include myocyte death and necrosis, myocardial hibernation or stunning, endothelial- and 
microvascular dysfunction including the no-reflow phenomenon, reperfusion arrhythmias, 
low cardiac output state, breakdown of the gastrointestinal barrier, and impaired cerebral 
function.13, 14 
Figure 2. Hypothesis of the complex cascade following human myocardial ischemia and reperfusion. 
Free radicals, thrombocytes, neutrophils, inflammatory mediators, complement components, and 
endothelial cell activation have frequently been suggested to play a role in the initiation of the complex 
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1
Figure 3. Sequence of biochemical and metabolic events upon myocardial reperfusion.
Abbreviations: ATP, adenosine triphosphate; DNA, deoxyribonucleic acid; GSH, Glutathione; mPTP, 
mitochondrial Permeability Transition Pore; NADPH, Nicotinamide Adenine Dinucleotide Phosphate; 
Pcr, Phosphocreatine; RONS, Reactive Oxygen and Nitrogen Species.
EffEcts of I/R InjuRy on REmotE, non-IschEmIc oRGans
Taken together, the consequences of I/R injury may thus extend beyond the local effects. 
Reperfusion of ischemic tissue can lead to both a local and a systemic response that may 
be followed by a widespread altered tissue barrier function. Ultimately, it may even result 
in a systemic inflammatory response syndrome (SIRS) and a multiple organ dysfunction 
syndrome (MODS).10, 15 These two systemic remote effects of reperfusion can be devastating 
and fatal. 
SIRS is a generalized, nonspecific inflammatory response to injury in the absence of 
infection.16 Two or more of the following conditions must be present to diagnose SIRS: a 
temperature > 38°C, a heart rate > 90 beats per minute, a respiratory rate > 20 breaths per 
minute or a carbon dioxide tension < 32 mmHg, and a white blood cell count > 12.000/mm3 








































16  •  Chapter 1
with the use of cardiopulmonary bypass already induce these hemodynamic, respiratory, 
and hematologic changes necessary for inclusion in the SIRS definition. Therefore, the 
definition of SIRS is complex in relation to cardiac surgery. The severity of this syndrome 
is variable in patients with heart failure undergoing cardiac surgery. It does manifest with 
severe hemodynamic disturbance in only a minority of the patients. Moreover, SIRS is not 
necessarily deleterious, it can be a controlled self-limiting inflammatory response. The 
postulated beneficial effects of SIRS are immune system priming, prevention of infection, 
and improved wound healing.16
MODS is a frequent complication of SIRS and is characterized by the development of 
progressive and potentially reversible physiologic dysfunction in two or more organs or 
organ systems.17 Acute respiratory distress syndrome (ARDS), due to increased permeability 
in the lung vasculature, is often the first clinical sign of MODS.10, 18 The start of this 
respiratory dysfunction is frequently characterized by an abnormal gas exchange, increased 
pulmonary vascular resistance, and increased alveolar-arterial oxygen pressure gradient.19 
This dysfunction, often called acute lung injury, commonly occurs within 24-72 hours after 
the initiating ischemic event.10, 15 In daily clinical practice, this dysfunction leads to increased 
oxygen demands, greater dependence on artificial ventilation and prolonged stay in the 
intensive care unit. Pulmonary infiltrates are often seen at the chest X-ray with a delay of 
24 hours. 
In addition, MODS after myocardial I/R can involve hepatic, renal, gastrointestinal, and 
central nervous system dysfunction.10 The mortality is directly correlated with the number of 
failed organ systems: 30-40% if one organ system fails, 50-60% if two organ systems fail and 
80-100% when three or more organ systems fail.13 Respiratory insufficiency and renal failure 
are the most common complications after cardiac surgery. The underlying mechanism is 
damage to vascular beds, causing fluid extravasation and tissue edema. Moreover, MODS is 
also characterized by dysfunction of the immune and coagulation systems.10 
Neutrophils, complement components, adhesion molecules, reactive oxygen species, and 
cytokines have been implicated as key mediators of remote organ damage.10, 18, 20 In specific, 
elevated levels of inflammatory markers, like tumor necrosis factor (TNF)-alfa, interleukin 
(IL)-1 beta, IL-6, and IL-8, are associated with increased mortality and increased risk for SIRS 
and MODS.21, 22 Given the local and systemic effects of clinical I/R injury, understanding of 









































General Introduction  •  17
1
PAtHoPHySIology oF MyoCARDIAl I/R InjuRy
Reactive oxygen and nitrogen species
Reactive oxygen and nitrogen species (RONS) are considered key initiators of I/R injury. 
Previous studies have shown that the substrates of xanthine oxidase, xanthine and 
hypoxanthine, accumulate during ischemia and are responsible for the formation of 
free radicals in reperfused isolated rat hearts within minutes after reperfusion.23, 24 In 
other words, ischemia-related metabolic adaptations and dysregulated mitochondrial 
homeostasis are thought to result in release of RONS upon reintroduction of oxygen. 
Zorov et al. showed that RONS can activate the opening of the mitochondrial permeability 
transition pore, resulting in a vicious circle of additional free radical release from the 
mitochondria of cardiac myocytes.25 This RONS overload can overwhelm the endogenous 
antioxidant system, resulting in oxidative damage. This may trigger processes such as 
inflammatory responses.26-29 As a result, it was hypothesized that antioxidant therapy 
attenuates reperfusion injury. The validity of this concept has been proven in various pre-
clinical studies, which all demonstrate that antioxidant therapy ameliorates I/R injury.12, 30, 
31 Despite these findings, studies in humans consistently fail to show any clinical relevant 
effect.12, 32-35 The basis for this discrepancy between human and animal studies is still unclear. 
An explanation could be that the contribution of RONS to I/R injury in humans is less than 
commonly thought.
Complement components
Complement activation is considered one of the key mediators of myocardial I/R induced 
tissue damage.36-39 During cardiac surgery, the complement cascade is activated as a result 
of the surgical trauma, use of cardiopulmonary bypass, and I/R injury. There are three 
pathways of activation of the complement system (classical, alternative, and mannose 
binding lectin), whereby C5a and C5b-9 are believed to be primarily responsible for I/R 
injury.40 C5a can induce chemotaxis of leukocytes and the amplification of the inflammatory 
response by initiating the production of TNF-α, IL-1, IL-6, and monocyte chemoattractant 
protein-1 (MCP-1).13, 41 C5b-9 can activate endothelial nuclear factor-kappa B to increase 
leukocyte adhesion molecule transcription and expression, and can induce chemotactic 
mediators like IL-8 and MCP-1.13, 41 In addition, complement components can induce cell 
injury by increasing the permeability of the cell. Moreover, complement components 
can release histamine and platelet activating factor, and can also stimulate neutrophil 
adherence, and superoxide production. Complement inhibitors are highly effective in 








































18  •  Chapter 1
complement therapy in human myocardial I/R injury has led to differential results without 
clinical relevant benefits so far.44-46 Whether the pathophysiology of human myocardial I/R 
injury is mainly based on complement activation can therefore be questioned. The limited 
human studies concerning complement activation in myocardial I/R injury have shown that 
there is an increased systemic activation of complement components the first hours after 
reperfusion.38, 47 Those systemic levels show a biphasic pattern with inhibitory mechanisms 
from eight hours postoperatively onwards.39 If the complement activation after cardiac 
surgery is well balanced and controlled, it contributes to defense against infection and 
wound healing. Nevertheless, extreme activation of the complement system can contribute 
to organ dysfunction resulting in increased morbidity and mortality postoperatively.48 
Thrombocyte activation 
Pre-clinical evidence points towards the possibility that platelets are involved in the 
pathogenesis of I/R injury.49-52 Platelets are specialized cells of the innate immune system 
and modulators of the inflammatory response in addition to their evident role in hemostasis. 
Upon their activation, platelets secrete various mediators into the circulation by exocytosis, 
like leukotrienes, P-selectin, beta-thromboglobulin, platelet-derived growth factor, and 
Regulated upon Activation, Normal T-cell Expressed and Secreted (RANTES), thereby 
increasing inflammation and damage to cardiac myocytes.53, 54 In addition, thromboxane 
A2 and serotonine55, released by activated thrombocytes, may exacerbate microcirculatory 
spasms, leading to a decreased coronary flow. Moreover, the externalization of P-selectin 
mediates adhesion of neutrophils, which release free radicals and proteins that also injure 
the cardiac myocytes. In contrast to existing pre-clinical data, the involvement of platelets 
as key regulators of clinical I/R in general, and more specifically in myocardial I/R injury, is 
unclear.56, 57
Endothelial cell activation 
Endothelial cells are activated during exposure to hypoxia and inflammatory mediators, 
leading to the release of vasoactive substances upon I/R, like endothelin and nitric 
oxide.58 This causes either vasodilatation or vasoconstriction of underlying smooth muscle 
cells.59 In high concentrations, nitric oxide promotes the formation of RONS. However, 
endothelial cells are not only a source of reactive species, but also a target for reactive 
species as shown by Arroyo et al. with spin trapping methods.60 Experimental data show that 
increased permeability of the endothelium occurs due to reoxygenation upon reperfusion.61 
Endothelial cell activation and injury increase vascular permeability and activate the 
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adhesion molecules. Those adhesion molecules promote tissue invasion by inflammatory 
cells, mainly neutrophils, T-lymphocytes, and macrophages. Carden et al. and Panes et al. 
have shown that those inflammatory cells are harmful to the myocardium because they 
generate RONS, secrete proteases, and occlude the microvasculature.10, 62 Yet, the role of 
the various endothelial cell activation markers and adhesion molecules in the clinical setting 
of I/R injury is unknown. An increased understanding of this role may allow therapies to be 
designed to further attenuate the post-reperfusion response. 
Chemokines and cytokines
In response to tissue injury, an immune response is initiated that arranges homeostatic 
responses and is a prerequisite for subsequent healing of the lesion. However, an 
exaggerated inflammatory response contributes to maladaptive tissue damage. For 
myocardial I/R in specific, animal studies have shown that a complex cascade of events 
ultimately results in a myocardial inflammatory response upon reperfusion.63-65 Whether this 
can be extrapolated to the more complex situation in humans remains in question. Overall, 
there is a correlation between elevated levels of pro-inflammatory cytokines and adverse 
events after cardiac surgery as outlined below.66 The pro-inflammatory mediators TNF-α 
and IL-1β are elevated early after cardiac surgery, with IL-6 and IL-8 peaking thereafter.66, 67 
TNF-α is produced mainly by activated monocytes and plays a very important, and initiating 
role in inflammation. TNF-α can cause hypotension, coagulopathy, and renal dysfunction. 
Moreover, it plays a major role in increased microvascular permeability. Elevated levels of 
TNF-α are also associated with SIRS and MODS.68 IL-1β is mainly produced by macrophages 
and monocytes, and is primarily responsible for the release of pro-inflammatory cytokines 
and the synthesis of endothelial adhesion molecules. The most significant effects of IL-6, 
produced by macrophages, are the coordination of the acute phase response and activation 
of lymphocytes. High IL-6 levels after elective cardiac surgery correlate with hepatic and 
renal dysfunction.69 IL-8 is mainly produced by macrophages and plays a major role in 
polymorphonuclear trafficking (chemotaxis). High IL-8 levels after elective cardiac surgery 
correlate with respiratory dysfunction and duration of inotropic support.69 IL-10, one of the 
anti-inflammatory cytokines, is produced mainly by macrophages and is a strong inhibitor of 
TNF-α, IL-1β, IL-6, and IL-8. IL-1 receptor antagonist is a specific antagonist of IL-1β, thereby 
limiting the inflammatory response. Overall, the clinical prognosis after cardiac surgery is 
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Inflammatory cells
Zuidema et al. and Linfert et al. outline in their reviews that inflammatory cells are involved 
in I/R injury.71, 72 Upon tissue damage, the activation and recruitment of neutrophils are 
promoted by several cytokines, like IL-1, IL-6, IL-8, and TNF-α. In animals, accumulation and 
activation of neutrophils in the post-ischemic area occurred within the first hours after the 
initiation of myocardial reperfusion.73, 74 Neutrophils can release free radicals, proteases, 
and pro-inflammatory markers. This directly amplifies the influx of other neutrophils in 
myocardial tissue, thereby contributing to damage.73, 75 However, it is uncertain whether 
neutrophil accumulation is a cause or a consequence of I/R injury.76, 77 Secondly, monocytes 
migrate from the circulation into tissue where they mature to macrophages and take up 
residence. Macrophages secrete a variety of pro-inflammatory cytokines, such as IL-1β, 
TNF-α, IL-6, IL-8, and IL-12. These inflammatory mediators also recruit neutrophils and other 
leukocytes, amplifying the inflammatory response. Moreover, recent data suggest that 
lymphocytes have a significant role in the response to I/R injury.72 Animal models showed 
that T-lymphocytes are harmful during myocardial I/R injury.78, 79 In general, the role of the 
various inflammatory mediators in clinical I/R injury is complex and not fully unraveled yet. 
They frequently play a detrimental role in I/R injury, although some also appear to have 
cardioprotective effects. 
tReAtMent StRAtegIeS FoR I/R InjuRy
Although the precise mechanisms of I/R injury are still incompletely understood, numerous 
treatment strategies have been investigated targeting some of the postulated mechanisms 
of I/R injury. Most of them were promising in animal trials, but did not show a substantial 
clinical benefit in humans or still have to reach human clinical trials as outlined in Table 1.12, 
14, 80 Potential mechanisms contributing to the discrepancy between promising data of pre-
clinical studies and disappointing results in clinical trials are outlined in Table 2.12, 81, 82 Three 
often mentioned treatment options for human myocardial I/R injury will be outlined briefly: 
antioxidant therapy, anti-complement therapy, and preconditioning. 
Experimental data clearly showed that antioxidant therapy effectively ameliorates I/R 
injury.31, 83 Clinical trials on the other hand did not show any substantial, clinically relevant 
effect of antioxidant administration.12, 33, 34, 83-85 At present, there is no clinical indication 
established recommending the routine use of antioxidants in I/R.86 However, a large amount 
of data support the role of oxidative stress in myocardial I/R injury and stress the value of 
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table 1. treatment strategies for human myocardial I/R injury.
treatment Positive clinical trials
Ischemic preconditioning97-100 Yes / No: reduced myocardial injury; beneficial 
effects on mortality await larger trials
aprotinin101-103 Yes / No: modest reduction in risk of massive 
bleeding; higher mortality and adverse events like 
renal impairment, myocardial infarction, stroke and 
anaphylactic reactions104, 105 
mPtP inhibitors (e.g. Cyclosporine)106 Yes / No: smaller infarct size after acute myocardial 
infarction; larger trials necessary and more specific 
inhibitors need to be developed
activation of protein kinase c (e.g. KaI-9803)107 Yes / No: trends for smaller infarct size after acute 
myocardial infarction; larger trials necessary
activation of the RIsK pathway 
	 Erythropoetin108-110 
	 statins111, 112 
Yes / No: Improved myocardial function and reduced 
infarct size versus no reduced myocardial injury; 
larger trials necessary
Volatile anesthetics113-116 Yes / No: contradictory results concerning 
biochemical markers for myocardial dysfunction; 
larger trials necessary
na-h-exchange-inhibition (e.g. cariporide)12, 117-120 Yes / No: contradictory results concerning mortality 
and no beneficial effects concerning myocardial 
infarction in patients with unstable angina; increase 
in cerebrovascular events, only beneficial if 
administrated prior to the onset of ischemia
Adenosine (e.g. Acadesine)121-128 Yes / No: no difference in death or occurrence of 
congestive heart failure with anterior myocardial 
infarction; smaller infarct size; 
beneficial effects seen if administrated prior to the 
onset of ischemia
anti-complement (e.g. soluble complement 
receptor type 1/C1-inhibitors)12, 44-46, 89, 129, 130 
Yes / No: contradictory results concerning reduced 
myocardial I/R injury and improved cardiac function
antioxidants (e.g. super oxide dismutase, 
vitamin e)12, 83, 86
No
anti-apoptosis131 No
neutrophil depletion77, 132 No
Poly aDP-ribose polymerase (PaRP)-inhibition133 No
metabolic additives in cardioplegia solution 




Calcium channel blockers (e.g. Verapamil)140-143 No








































22  •  Chapter 1
table 2. major differences between animal models and clinical studies of myocardial ischemia/ 
reperfusion injury.
type Animal models Clinical studies
Subjects Homogenous, healthy, young, 
small animals, often males, no 
coexisting diseases
Heterogeneous, middle-aged 
and elderly, often collaterals 
formed, coexisting diseases like 
diabetes mellitus 
concomitant medication No Often multiple drugs
Period of ischemia Same brief duration (30-60 
minutes) and same severity 
Variable longer duration (3-12 
hours) and variable severity 
Reperfusion time Short (2 hours – 3 days) Longer: infarct healing and left 
ventricular remodeling
Preconditioning Heart not exposed to ischemia 
prior to cardiac surgery
Often repeated ischemic insults 
(angina, infarction) prior to 
cardiac surgery
nutritional state Non-fasting Fasting
timing of intervention Similar in all animals Variable between patients
therapeutics Low dose High dose, timing essential
expression of size of myocardial 
damage
Large volume of whole 
myocardium at risk
Small volume of left ventricular 
volume
Endpoints for cardioprotection Often left ventricular function or 
infarct size
Short- and long-term effects on 
morbidity and mortality
Furthermore, anti-complement therapy showed inconsistent results in human trials. 
Although the recombinant soluble form of complement receptor 1 showed reduced local and 
remote organ injury in animals after I/R, clinical data were disappointing.87, 88 Administration 
of pexelizumab, an anti-C5 complement antibody, fails to inhibit the assembly of C5b-9 in 
patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary 
intervention.89 In contrast, the same antibody showed to attenuate the activation of the 
complement system, activation of leukocytes, myocardial injury, and early postoperative 
mortality in humans undergoing coronary artery bypass grafting.90, 91 Moreover, the 
administration of a C1-esterase inhibitor in patients undergoing coronary bypass surgery 
showed reduced myocardial I/R injury and improved cardiac function.44, 45 
The most widely studied form of possible protection against I/R-induced myocardial 
injury is preconditioning. A special form of this preconditioning is ischemic preconditioning. 
Brief periods of ischemia followed by reperfusion induce cardioprotection, although the 
precise mechanisms remain elusive.92 Ischemic preconditioned tissues have reduced 
energy requirements, altered energy metabolism, decreased intracellular calcium overload, 
improved endothelial function, better electrolyte homeostasis, less RONS and neutrophils, 
less apoptotic cardiomyocyte death, and diminished systemic dysfunction.93 In addition, 
this form of preconditioning also protects against lethal reperfusion injury by activating the 








































General Introduction  •  23
1
permeability transition pore.94, 95 Therefore, ischemic preconditioned tissue is better able to 
tolerate I/R. Nonetheless, clinical data about ischemic preconditioning are limited. Whether 
preconditioning has beneficial or harmful clinical effects still has to be elucidated.96 Other 
studied forms of ‘conditioning’ are therapeutic pre- and postconditioning. Several targets 
have been postulated for these kinds of conditioning. Of these targets, non have made it 
from the laboratory to routine use in daily clinical practice. 
In conclusion, no established targeted therapy is currently available to safely and 
significantly reduce the effects of clinical I/R injury despite amelioration of I/R injury in 
various pre-clinical studies. Timely reperfusion of ischemic tissue remains the cornerstone 
in daily clinical practice. The basis for the discrepancy between human and animal studies 
is still unclear, yet it may suggest that pathophysiological mechanisms are different or 
more complex in humans. Therefore, a clinical model of planned myocardial I/R injury in 
the setting of cardiac surgery was used in this thesis to study the pathophysiology in more 
detail. Myocardial release of various mediators associated with I/R injury were assessed 
during planned I/R by cannulation of the efferent vein, i.e. the coronary sinus. With this 
approach, sensitive and organ specific measurements of net changes in various mediators 
over the reperfused heart were conducted. 
outlIne oF tHIS tHeSIS
Chapter 2 of this thesis provides background information regarding systemic complications 
after cardiac surgery, such as vasoplegia, sepsis, prolonged ventilation, and organ 
dysfunction. The impact of preexisting heart failure on complications after correction for 
pump failure was evaluated by differentiating between complications categorized as not, 
possibly or definitely related to pump failure. 
In Part I six studies are described reflecting the pathophysiology of I/R injury. Chapter 3 
challenges the prevailing paradigm on RONS-mediated I/R injury in both patients undergoing 
kidney transplantation and heart valve surgery. In Chapter 4 the role of complement 
activation in the early myocardial reperfusion phase following cardiac surgery was evaluated. 
C5b-9 and C5a were assessed in patients with non-ischemic and ischemic heart failure, and 
patients without heart failure. Myocardial and endomyocardial depositions of C3d and C5b-9 
were also studied and compared with pre-transplantation tissue from myocardial allografts. 
The role of platelet activation (Chapter 5) and endothelial cell activation (Chapter 6) upon 
myocardial reperfusion are described in two observational studies. Chapter 7 reports about 
the myocardial inflammatory response after cardiac surgery in patients with non-ischemic 
and ischemic heart failure, compared with patients without heart failure. Specific attention is 
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Chapter 8 the role of galectin-3 is described in relation to left ventricular reverse remodeling 
after mitral valve repair in patients with non-ischemic and ischemic heart failure. 
To investigate the translation of pathophysiological mechanisms from bench to bedside, 
two studies were performed in the second part of this thesis (Part II). Effects of influencing 
the response to I/R injury were analyzed in more detail. Chapter 9 describes the effects of 
intramyocardial delivery of sevoflurane on myocardial damage and inflammatory responses. 
In Chapter 10 inhibition of interleukin-9 in a murine renal I/R injury model is reported. 
Finally, the main findings of the different studies presented in this thesis are discussed 
in a general discussion section, including aspects for future studies towards unraveling the 
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AbStRACt 
background: Heart failure is characterized as a strong risk factor for systemic failure after 
cardiac surgery. However, the impact has never been substantiated. 
Methods: Patients with heart failure (n = 48) – scheduled for elective ventricular 
reconstruction or external constraint device – were compared with a one-to-one matched 
control group of patients without heart failure undergoing cardiac surgery between 2006 
and 2009. 
Results: As expected, patients with heart failure more frequently experienced complications 
definitely related to pump failure (P = 0.01). However, complications not related to their pump 
failure were also more often observed, such as prolonged mechanical ventilation, sepsis 
and vasoplegia (P = 0.01). Overall, organ dysfunction – circulatory, renal, and pulmonary 
failure – was often observed in heart failure patients, contributing to a prolonged stay in the 
intensive care unit (P < 0.001) as well as in hospital (P = 0.01).
Conclusions: The adverse postoperative course in patients with heart failure is not only 
directly related to circulatory failure, but merely reflects a systemic dysregulation. Our 
findings suggest that heart failure impacts outcome and should therefore be included in 
prevailing risk classification systems. Offensive perioperative treatment strategies, focused 
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IntRoDuCtIon
Heart failure is one of the most common, costly, disabling, and potentially deadly pathologies 
worldwide.1, 2 Aging of the population and improved treatments of the causes of heart 
failure will lead to an increased incidence and prevalence of heart failure. Due to the limited 
availability of donor organs, heart transplantation is only an option for very few patients. 
Alternative surgical therapies are important and aimed at improving the myocardial function. 
Although the efficacy of several surgical interventions has been established for patients 
with heart failure3-5, perioperative morbidity and mortality remain significant and hamper 
widespread use. The observed complications can not only be explained by the preoperative 
high risk state of the patient or the low cardiac output state alone. They are rather explained 
by systemic responses such as vasoplegia and a systemic inflammatory response syndrome. 
Our hypothesis is that postoperative complications in patients with preexisting heart 
failure are often not related to pump failure. In other words, the preoperative risk stratification, 
which only includes ejection fraction as a measure of pump failure, is inadequate to predict 
an adverse postoperative course. To test this hypothesis, we compared patients with and 
without heart failure undergoing cardiac surgery in order to have comparable surgical 
injury. Our aim was to systematically examine the impact of preexisting heart failure on 
complications after correction for pump failure by differentiating between complications 
not, possibly or definitely related to pump failure. 
MetHoDS
Patient characteristics
Between January 2006 and December 2009, all patients with preexisting heart failure 
scheduled for an elective external cardiac support device or ventricular reconstruction were 
included in this retrospective study (n = 48). Heart failure was defined as an inadequate 
pump function of the heart with an echocardiographically estimated ejection fraction 
biplane <30% and New York Heart Association (NYHA) class III or IV. Exclusion criteria were 
minimal access procedures, previous sternotomy, emergency procedures or heart failure 
hospitalization prior to admission to our department. Hospitalization is often an indication 
for an aggravated acute state of heart failure, affecting outcomes. All patients were 
scheduled for a restrictive mitral annuloplasty in addition to their external constraint device 
or ventricular reconstruction. To examine the impact of heart failure on adverse outcomes, 
all 48 heart failure patients were matched on a one-to-one basis with patients without heart 
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(ejection fraction biplane ≥ 50%) and presented in NYHA class I or II. Each patient with heart 
failure was first matched for gender and year of surgery, and then for the most closely 
resembling age. Controls were scheduled for at least reconstructive mitral valve surgery 
to limit heterogeneity and to have a comparable duration of surgery between the groups. 
Moreover, mitral valve surgery is a common procedure in both patients with and without 
heart failure.6-8 Our study protocol was approved by the local ethics committee, who waived 
the need for individual informed consent due to the retrospective and anonymous nature 
of the study. 
Performed surgical procedures
Surgical procedures were performed according to the local standard. An external cardiac 
support device (CorCap cardiac support device, Acorn Cardiovascular, St. Paul, MN, USA) 
was placed if a left ventricular end-diastolic diameter above 65 mm was measured on 
the preoperative echocardiographic examination. Patients were considered eligible for 
ventricular reconstruction as described by Dor et al.9 if they had a large area of anterior 
akinesia or dyskinesia.10 Tricuspid valve annuloplasty, coronary artery bypass grafting and 
ablation procedures were performed if indicated. 
Endpoints and data collection
The complicated course of patients with heart failure is of high interest in current 
pathophysiological investigations. Complications, with often unravelled etiology, were 
categorized prior to the start of our study and were based on the opinion of experts in the 
field of heart failure surgery, i.e. cardiac surgeons and intensivists. Primary endpoints were a 
composite of complications not, possibly and definitely related to pump failure in an attempt 
to differentiate between pump failure and systemic failure. Secondary endpoints included 
the individual components of these primary endpoints in addition to other complications 
(Table 1). Patients were followed until discharge from hospital or death. Mortality was 
compared with a preoperative risk-adjusted model (logistic EuroSCORE).11-13 Data collection 
was performed by examination of the patients’ electronic or hard copy medical records 
of standard postoperative procedures, or by interviewing their general practitioner by 
telephone. Serum creatinine levels (Roche Diagnostics, Mannheim, Germany) were 
assessed within three months prior to surgery and blood pressure was measured the day 
before surgery. Excessive bleeding was defined as blood loss of more than two liters within 
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table 1. Definitions of the primary and secondary endpoints.
Composite endpoints
not related to pump failure
Possibly related to pump failure
Definitely related to pump 
failure
Mechanical ventilation ≥ 48 hours, sepsis and vasoplegia 
(norepinephrine ≥ 0.2 μg/kg/min, 12-24 hours in the ICU); 2 or 3 
present
Early mortality and acute kidney injury; both present
Inotropic support (dobutamine ≥ 5 μg/kg/min, 12-24 hours in the 
ICU) and use of mechanical assist devices (intra-aortic balloon pump 




All-cause mortality occurring within 30 days or in hospital12






Use of an intra-aortic balloon pump or use of a ventricular assist 
device 
Transient ischemic attack (fully reversible symptoms of short 
duration), stroke (neurological deficit persisting ≥ 72 hours) confirmed 
by clinical findings and computed tomography scan, and documented 
critical illness neuropathy
Acute kidney injury (50% increase in creatinine values ≤ 48 hours 
postoperatively17 and/or a postoperative creatinine value ≥ 200 
μmol/L) and use of continuous venovenous hemofiltration 
Mechanical ventilation ≥ 48 hours, re-intubation, tracheostoma, 
ventilator-associated pneumonia or pneumothorax
Sepsis Clinical suspicion confirmed by a positive blood culture (gold 
standard)
Abbreviation: ICU, Intensive Care Unit.
Statistical analysis
The occurrences of the primary and secondary endpoints were compared between the two 
patient groups. All statistical analyses were performed with the Statistical Package for the 
Social Sciences 17.0 (SPSS Inc., Chicago, IL, US). Continuous variables were expressed as 
mean ± standard deviation (SD) and categorical data as number of patients. Continuous 
variables were analyzed with the unpaired t-test or the Mann-Whitney U-test where 
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ReSultS
Patient characteristics
Baseline patient variables and an overview of surgical procedures are shown in Table 2 and 
the Supplementary data, Table 1, respectively. Equal age and gender distribution reflect the 
matching process. As expected, patients with heart failure had a higher logistic EuroSCORE 
and NYHA functional class. Heart failure patients had lower blood pressure values and 
higher creatinine values at baseline. 
table 2. Baseline variables of patients with heart failure and controls.
HF (n = 48) Controls (n = 48) P value
clinical characteristics
Age (years)
gender (male / female)




mI < 3 months prior to surgery (no. of patients)
significant caD (no. of patients)
Logistic EuroscoRE (%)

































Duration of surgery (min.)
cardiopulmonary bypass time (min.)










Details noted as mean ± standard deviation (SD). 
Abbreviations: CAD, Coronary Artery Disease; HF, Heart Failure; MI, Myocardial Infarction. 
Primary endpoints
The three primary endpoints are listed in Table 3. The composite endpoint of complications 
not related to pump failure was observed more frequently in patients with heart failure (P = 
0.01). In detail, this first endpoint was observed in 10/48 heart failure patients (20.8%) and 
0/48 controls (0.0%). Secondly, the composite endpoint of complications possibly related 
to pump failure was observed in 6 of the 48 patients with heart failure (12.5%) and in 1 
of the 48 controls (2.1%). This second endpoint was, although six times more often, not 
significantly different between the groups (P = 0.12). This result indicates that early mortality 
and acute kidney injury may be related to pump failure but may also be related to other 
factors influencing these outcomes. For example, acute kidney injury may also be drug-
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definitely related to pump failure was, as expected, significantly different between the 
groups (P = 0.01). This last endpoint occurred in 8/48 heart failure patients (16.7%) and in 
0/48 controls (0%). 
Secondary endpoints
Secondary endpoints are shown in Table 3. Early mortality was more common in heart failure 
patients as compared with controls (8/48 patients (16.7%) versus 1/48 patients (2.1%), 
respectively). One heart failure patient died in the operating room due to circulatory failure 
after ventricular reconstruction. In both groups the primary causes of early mortality were 
septic and cardiogenic shock. Surprisingly, the early mortality in patients with heart failure 
exceeded the predicted mortality based on the logistic EuroSCORE (10.4%), while in the 
controls the early mortality was lower than the predicted mortality (3.3%). Late mortality 
was similar between the groups: 3/48 patients with heart failure (6.3%) and 1/48 controls 
(2.1%). Those three heart failure patients died as a result of terminal or acute heart failure. 
The cause of late mortality of the control patient is unknown. 
Organ dysfunction was divided into circulatory failure, neurological events, renal failure 
and pulmonary complications. Circulatory failure was more often observed in patients with 
heart failure, as expected due to their pump failure. These patients more often needed 
an intra-aortic balloon pump as a temporary cardiac assist device. The occurrence of 
neurological events was similar between the groups. The incidence of acute kidney injury 
was higher, although not significant, in patients with heart failure as compared with 
controls. Use of renal replacement therapy was strongly associated with mortality: 5/8 
heart failure patients who needed continuous venovenous hemofiltration died in hospital. 
Also the control patient who died early needed dialysis. Prolonged ventilatory support (≥ 48 
hours) and ventilator-associated pneumonias were more often observed in patients with 
heart failure. The more complex postoperative course for patients with heart failure was 
also reflected by the use of high concentrations of norepinephrine to treat vasoplegia and 
dobutamine as inotropic support. Overall, organ dysfunction was frequently observed in 
heart failure patients, contributing to a prolonged stay in the intensive care unit (P < 0.001) 
as well as a longer total stay in hospital (P = 0.01; Figure 1).
The number of patients with excessive bleeding postoperatively was similar between 
the groups (P = 0.98); three heart failure patients versus two controls. Early and late re-
explorations for excessive bleeding or tamponade were similar in both groups (one early 
and one late re-exploration in patients with heart failure versus two early and two late re-
explorations in the controls, both P = 1.00). All patients with a late pericardial tamponade 
could be treated by pericardial puncture. Patients with heart failure underwent a reoperation 
five times more often, although this was not significant (n = 5 versus n = 0, respectively, 
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table 3. Postoperative outcomes of patients with heart failure and controls.
Postoperative outcomes (no. of patients) HF (n = 48) Controls (n = 48) P value
Composite endpoints
not related to pump failure 
Possibly related to pump failure 
























Documented critical illness neuropathy
Renal failure
Acute kidney injury
continuous venovenous hemofiltration 
Pulmonary complications






































Sepsis 7 1 0.06
Pharmacological support 12-24 hours in the ICu
norepinephrine ≥ 0.2 μg/kg/min 







Abbreviations: HF, Heart Failure; ICU, Intensive Care Unit.
figure 1. Intensive care unit stay and total stay in hospital of patients with heart failure and controls. 
Patients with preexisting heart failure experienced a longer stay in the intensive care unit (P < 0.001) 
than controls (median ± interquartile range of 3.2 (1.9-11.0) versus 1.0 (0.9-1.8) days). In addition, 
they experienced a longer total stay in hospital (P = 0.01) than controls (median ± interquartile range 
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DISCuSSIon
This study confirms the clinical observation that preexisting heart failure is a risk factor for 
systemic dysregulation after cardiac surgery. Not all adverse outcomes were related to the 
insufficient pumping capacity of the heart itself but merely to a cluster of organ dysfunction, 
suggesting systemic dysregulation. In an attempt to differentiate between pump failure and 
systemic failure, three composite endpoints were determined. As expected, the composite 
endpoint of complications definitely related to pump failure was significantly different 
between the groups. The composite endpoint of complications possibly related to pump 
failure – containing early mortality and acute kidney injury – was, however, not significantly 
different. This could first of all be the result of the relatively small patient numbers in this 
study, because this endpoint was observed six times more often in patients with heart failure. 
Moreover, during the postoperative period the serum creatinine values to assess acute 
kidney injury may not be accurate because of imbalances between creatinine production 
and elimination. Most interestingly to support our hypothesis was the composite endpoint 
of complications not related to pump failure. This endpoint was observed ten times more 
often in patients with heart failure, indicating systemic dysregulation. 
The early mortality in patients with heart failure was higher than the preoperative 
expected mortality, based on the logistic EuroSCORE; while in the controls the early mortality 
was lower than the predicted mortality. In our opinion, the syndrome of heart failure is 
underestimated when using the logistic EuroSCORE to predict the mortality of patients with 
heart failure. This can be explained by the way the EuroSCORE was established.11 There 
is an additive effect of heart failure on mortality, which is not well represented by only 
the ejection fraction in this scoring system. This suggests that heart failure surgery needs a 
modified risk stratification system. It is also the question if there were enough patients with 
heart failure included in the data collection for the development of the new version of the 
EuroSCORE system. 
In this study it became clear that heart failure patients more often experience a systemic 
dysregulation postoperatively. The prolonged intensive care unit stay and total stay in 
hospital are mainly caused by sepsis, vasoplegia, prolonged mechanical ventilation with 
ventilator-associated pneumonias as a result, and organ dysfunction in general. The exact 
mechanisms of these outcomes are not yet unravelled, but were not directly related to 
the insufficient pumping capacity of the heart. Systemic disturbances are recognized to 
contribute to patient morbidity and mortality after cardiac surgery.15 Those disturbances 
may comprise complement activation, immune cell activation, oxidative stress and others 
in addition to inflammation. One of the underlying mechanisms might be the different 
response to ischemia/reperfusion injury. In our opinion, this nearly inevitable phenomenon 
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be the cause of the observed systemic dysregulation. However, further research is needed 
to assess the individual contribution of those underlying pathophysiological mechanisms to 
the observed systemic dysregulation. 
Some issues merit mention. Patients with preexisting heart failure were frequently 
hospitalized prior to admission to our department. Although they are usually hospitalized 
at least once for adaptation of the treatment before they are considered for surgery, 
hospitalization in the days prior to surgery is often seen in patients with acute heart failure. 
In our opinion, including these patients would give an overestimation of the primary and 
secondary endpoints. However, excluding these hospitalized patients contributed to the 
relatively small patient numbers. Baseline differences for systolic blood pressures between 
the groups may reflect pharmacological treatment, because the therapy for heart failure is 
aimed at lowering the blood pressure with beta-blockers and ACE-inhibitors. The logistic 
EuroSCORE identified various preoperative risk factors related to mortality, but none of our 
statistically different baseline variables between the two groups are included in this scoring 
system. Compared with a study by Conlon et al.16, our percentages of patients requiring 
renal replacement therapy are relatively high, but are influenced by local policy to treat 
acute kidney injury early and aggressively to prevent further deterioration of the kidney 
function. 
Conclusion
This study shows that the majority of observed complications in patients with preexisting 
heart failure are not directly related to the insufficient pumping capacity of the heart, 
but merely reflect a systemic dysregulation. Further research is necessary to unravel 
underlying mechanisms for this adverse postoperative course. Moreover, the great impact 
of heart failure on adverse outcomes emphasizes the importance of adapting current risk 
stratification systems, such as the EuroSCORE. Offensive perioperative treatment strategies 
focused on the described complications will lead to improved results for patients with heart 
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supplementary data, table 1. Performed surgical procedures in patients with heart failure and 
controls.
Surgical procedures (no. of procedures) HF (n = 48) Controls (n = 48)
external cardiac support device
Left ventricular reconstruction 
Mitral valve repair
tricuspid valve annuloplasty
aortic valve repair / reconstruction
coronary artery bypass grafting 




















Abbreviation: HF, Heart Failure.
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AbStRACt
background: Ischemia/reperfusion (I/R) injury is a common clinical problem. Although 
the pathophysiological mechanisms underlying I/R injury are unclear, oxidative damage 
is considered a key factor in the initiation of I/R injury. Findings from preclinical studies 
consistently show that quenching reactive oxygen and nitrogen species (RONS), thus limiting 
oxidative damage, alleviates I/R injury. Results from clinical intervention studies on the 
other hand are largely inconclusive. In this study, we systematically evaluated the release 
of established biomarkers of oxidative and nitrosative damage during planned I/R of kidney 
and heart in a wide range of clinical conditions.
Results: Sequential arteriovenous concentration differences allowed specific measurements 
over the reperfused organ in time. None of the biomarkers of oxidative and nitrosative 
damage (that is, malondialdehyde, 15(S)-8-iso-prostaglandin F2α, nitrite, nitrate and 
nitrotyrosine) were released upon reperfusion. Cumulative urinary measurements confirmed 
plasma findings. As of these negative findings, we tested for oxidative stress during I/R and 
found activation of the nuclear factor erythroid 2-related factor 2, the master regulator of 
oxidative stress signaling. 
Innovation: This comprehensive, clinical study evaluates the role of RONS in I/R injury in 
two different human organs (kidney and heart). Results show oxidative stress, but do not 
provide evidence for oxidative damage during early reperfusion, thereby challenging the 
prevailing paradigm on RONS-mediated I/R injury. 
Conclusions: Findings from this study suggest that the contribution of oxidative damage 
to human I/R may be less than commonly thought and propose a re-evaluation of the 
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IntRoDuCtIon
Ischemia/reperfusion injury (I/R) is the paradoxical increase of tissue damage upon 
reperfusion of ischemic tissue. I/R is considered a major contributor to tissue damage in 
multiple clinical situations such as myocardial infarction, stroke and organ transplantation. 
The pathophysiology of I/R injury is complex and incompletely understood, and effective 
treatment is currently lacking. 
Reactive oxygen and nitrogen species (RONS) are considered key initiators of I/R injury. 
Ischemia-related metabolic adaptations and dysregulated mitochondrial homeostasis are 
thought to result in substantial RONS release upon reintroduction of oxygen. This RONS 
overload can overwhelm the endogenous antioxidant system, resulting in oxidative damage. 
This may trigger secondary processes such as a pro-inflammatory response.1-4 
It has long been supposed that antioxidant therapy mitigates I/R injury. The validity of 
this concept has been proven in numerous animal studies, which all clearly demonstrate 
that antioxidant therapy ameliorates I/R injury.5-7 Despite these findings, studies in humans 
consistently fail to show any clinically relevant effect.5, 8-11 The basis for this discrepancy 
between human and animal studies is still unclear, yet it may suggest that the contribution 
of RONS to I/R injury in humans may be less than commonly thought.
In this study, a double approach was used to evaluate the role of RONS in clinical I/R 
injury. First, release of established biomarkers of oxidative damage from the human kidney 
and heart was assessed during planned I/R. By cannulation of the efferent vein, that is, the 
renal vein during kidney transplantation and the coronary sinus during cardiac valve surgery, 
sensitive and organ-specific measurements of net changes in oxidative damage biomarkers 
over the organ were conducted. Next, as none of the biomarkers were released during 
the reperfusion phase, we tested for presence of oxidative stress during early reperfusion, 
which did show activation of nuclear factor erythroid 2-related factor 2 (Nrf2), a critical 
transcription factor in oxidative stress signaling. All together, results from these studies, 
comprising different organs, clinical settings and durations of ischemia, are highly consistent 
and do indicate oxidative stress, but no RONS-related damage during the acute reperfusion 
phase in humans, suggesting that the endogenous antioxidant system is able to cope with 
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MetHoDS
Patients and surgical procedures
This prospective observational study involved patients undergoing renal I/R during kidney 
transplantation with living donor (LD) and deceased donor (DD) grafts, and patients 
undergoing myocardial I/R (that is, during cardiac valve surgery) with and without preexisting 
heart failure. The study protocols were approved by the local ethics committee, and written 
informed consent was obtained from each patient. 
Kidney transplantation
Twenty-four patients undergoing renal allograft transplantation were included: eight 
patients receiving a kidney from a LD and 16 patients receiving a kidney from a DD (nine 
brain-dead donors and seven cardiac-dead donors). LD and DD kidney transplantations 
were separately analyzed and compared because of large differences in ischemia times, pre-
transplantation graft handling, and clinical outcome between these groups. Within groups 
variability of patient and graft characteristics was small for both donor types, rendering the 
comparison more reliable. LD kidney transplantations allowed for measurements in urine 
produced by the graft directly after reperfusion, providing a more cumulative measure than 
the arteriovenous measurements. 
Kidney transplantations were performed according to the local standardized protocol. For 
technical reasons (renal vein sampling), only patients receiving a left kidney were included. 
In LDs a minimally invasive open nephrectomy was performed. The immunosuppressive 
regimen was based on induction therapy with basiliximab followed by maintenance therapy 
with tacrolimus or cyclosporine A in addition to mycophenolate mofetil and steroids. 
Cardiac valve surgery
Myocardial I/R was studied in patients undergoing cardiac valve surgery with aortic cross-
clamping (that is, cessation of blood flow in the coronary arteries). Twenty-four patients 
scheduled for elective mitral valve annuloplasty with use of cardiopulmonary bypass were 
included: 12 patients with preexisting heart failure and 12 patients without heart failure. 
Heart failure was defined as an inadequate pump function with an echocardiographically 
estimated ejection fraction biplane below 35%12 and the presence of one or more clinical 
symptoms of heart failure (New York Heart Association classification).13 Exclusion criteria 
were perioperative corticosteroid therapy, minimal invasive surgical procedures, emergency 
cardiac operations and previous cardiac surgery. 
Cardiac surgery was performed according to the local standardized protocol. All surgical 
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bypass (Jostra Maquet, Maquet, Hirrlingen, Germany) with intermittent potassium-enriched 
antegrade warm-blood cardioplegia. This solution was administered every 15 to 20 minutes 
throughout the entire ischemic period. The cardiopulmonary bypass system was coated 
with a heparin softline coating. No antioxidants or other preservational or therapeutical 
substances were added. 
During cardioplegia-induced cardiac arrest (myocardial ischemia), valve surgery was 
executed. Eventually, the aortic cross-clamp was removed to restore the blood flow through 
the heart (start of reperfusion). 
Arteriovenous measurements
Arterial and venous blood samples were collected directly over the reperfused organ, that 
is, from the afferent and efferent blood vessel. Comparison of multiple biomarkers in these 
samples allowed for accurate and specific assessment of locally ongoing processes in the 
reperfusion phase.14 This method was used to determine the release of biomarkers of 
oxidative damage in both kidney and heart I/R. 
Kidney transplantation
Arterial and renal venous blood samples were obtained as described before.14 Via an 
umbilical vein catheter placed in the renal vein, blood aliquots were sampled at 30 seconds, 
3, 10, and 30 minutes after reperfusion. Paired arterial blood samples were simultaneously 
obtained via the iliac artery at 0, 3, 10, and 30 minutes after reperfusion (Figure 1A). The 
endpoint of sampling was reached 30 minutes after reperfusion by closing the abdominal 
wall. The initial urine produced by the graft in the first 10 minutes after reperfusion was 
collected directly from the graft’s ureter. Control urine was collected from the urethral 
catheter of LDs during the nephrectomy procedure before kidney ischemia was induced. 
All samples were collected in pre-cooled tubes containing ethylenediaminetetraacetic acid 
(EDTA) (BD Vacutainer, Plymouth, UK) and placed on melting ice immediately. Blood and 
urine samples were centrifuged (1.550 g, 20 min, 4°C) within one hour after collection and 
the derived plasma or supernatant was re-centrifuged (1.550 g, 20 min, 4°C) to deplete it 
from remaining leukocytes and platelets. Material was aliquoted and stored at -70°C until 
analysis. 
Cardiac valve surgery
A 5 French indwelling jugular vein catheter (PICC, Arrow International Inc., REF PS-01651, PA, 
USA) was inserted in the right atrium and placed in the coronary sinus during cardiac surgery 
(Figure 1B). As all patients underwent mitral valve surgery using a vertical transseptal incision, 
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catheter was routinely placed in the radial artery. Arterial and paired myocardial venous 
blood (coronary sinus) samples were obtained at 0, 15, 30, and 60 minutes after reperfusion 
as described recently.15 All samples were collected in pre-cooled tubes containing EDTA 
(BD Vacutainer, Plymouth, UK) and placed on melting ice immediately. Blood samples were 
centrifuged (1.550 g, 10 min, 4°C) within one hour after collection and the derived plasma 
was re-centrifuged (10.000 g, 4 min, 4°C) to obtain leukocyte and platelet poor plasma. 
Aliquots were stored at -70°C until analysis. 
figure 1. schematic representation of the arteriovenous measurements of the kidney and heart. 
The figure shows the position of the arterial and renal venous catheter in the kidney (A), and the 
coronary sinus catheter in the heart (B). 
Biopsy collection
A pre-transplantation renal cortical biopsy was obtained just before transplantation, 
when the graft was still on ice. A paired needle biopsy of the same kidney was collected 
45 minutes after reperfusion. Myocardial biopsies were collected at start of cardioplegia-
induced cardiac arrest and a paired, second biopsy was obtained at the end of the 
ischemic period, just before reperfusion of the heart. Because of technical reasons, a post-
reperfusion biopsy could not be collected since most of the included heart failure patients 
were hemodynamically unstable in the early reperfusion phase. Lifting the heart, to take 
a post-reperfusion biopsy, was considered unsafe. All biopsies were snap-frozen in liquid 
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Laboratory plasma measurements
To validate the method of arteriovenous measurements and to assess whether there is 
oxygen consumption by the reperfused organ, the oxygen saturation level was assessed in 
arterial as well as venous blood samples of a LD by means of a routinely used validated blood 
gas analyzer. The extent of RONS-mediated damage was evaluated by measuring different 
well-established biomarkers of oxidative and nitrosative damage by state of the art stable 
isotope dilution gas chromatography-mass spectrometry (GC-MS) and gas chromatography-
tandem mass spectrometry (GC-MS/MS) methods. Malondialdehyde (MDA) and 15(S)-
8-iso-prostaglandin F2α (15(S)-8-iso-PGF2α) are widely recognized biomarkers of lipid 
peroxidation.16 In humans, nitrite and nitrate are reliable indicators of nitric oxide synthesis 
and frequently measured breakdown products of RONS.16-18 
MDA and total 15(S)-8-iso-PGF2α, that is, free and esterified 15(S)-8-iso-PGF2α, were 
assessed with an extensively validated GC-MS/MS method as described previously.19, 
20 In parallel, the thiobarbituric acid-reactive substances (TBARS) method was used to 
detect MDA in plasma as well as in urine samples.21 Free 15(S)-8-iso-PGF2α in urine was 
measured by GC-MS/MS.20 Nitrite and nitrate were measured simultaneously by GC-
MS in plasma and urine aliquots as described elsewhere in detail.19, 22 The prostaglandin 
E2 (PGE2) concentration in urine was measured by GC-MS/MS after immunoaffinity 
column chromatography extraction.20 Urinary parameters were corrected for creatinine 
excretion.23 Study samples were analyzed alongside quality control (QC) samples 
as described previously.19, 22, 23 The MDA plasma concentration in the QC samples 
was determined to be 57.3 ± 7.8 nmol/L (mean ± standard deviation (SD), n = 25) 
corresponding to an imprecision (relative SD) of 13.7 %. The total 15(S)-8-iso-PGF2α plasma 
concentration in the QC samples was determined to be 157 ± 6.4 pmol/L (mean ± SD, 
n = 10) corresponding to an imprecision of 4.1%. In the QC samples for plasma nitrite and 
nitrate (n = 30), accuracy and imprecision were 90% to 112% and below 6%, respectively. 
3-Nitrotyrosine in proteins, a biomarker of nitrosative damage, was measured by ELISA in 
accordance with the manufacturer’s instructions (Biotech nitrotyrosine EIA, Oxis, Portland, 
Oregon, USA).16
Nrf2/ARE pathway
Nrf2 activation was assessed in whole-cell lysate. Snap-frozen renal biopsies were 
homogenized and whole-cell extracts were prepared according to the manufacturers’ 
instructions (Nuclear extract kit, Active Motif, Carlsbad, CA, USA). Next, activated Nrf2 in cell 
lysates was quantified by DNA-binding ELISA according to the manufacturers’ instructions 
(TransAM Nrf2, Active Motif, Carlsbad, CA, USA). Total RNA was extracted from renal or 
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(GAPDH) as internal control.24 For expression profiling, the integrity of each RNA sample was 
examined by Agilent Lab-on-a-chip technology using the RNA 6000 Nano LabChip kit and a 
bioanalyzer 2100 (Agilent Technologies, Amstelveen, The Netherlands). RNA preparations 
were considered suitable for array hybridization only if samples showed intact 18S and 
28S rRNA bands, and displayed no chromosomal peaks or RNA degradation products (RNA 
Integrity Number > 8.0).25 Subsequent microarray analysis was performed using Illumina 
whole-genome gene expression BeadChips (Illumina BeadArray®, San Diego, CA, USA) 
according to instructions of the manufacturer at Service XS (Leiden, The Netherlands). 
Selected probes from the canonical Nrf2 pathway were used as an input for pathway 
analysis through the Ingenuity Pathway Analysis suite (http://www.ingenuity.com). 
Hierarchical clustering and heatmap visualization were carried out using Hierarchical 
Clustering Viewer and Heatmap Viewer modules within the GenePattern analysis suite.26-28
Histological analyses
In kidney biopsies collected before and after reperfusion, presence of various antioxidant 
enzymes and RONS generation by xanthine oxidase (XO) was assessed. Antioxidant enzymes 
superoxide dismutase (SOD) and peroxidases (catalase and glutathione peroxidase) were 
measured by histochemical methods as described previously in detail.29 The XO activity was 
measured in renal tissue, based on the generation of superoxide anions from hypoxanthine, 
as described earlier.30 Specificity of the assay was demonstrated by inhibition of XO by 
allopurinol. Rat liver tissue was included as positive control. 
Statistical analysis
Statistical analysis was performed with the Statistical Package for the Social Sciences 
16.0 (SPSS Inc., Chicago, IL, USA). All data in the text and tables are expressed as mean 
± SD. Patient characteristics were compared by paired t-test. The area under the curve 
(AUC) was calculated for the arterial and venous curve. AUC’s and urinary measurements 
were compared by using the Wilcoxon signed rank test. Differential expression of probes 
was assessed using unpaired moderated t-test (LIMMA) through the Remote Analysis 
Computation for gene Expression data (RACE) suite at http://race.unil.ch.31 A P value less 
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ReSultS
Patient characteristics and outcome
Patient characteristics for kidney transplantation and cardiac valve surgery are summarized 
in Tables 1 and 2, respectively. One-year patient and graft survival was 100% for the patients 
who underwent kidney transplantation. One-year survival was also 100% for all patients 
who underwent cardiac valve surgery.
table 1. transplantation and outcome characteristics in living donor and deceased donor kidney 
transplantations.
lD DD P value
n 8 16
Recipient age (years)
    Mean ± SD
41.1 ± 10.5 54.6 ± 12.2 0.02
Recipient gender
    (% male)


























Donor age (years)  
     Mean ± SD 
43.9 ± 10.6 53.5 ± 16.1 0.14
Donor gender 
     (% male)
75 (n = 6) 44 (n = 7) 0.15














Preservation fluids HTK (n = 8) UW (n = 11)
HTK (n = 5)
0.001
CIt (min)
     Mean ± SD
179.1 ± 18.6 1117.7 ± 299.1 < 0.001
wIt (min)
     Mean ± SD
34.0 ± 6.3 33.5 ± 6.1 0.85
Abbreviations: ADPKD, Autosomal Dominant Polycystic Kidney Disease; BDD, Brain-Dead Donor; BM, 
Basement Membrane; CDD, Cardiac-Dead Donor; CIT, Cold Ischemia Time; DD, Deceased Donor; FSG, 
Focal Segmental Glomerulosclerosis; HTK, Histidine–Tryptophan–Ketoglutarate; LD, Living Donor; MPG, 
Membranous Glomerulonephritis; SAH, Subarachnoid Hemorrhage; UW, University of Wisconsin; WIT, 
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table 2. characteristics of patients with and without heart failure undergoing cardiac surgery.
Heart failure no heart failure P value
n 12 12
gender 
     (% male)
75 (n = 9) 42 (n = 5) 0.11
Age (years)
     Mean ± SD
66.8 ± 8.9 62.7 ± 11.7 0.20
Ischemia time (min) 
     Mean ± SD
128.3 ± 50.7 127.0 ± 32.6 0.89
Duration Icu stay (h)*
     Mean ± SD 
62.5 ± 40.8 31.6 ± 23.9 0.02
Abbreviation: ICU, Intensive Care Unit.
Validation of arteriovenous measurements
The methodology of the arteriovenous sampling is schematically shown in Figure 1. The 
principle of the method is illustrated by arterial and venous oxygen saturation levels 
measured during early reperfusion, showing an effective and consistent consumption of 
oxygen (Figure 2).
figure 2. a typical example of arteriovenous oxygen saturation differences during reperfusion of 
the kidney. 
Arterial and renal venous oxygen saturation was measured during the first 30 minutes of reperfusion. 
The consistently lower venous oxygen saturation level indicates the uptake of oxygen by the reperfused 
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Biomarkers of oxidative damage 
Renal I/R is not associated with oxidative damage 
MDA and 15(S)-8-iso-PGF2α were measured as established biomarkers of RONS-mediated 
damage. Arteriovenous measurements of MDA did not indicate its release from the 
kidney during the first 30 minutes of reperfusion of LD kidneys by either GC-MS (P = 0.17; 
Supplementary data, Figure 1) or TBARS method (P = 0.06). Urinary MDA levels (TBARS 
method) were also assessed in the first urine produced immediately after reperfusion (LDs 
only) as an aggregate measure of total MDA formation in the kidney. The MDA levels in 
this first urine collected after reperfusion were similar to the control urine, that is, urine 
produced by the kidney before its removal from the donor (P = 0.40). 
Minimal release was observed for 15(S)-8-iso-PGF2α from reperfused LD kidney grafts 
(P = 0.03). However, clinically more vulnerable DD kidneys did not show any 15(S)-8-iso-
PGF2α release upon reperfusion (P = 0.16; Figure 3). Arteriovenous measurements over 
the non-ischemic kidney in LDs, that is, before donor nephrectomy, revealed no release of 
15(S)-8-iso-PGF2α (P = 0.69), demonstrating that its post-reperfusion release is specific for 
I/R. Urinary 15(S)-8-iso-PGF2α levels were not influenced by reperfusion (P = 0.35; Table 3). 
table 3. AuC venous minus AuC arterial (delta AuC) of the measured plasma biomarkers for 
oxidative and nitrosative damage during the early reperfusion phase.
Kidney transplantation Cardiac valve surgery

























nitrosative stress and damage
nitrite (nmol/l×min)































* Delta AUC: AUC venous minus AUC arterial (P value) of the measured plasma markers during the early 
reperfusion phase. A positive number indicates a release from the reperfused organ, whereas a negative 
number indicates an uptake of the biomarker. 
† Results in urine indicate P values of the difference of the pre- and post-reperfusion measure. 
‡ Significant venous release (P < 0.05).
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figure 3. arterial and venous plasma concentrations of 15(S)-8-iso-prostaglandin f2α.
(A) Arterial and renal venous plasma 15(S)-8-iso-PGF2α concentrations during the first 30 minutes of 
reperfusion in living donor (LD) kidney transplantation showed a small, but significant release from 
the kidney (P = 0.03); (B) In deceased donor (DD) kidney transplantation, 15(S)-8-iso-PGF2α was 
not released from the reperfused kidney during the first 30 minutes of reperfusion (P = 0.16); (C) 
Arterial and myocardial venous plasma 15(S)-8-iso-PGF2α concentrations during the first 60 minutes 
of reperfusion in patients with preexisting heart failure showed a small, but significant release from 
the myocardium (P = 0.02); (D) In patients without preexisting heart failure, 15(S)-8-iso-PGF2α was not 
released from the reperfused heart during the first 60 minutes of reperfusion (P = 0.18).
Urinary PGE2 was measured as marker of cyclooxygenase-2 (COX-2) activity. PGE2 levels in 
the first urine collected after reperfusion were higher than those of the control urine, that 
is, urine produced by the kidney prior to its removal from the donor (P = 0.02; Figure 4). 
This shows that in contrast to the absence of apparent oxidative damage, oxidative stress 
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Figure 4. Prostaglandin e2 excretion in urine. 
Creatinine-corrected levels of prostaglandin E2 (PGE2) in the first urine collected after reperfusion 
(post) were higher than those of control urine (pre), that is, urine produced by the kidney before its 
removal from the donor (P = 0.02). 
Myocardial I/R is not associated with oxidative damage
Results of myocardial I/R resembled those of the kidney. There was no myocardial MDA 
release during the first hour after reperfusion in both patients with and without heart failure 
(P = 0.05 and P = 0.43, respectively; Table 3, and Supplementary data, Figure 1). In fact, 
venous MDA levels tended to be lower than arterial levels in patients with heart failure. 
15(S)-8-iso-PGF2α showed a small local release early after reperfusion in patients with 
preexisting heart failure (P = 0.02; Figure 3). In contrast, arteriovenous measurements 
of 15(S)-8-iso-PGF2α in patients without preexisting heart failure did not indicate a local 
release during the first hour after reperfusion (P = 0.18; Table 3).
Biomarkers of nitrosative damage
No evidence for nitrosative damage in human kidney transplantation
Nitrite concentrations were equal in renal arterial and venous blood samples (LDs P = 0.50, 
DDs P = 0.87; Supplementary data, Figure 2). Likewise, nitrate was not released from the 
reperfused graft either (LDs P = 0.50, DDs P = 0.98; Supplementary data, Figure 3). These 
findings were confirmed by the additional measurement of plasma nitrotyrosine in LD 
kidney grafts, indicating no such release (P = 0.93, Supplementary data, Figure 4). The 
integral urinary measurement of nitrite and nitrate remained similar after reperfusion in LD 
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No evidence for nitrosative damage after reperfusion of the myocardium
Arterial nitrite concentrations were higher than venous concentrations in both patient 
groups during the early reperfusion phase (P = 0.002 preexisting heart failure, P = 0.03 
no preexisting heart failure; Supplementary data, Figure 2), excluding myocardial nitrite 
release. Nitrate did not change over the reperfused myocardium in both patient groups 
(P = 0.53 preexisting heart failure, P = 0.81 no preexisting heart failure; Table 3, and 
Supplementary data, Figure 3).
Oxidative stress
Kidney
Since the above-mentioned results indicated no extracellular evidence for RONS-mediated 
damage, we tested for the occurrence of oxidative stress during I/R by assessing activation 
of Nrf2, the master regulator of the antioxidant stress response. 
Activation of Nrf2 was quantified, as well as the upregulation of Nrf2 responsive genes, 
heme oxygenase-1 (HMOX-1), NAD(P)H quinone oxidoreductase (NQO1), and glutathione 
S-transferase A2 (GSTA2) in pre- and post-biopsies collected from both kidney and heart 
(Figure 5). Using a DNA binding ELISA for activated Nrf2, we found clear activation of this 
transcription factor upon reperfusion (P = 0.01; Figure 6), while Nrf2 gene expression 
increased as well in both LD and DD kidney grafts (P = 0.03, P = 0.04, respectively; Figure 
7). Pathway-based analysis of Nrf2 downstream genes (Ingenuity Pathway Analysis suite, 
Supplementary data, Figure 5) showed highly significant (P = 7.06*10-12) upregulation of the 
canonical antioxidant responsive element (ARE) pathway in kidneys from LDs.
Conversion of xanthine reductase to XO and accumulation of hypoxanthine during 
ischemia has been proposed as a major source of oxygen radicals during I/R injury. 
Histochemical analysis of kidney biopsies collected before and after reperfusion did not 
indicate the XO activity in renal tissue, whereas ample XO activity and abundant hypoxanthine 
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figure 5. schematic representation of the nuclear factor erythroid 2-related factor 2 / antioxidant 
responsive element pathway and antioxidant responsive element induced gene expression. 
Environmental stress exerts oxidative stress on cells through production of reactive oxygen and 
nitrogen species (RONS). The oxidative stress response is largely coordinated by a transcription factor, 
nuclear factor erythroid 2-related factor 2 (Nrf2). Under homeostatic conditions, there is only an 
inactive minimal basal level of Nrf2-directed gene expression under tight control of protein Keap 1. 
RONS lead to the activation of mitogen-activated protein kinases (such as MAPK, ERK, p38), protein 
kinase C (PKC), phosphatidylinositol 3 kinase (PI3K), and others, which phosphorylate Keap1 and Nrf2. 
The Keap1-Nrf2 complex is then disrupted and the transcriptionally active Nrf2 is translocated to the 
nucleus where it binds to antioxidant responsive elements (AREs) in association with Maf proteins. 
This results in an increase of the transcriptional expression of Nrf2-inducible genes such as those 
encoding heme oxygenase-1 (HMOX1), NAD(P)H quinone oxidoreductase (NQO1), and glutathione 
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figure 6. nuclear factor erythroid 2-related factor 2 activation upon renal reperfusion.
Nuclear factor erythroid 2-related factor 2 (Nrf2) in renal tissue was significantly converted to its 
activated form after reperfusion (P = 0.01) during living donor (LD) kidney transplantation. 
Antioxidant enzyme activities
SOD and peroxidase activities (catalase and glutathione peroxidase) were evaluated by 
histochemical analyses of kidney biopsies taken before and 45 minutes after reperfusion. 
Results of this analysis show abundant and similar antioxidant activities before and after 
reperfusion (Supplementary data, Figure 7). 
Figure 7. Changes in renal expression of nuclear factor erythroid 2-related factor 2 gene.
Renal expression of nuclear factor erythroid 2-related factor 2 (Nrf2) gene in biopsies collected before 
(pre) and 45 minutes after (post) reperfusion during living donor (LD) and deceased donor (DD) kidney 
transplantation. Y-axis shows the relative change in gene expression as calculated by log(1/2ddCt), 
where the dCt is the Ct of studied gene minus the Ct of GAPDH, and ddCt is dCt of post-biopsy minus 
dCt of pre-biopsy. A positive number indicates an increase in expression after reperfusion, whereas 
a negative number indicates a downregulation after reperfusion. Expression of the transcription 
factor Nrf2 gene NFE2L2 was significantly upregulated after reperfusion in both LD (P = 0.03) and DD 
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DISCuSSIon
Oxidative damage is long considered a key factor in the initiation of I/R injury. Although 
animal studies repeatedly showed the involvement of free radicals in I/R injury, studies 
in humans are scarce, and results of clinical intervention studies using antioxidants are 
inconclusive. Our study shows minimal release of markers of oxidative and nitrosative 
damage, and did not indicate upregulation of the classical oxidative response genes in both 
heart and kidney I/R. Results of our study are highly consistent and suggest that the role 
of oxidative and nitrosative damage in the initiation of clinical I/R injury may be less than 
commonly thought. 
RONS have long been held responsible for the initiation and propagation of I/R injury 
in many different tissue types, including the kidney, liver, and heart.32 Initial studies date 
back to 20 years ago when an increase in lipid peroxidation was shown after experimental 
reperfusion of rat kidneys.33 Since then, further animal studies have supported a role for 
oxidative damage in I/R.34-36 In contrast, studies in humans are scarce and findings are 
inconclusive. In a clinical study of Grech et al., it was confirmed that RONS are formed after 
I/R.37 By using direct spin trapping methods, they demonstrated an immediate free radical 
production during the first four hours after myocardial reperfusion. However, whether 
RONS actually lead to tissue damage was not studied. Further studies on oxidative damage 
in I/R injury in humans show conflicting results. Zahmatkesh et al. showed that after kidney 
transplantation circulating lipid peroxidation biomarkers rise in peripheral blood.38 Whether 
this can be attributed to oxidative damage in the kidney itself or in any other part of the body 
can not be distinguished by peripheral measurements. Some studies involving myocardial 
I/R used more specific methods, that is, arteriovenous measurements over the reperfused 
heart, after percutaneous transluminal coronary angioplasty (PTCA). F2-isoprostanes were 
released from the reperfused myocardium after PTCA.39, 40 However, results on MDA release 
were contradictory, showing no myocardial release after PTCA 41 and low extent MDA release 
during coronary artery bypass grafting.42 
Although available antioxidant intervention studies are limited and results are 
inconclusive, antioxidant treatment appears a potential therapy to study in humans. 
Somehow, only few trials using antioxidants in human I/R injury are known, and it seems 
reasonable that a certain amount of publication bias has been introduced. El-Hamamsy et 
al. showed that administration of the antioxidant N-acetylcysteine during human coronary 
artery bypass surgery did not lead to improvement in clinical endpoints or decreased 
release of biochemical markers.10 Administration of tirilazad mesylate, a non-glucocorticoid 
21-aminosteroid inhibiting lipid peroxidation, to patients with acute ischemic stroke even 
increased the end-point of death instead of having beneficial effects.8 In kidney I/R only two 
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administered SOD intravenously before and one hour after reperfusion, but no beneficial 
effects were observed with respect to early graft function.43 One year later, Land et al. 
administered a single, higher intravenous dose of SOD, immediately before reperfusion. The 
results demonstrated a significant reduction in first acute rejection.44 However, up to now, 
none of both observations have been confirmed in other studies or have led to application 
in daily practice. 
Thus, despite encouraging results of antioxidant I/R therapy in animals, published clinical 
studies lack an appreciable, clinically relevant effect thus far.5, 8-11 Let alone minor differences 
in clinical set up, there appears to be a mechanistic disparity in the role of oxidative 
damage and endogenous antioxidant capacity in I/R injury between animals and humans. 
An explanation could be derived from studies on aging that have shown that organisms 
with large mass-specific metabolic rate, such as mice, have a relative high RONS production 
and a weak capacity to maintain homeostasis compared with humans.45 This difference 
in homeostatic capacity may explain differences in the role of oxidative damage between 
species as well. Thus, it can be suggested that endogenous antioxidant systems in humans 
are sufficiently equipped to handle the excess RONS load during clinical reperfusion, thus 
preventing damage. A finding that is supported by abundant SOD and peroxidases activities 
before and after I/R. 
Whether oxidative damage is indeed prevented in human I/R injury was assessed in 
this study. RONS have a transient nature and are difficult to assess in vitro and in vivo.22 
Consequently, we measured more stable oxidation products caused by RONS to determine 
the extent of oxidative damage in I/R injury. By combining multiple biomarkers, a footprint 
of oxidative and nitrosative damage could be reconstructed. Arteriovenous concentration 
differences of various established oxidative and nitrosative damage biomarkers were 
sequentially measured during reperfusion in kidney transplantation. To exclude organ- and 
procedure-specific findings, kidney results were compared with a different clinical setting, 
that is, myocardial I/R. 
Arteriovenous measurements did not indicate release of oxidative or nitrosative damage 
biomarkers upon reperfusion of both the kidney and heart with the sole exception of a 
minimal and transient release of 15(S)-8-iso-PGF2α in a selection of patients. Although 
the arteriovenous measurements provide important information on local processes in the 
reperfused organ, sensitivity may be restricted by dilution of released biomarkers because 
of high flow rates. Therefore, accumulation of oxidative damage markers was measured 
in urine produced by the transplanted kidney (LD) during the first minutes of reperfusion. 
Urinary measurements were in accordance to plasma findings, showing no release of 
oxidative or nitrosative damage biomarkers, including 15(S)-8-iso-PGF2α. 
In the absence of other markers, it can be questioned whether venous 15(S)-8-iso-
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or alternatively reflects activation of inflammatory pathways. Since all other markers 
refute oxidative damage, it is highly unlikely that 15(S)-8-iso-PGF2α is the sole reflection of 
oxidative damage. All together, the multiple biomarkers of oxidative and nitrosative damage 
showed no consistent release upon reperfusion, denying RONS-mediated tissue damage. 
Absence of venous release of oxidative and nitrosative damage markers may suggest 
that oxidative and nitrosative stress during I/R is less pronounced than commonly thought 
or may even be absent. We evaluated activation of Nrf2, the master regulator in cellular 
oxidative defense pathways, in a DNA-binding ELISA that exclusively measures the activated 
form of this transcription factor. Moreover, the activation of the conical downstream 
pathway of Nrf2 was evaluated through pathway analysis. Clear increases in Nrf2 activation 
and its downstream pathway show that oxidative stress does occur during I/R. 
Evaluation of the XO activity, an often referred source of oxygen radicals in I/R injury, did 
not indicate XO activity in human kidney, although abundant XO was found in rat liver. These 
observations are in line with previous reports showing abundant XO activities in rodent 
tissue but not in human tissue.46 XO therefore appears not to be a prominent source of 
RONS generation in human tissue. 
Limitations 
This is a clinical study, and as such, procedures and timing were dictated by the operative 
procedures. We did include two clinically distinct situations of I/R to identify universal 
mechanisms of free radical-mediated damage after reperfusion. In human kidney 
transplantation, I/R included extremes in both short and long cold ischemia duration, the 
use of antioxidant preservation fluids, corticosteroids, and other immunosuppressive drugs. 
In cardiac surgery, I/R involved a normothermic ischemic period, and no antioxidants, 
corticosteroids, or other immunosuppressive drugs were administered. Throughout this 
whole spectrum of clinical conditions, independent of antioxidant use or immunosuppression, 
results unequivocally showed no dominant role of oxidative and nitrosative damage in 
human I/R injury. 
Sampling in our study was restricted to less than an hour post-reperfusion. This time 
window should be adequate as it is generally assumed that I/R injury is an acute process, 
initiated directly after reperfusion.18 This notion is supported by spin trap experiments 
indicating free radical formation within 15 minutes after reperfusion.37 Yet, we can not 
exclude that I/R injury is less acute than commonly thought and that oxidative damage 
occurs after an hour of reperfusion. 
A second limitation of the study is that it largely relies on repetitive measurement of 
arteriovenous concentration differences. Although this methodology has the advantage of 
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I/R,14, 47 the high flow rates over the organs may compromise the sensitivity. To compensate 
for this limitation, we considered an evaluation of the first urine produced after I/R and 
measurement of the classical redox response genes relevant. 
Conclusion 
The findings from this study do not indicate a dominant role for RONS-induced damage 
in the pathophysiology of early I/R injury. The production of RONS during I/R is explicitly 
not questioned by our findings. In fact, Nrf2 activation and the higher PGE2 levels in post-
transplantation urine indicate increased COX activity after reperfusion, suggesting that 
oxidative stress does occur during early reperfusion. Yet, the generated RONS apparently do 
not induce tissue damage in human I/R. These observations suggest an efficient antioxidant 
system, providing an explanation for the limited efficacy of antioxidant therapy in human 
I/R. All together, this study challenges the prevailing paradigm of prominent involvement of 
oxidative damage in the initiation of human I/R injury. 
Innovation
I/R injury is a common clinical problem, complicating myocardial infarction, cardiovascular 
surgery, and organ transplantation. As such, it is of great importance to unravel the exact 
pathophysiological mechanisms leading to I/R injury. This comprehensive clinical study 
systematically assessed the putative role of oxidative stress in human I/R injury in two 
diverse clinical settings. Findings for all biomarkers studied were highly consistent and 
did not indicate release of markers of oxidative damage from the reperfused organs nor 
did we observe upregulation of redox-response genes. As such, this study questions the 
involvement of RONS in the pathophysiology of I/R injury in humans.
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supplementary data, figure 1. arterial and venous plasma concentrations of malondialdehyde.
(A) Arterial and renal venous plasma malondialdehyde (MDA) concentrations during the first 30 
minutes of reperfusion in living donor (LD) kidney transplantation as determined by GC-MS/MS showed 
no MDA release (P = 0.17); (B) No MDA release was observed when determined by TBARS method (P 
= 0.06); (C) Arterial and myocardial venous plasma MDA concentrations during the first 60 minutes of 
reperfusion in patients with preexisting heart failure showed no release from the myocardium (P = 
0.05). In fact, venous MDA levels tended to be lower than the arterial levels in patients with preexisting 
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supplementary data, figure 2. arterial and venous plasma concentrations of nitrite.
(A) Arterial and renal venous plasma nitrite concentrations during the first 30 minutes of reperfusion 
in living donor (LD) kidney transplantation showed no release from the kidney (P = 0.50); (B) In 
deceased donor (DD) kidney transplantation, nitrite was not released either during the first 30 minutes 
of reperfusion (P = 0.87); (C) Arterial and myocardial venous plasma nitrite concentrations during the 
first 60 minutes of reperfusion in patients with preexisting heart failure showed no myocardial release. 
However, a myocardial uptake was observed (P = 0.002); (D) Similarly, in patients without preexisting 
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supplementary data, figure 3. arterial and venous plasma concentrations of nitrate.
(A) Arterial and renal venous plasma nitrate concentrations during the first 30 minutes of reperfusion 
during living donor kidney (LD) transplantation showed no release from the kidney (P = 0.50); (B) During 
deceased donor (DD) kidney transplantation, nitrate was not released during the first 30 minutes of 
reperfusion (P = 0.98); (C) Arterial and myocardial venous plasma nitrate concentrations during the 
first 60 minutes of reperfusion in patients with preexisting heart failure showed no myocardial release 
(P = 0.53); (D) Similarly, in patients without preexisting heart failure no myocardial nitrate release was 
observed (P = 0.81).
supplementary data, figure 4. arterial and venous plasma concentrations of nitrotyrosine.
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Supplementary data, Figure 5. nuclear factor erythroid 2-related factor 2 downstream genes.
Pathway-based analysis of nuclear factor erythroid 2-related factor 2 (Nrf2) downstream genes 
showed highly significant upregulation of the canonical antioxidant responsive element (ARE) pathway 
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supplementary data, figure 5, continued. nuclear factor erythroid 2-related factor 2 downstream 
genes.
Pathway-based analysis of nuclear factor erythroid 2-related factor 2 (Nrf2) downstream genes 
showed highly significant upregulation of the canonical antioxidant responsive element (ARE) pathway 













































   
supplementary data, figure 6. Xanthine oxidase activity.
Histochemical analysis showing minimal xanthine oxidase (XO) activity in pre- and post-reperfusion 
kidney biopsies. Liver biopsies showing XO activity in the presence (left) and absence of hypoxanthine 
(middle) are included as a positive control. Staining in the absence of hypoxanthine implies endogenous 

































































































































































































supplementary data, figure 7. Endogenous antioxidant enzymes. 
Histochemical analysis showing that the endogenous antioxidant enzyme systems superoxide 
dismutase (SOD), and peroxidases (catalase and glutathione peroxidase), are active in pre- and post-
reperfusion kidney biopsies.
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AbStRACt
background: Complement activation is considered an important mediator of myocardial 
ischemia/reperfusion (I/R) injury. Although complement inhibitors are highly effective in 
animals, clinical trials fail to show a substantial benefit in humans. This raises questions on 
the role of complement activation in human myocardial I/R injury.
Methods: Soluble C5b-9, i.e. terminal complement complex, and C5a were assessed in 
patients with non-ischemic (n = 10) and ischemic heart failure (n = 10), and patients without 
heart failure (n = 10) undergoing cardiac surgery. To study the pathophysiology of human 
I/R injury, a model of arteriovenous measurements over the reperfused heart was applied 
at consecutive time points during the early reperfusion phase. Furthermore, C3d and C5b-9 
depositions in pre-reperfusion myocardial and endomyocardial tissue were evaluated and 
compared with pre-transplantation tissue from myocardial allografts.
Results: Simultaneous assessment of soluble C5b-9 and C5a in systemical and myocardial 
venous blood samples revealed the absence of net release from the reperfused heart in all 
three patient groups. Biopsies of patients with non-ischemic heart failure showed the most 
abundant myocardial depositions of C3d and C5b-9: 4.8 times more C3d (P = 0.008) and 
4.7 times more C5b-9 (P = 0.004) than donor tissue. Also C3d was abundantly present in 
endomyocardial tissue of both heart failure groups compared with donors (both P = 0.02). 
Conclusions: No evidence was obtained that terminal complement activation is involved 
in the acute phase following myocardial reperfusion. Since complement deposition was 
already present before reperfusion, human complement inhibition might be more beneficial 
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IntRoDuCtIon
Ischemia/reperfusion (I/R) injury is considered a major contributor to reversible but also 
to irreversible cellular damage in multiple clinical situations such as heart transplantation, 
myocardial infarction and cardiovascular surgery. The pathophysiology of I/R injury is 
complex and incompletely understood. The innate immune system has been suggested 
to provide short-term adaptive responses to tissue injury. If the innate immune signaling 
becomes sustained or excessive, the activation of these beneficial homeostatic pathways is 
abolished by deleterious effects of inflammatory signaling.1 
The complement system is one of the basal defense mechanisms of the innate immune 
system consisting of a complex cascade of plasma proteins. The complement system is 
activated via three distinct pathways: the classical, alternative and lectin pathway. The 
end-result is activation of C5b-9, the cell-lysing membrane attack complex or terminal 
complement complex. When well-balanced and controlled, complement activation supports 
the defense against infections and facilitates wound healing. However, if the complement 
cascade is excessively activated it contributes to organ dysfunction leading to increased 
morbidity and mortality.2 
Complement activation is considered one of the key mediators of myocardial I/R-induced 
tissue damage.3-7 During cardiac surgery, the complement cascade is activated as a result of 
the surgical trauma, use of cardiopulmonary bypass (CPB) and I/R injury. 
Complement inhibitors are highly effective in reducing tissue damage in animal studies 
of myocardial I/R injury.4, 8, 9 However, anti-complement therapy in human myocardial I/R 
injury has lead to differential results without clinical relevant benefits.10-12 Whether the 
pathophysiology of human myocardial I/R injury is based on complement activation may 
therefore be questioned. The limited human studies concerning complement activation 
in myocardial I/R injury have shown that there is an increased systemical activation 
of complement components the first hours after reperfusion.5, 6 Those systemic levels 
show a biphasic pattern with inhibitory mechanisms from eight hours postoperatively 
onward.7 Those previous studies have used systemic values as read-out of local myocardial 
complement activation.
In this clinical study, an integrative approach was used to measure simultaneously 
activated complement components in coronary sinus and radial artery blood for up to 24 
hours after reperfusion. This set-up allows to specifically measure the myocardial uptake or 
release of circulating complement components such as C5a and soluble (s)C5b-9 instead of 
only measuring systemic values. In addition to the simultaneous collected blood samples, 
tissue samples were taken from the left ventricle during surgery and stained for C3d and 
C5b-9. The purpose of the present study was to examine the role of complement activation 
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MetHoDS
Patient characteristics 
To investigate the role of local complement activation in early I/R injury, 30 patients scheduled 
for elective cardiac valve surgery with use of CPB were studied. Ten patients with idiopathic 
non-ischemic heart failure were scheduled for an external constraint device. In addition, ten 
patients with ischemic heart failure were scheduled for a ventricular reconstruction after a 
large infarction (n = 5) or a coronary artery bypass grafting procedure (n = 5). Ten patients 
without heart failure undergoing cardiac surgery were also included. Their valve regurgitation 
was caused by organic pathology, with a predominance of prolapse disease. Heart failure 
was defined as an inadequate pump function of the heart with an echocardiographically 
estimated ejection fraction biplane below 35%13 and the presence of one or more clinical 
symptoms such as dyspnea – reflected by their NYHA class14 –, edema and fatigue existing 
for more than three months. All patients without heart failure had a moderate to normal 
pump function of the heart. These patients had no clinical signs of heart failure by physical 
examination and did not use high doses of diuretics. Exclusion criteria were perioperative 
corticosteroid treatment, minimal invasive surgical procedures, emergency operations and 
previous cardiac surgery. All included patients did not receive heparin, anti-complement 
therapy or immunosuppressive drugs before surgery, known to influence the measurements 
of complement activation markers. This single center study was approved by our local ethics 
committee and all patients provided written informed consent.
Anesthesia and surgical procedures
All participating patients received standardized anesthetic procedures, according to a 
fast-track protocol. Patients were premedicated with oral lorazepam 1-2 mg the evening 
and morning before surgery. The anesthetic regimen consisted of a continuous target 
controlled infusion of propofol with targets adjusted between 1.6 and 2 µg/mL to maintain 
a bispectral index value between 40 and 60. Sufentanil was infused at 0.1 µg/kg/hour and 
remifentanil target controlled infusion was guided by hemodynamic response on stimuli. 
If necessary, inotropics – dobutamine, norepinephrine, enoximone or a combination – 
were used. Cardiac surgery was performed according to the local standardized protocol. 
All surgical procedures were performed via a midline sternotomy under normothermic CPB 
(Jostra Maquet, Maquet, Hirrlingen, Germany) with intermittent antegrade warm-blood 
cardioplegia. The CPB system was coated with a heparin softline coating. Exclusion criteria 
related to the use of this CPB system were autologous priming and ultrafiltration, influencing 
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repair – procedure was performed. There is the possibility of introducing a coronary sinus 
catheter during this surgical procedure, since the transseptal approach of the mitral valve is 
the standard procedure in our hospital.
Biopsies
Five patients were selected from each patient group to obtain at two time points pre-
reperfusion biopsies from the left ventricle (Figure 1). These patients were selected by a 
blinded student based on their aortic cross-clamp time and on the time-frame between 
the collection of the biopsies and start of aortic cross-clamping. This method was applied 
to create comparability for the immunohistochemical analyses between the groups. In 
specific, the ischemic heart failure group contained two biopsies of patients scheduled 
for a ventricular reconstruction procedure and three biopsies of patients scheduled for a 
coronary artery bypass procedure. The early pre-reperfusion biopsies were taken through 
the mitral valve early after aortic cross-clamping. In other words, these biopsies were taken 
directly after opening of the heart and are therefore a good measure for preoperative 
involvement of complement activation. The late pre-reperfusion biopsy was obtained from 
the same location just before releasing the aortic cross-clamp, the moment of reperfusion. 
Only pre-reperfusion biopsies could be collected since most of the included heart failure 
patients were hemodynamically instable in the early reperfusion phase. Lifting the heart, to 
take a post-reperfusion biopsy from the left ventricle, was considered unsafe. Biopsies were 
immediately snap frozen in liquid nitrogen and stored at -70°C until analysis. To compare 
the tissue of our pre-reperfusion biopsies, pre-transplantation tissue was collected from 
myocardial allografts of four brain-death donors. 
Arteriovenous measurements
Arterial (radial artery, 10 mL) and myocardial venous blood samples (coronary sinus, 10 mL) 
were collected over the reperfused heart in all 30 patients (Figure 1). An arterial catheter 
was routinely placed in the radial artery. To collect the myocardial venous blood, a 5 French 
indwelling jugular vein catheter (PICC, Arrow International Inc, PA, USA) was inserted in 
the right atrium and was later, under direct vision of the surgeon, placed in the coronary 
sinus. This specific set-up allowed us to assess locally activated complement components in 
the early reperfusion phase. Simultaneous obtained arterial and myocardial venous blood 
samples were collected during the early reperfusion phase: 0, 15, 30, and 60 minutes after 
reperfusion. Two additional blood samples were drawn by venapunction the day before 
surgery (baseline) and 24 hours after reperfusion from the brachial vein (both 10 mL) and 
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ethylenediaminetetraacetic acid (BD Vacutainer, Plymouth, UK) and immediately placed 
on melting ice. Blood samples were centrifuged (1.550 g, 10 min, 4°C) and plasma was 
re-centrifuged (10.000 g, 4 min, 4°C) to obtain leukocyte and thrombocyte free plasma. 
Aliquots were stored at -70°C until analysis. 
figure 1. schematic representation of the coronary sinus catheter and location of the biopsy. This 
figure shows the position of the coronary sinus catheter in situ to collect myocardial venous blood 
samples. Moreover, the location of the left ventricular biopsy is depicted in this illustration showing 
endomyocardial and myocardial tissue. 
Immunohistochemistry
Sections (5 µm) of snap-frozen biopsies were air dried and acetone-fixed for 10 min. 
C3d and C5b-9 deposition was assessed using a monoclonal antibody to a neo-epitope 
on C3d (Quidel, San Diego, CA, USA) or C5b-9 (aE11; Hycult Biotechnology, Uden, The 
Netherlands), respectively. Antibody binding was detected with horseradish peroxidase 
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were incubated with tyramide-fluorescein isothiocyanate in tyramide buffer (NENTM Life 
Science Products, Boston, MA, USA), washed and incubated with HRP-labelled rabbit anti-
fluorescein isothiocyanate (DAKO, Glostrum, Germany) and developed with DAB (Sigma, 
St Louis, MO, USA). Sections were counterstained with hematoxylin (Merck, Darmstadt, 
Germany) and mounted with imsol (Klinipath, Duiven, the Netherlands). Quantification of 
immunohistochemistry was performed in a blinded manner by assessing ten consecutive 
high power fields (magnification, ×200) of myocardial and endomyocardial tissue on each 
section. Using Image J software®, the positive area in each image expressed in pixels was 
determined.
Plasma measurements
sC5b-9 and C5a levels were assessed by sandwich ELISA. In brief, 96-well ELISA plates 
(Nunc Bioscience, Belgium) were coated with a monoclonal antibody to a neo-epitope on 
C5b-9 (aE11; Hycult Biotechnology, Uden, The Netherlands) or monoclonal antibody to 
C5a (HM2079b; Hycult Biotechnology, Uden, The Netherlands), respectively. Plasma was 
incubated in the coated well and bound sC5b-9 or C5a was detected with a biotin-labeled 
monoclonal anti-C6 antibody (9C4; Hycult Biotechnology, Uden, The Netherlands) or anti-
C5a antibody (CL.561; Hycult Biotechnology, Uden, The Netherlands), respectively, followed 
by detection with streptavidin–poly-HRP (Sanquin, Amsterdam, The Netherlands). Enzyme 
activity was detected using 2,2-azino-bis3-ethylbenzothiazoline-6-sulphonic acid (Sigma 
Chemical Co., St. Louis, MO, USA). The optical density was measured at 415 nm using a 
microplate reader (Model 680; Biorad, Philadelphia, PA, USA). The detection limit for C5a 
was 1.95 ng/mL and for C5b-9 0.01 U/mL.
Statistical analysis
Differences between patient groups were analyzed using the Kruskal-Wallis test with post-
hoc analyses with Mann-Whitney U-tests whenever appropriate. Categorical variables were 
compared using the Chi-square test. Comparisons between baseline values and values at 24 
hours after reperfusion were analyzed with a Wilcoxon signed ranks test. The area under the 
curve (AUC) was calculated for the arterial and venous curves of the plasma measurements 
for the early (0-60 minutes) reperfusion phase. A delta AUC was calculated (venous minus 
arterial) and the null-hypothesis (delta AUC is 0) was tested by a paired t-test. Statistical 
analysis was performed using SPSS statistical analysis software version 17.0 (SPSS Inc, 
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ReSultS
Patient population
Patient characteristics and perioperative details are summarized in Table 1. Two patients 
died in hospital: one patient with non-ischemic heart failure died eight days after surgery 
as a result of ventricular fibrillation and the other patient with ischemic heart failure 
died 41 days after surgery as a result of therapy-resistant heart failure after a ventricular 
reconstruction. 
Immunohistochemistry
To evaluate whether local complement deposition plays a role in myocardial I/R injury, 
presence and localization of C3d and C5b-9 were studied in human left ventricular tissue 
collected in the early phase of the ischemic period of the heart, i.e. the pre-reperfusion 
phase. No differences in deposition of C3d and C5b-9 were observed between the early and 
late pre-reperfusion biopsies (Supplementary data, Figure 1). Therefore, only the early pre-
reperfusion biopsies were used, as read-out for preoperative involvement of complement 
activation. Immunohistochemical stainings showed deposition of C3d and C5b-9 in the 
vascular wall of small arteries in all pre-reperfusion biopsies (Figure 2). 
C3d and C5b-9 deposition in myocardial tissue
Patients with non-ischemic heart failure showed the most abundant myocardial depositions 
of C3d and C5b-9: 4.8 times more C3d (P = 0.008) and 4.7 times more C5b-9 (P = 0.004) 
than donors. C3d deposition was accompanied by extensive C5b-9 deposition in patients 
with non-ischemic heart failure, which was less pronounced in patients with ischemic heart 
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figure 2. c3d and c5b-9 depositions in pre-reperfusion myocardial tissue. 
Early ischemic myocardial tissue of patients with non-ischemic heart failure (NIHF), ischemic 
heart failure (IHF), non-heart failure patients (NHF) and donors were stained for C3d and C5b-9. 
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figure 3. Quantification of complement deposition in myocardial tissue. 
The amount of C3d was significantly different between patients with non-ischemic heart failure and 
donors (P = 0.008). Also C5b-9 was significantly higher in tissue of patients with non-ischemic heart 
failure compared with donor tissue (P = 0.004). Graph error bars represent mean ± SEM. 
Abbreviations: IHF, ischemic heart failure; NHF, non-heart failure; NIHF, non-ischemic heart failure. 
C3d and C5b-9 deposition in endomyocardial tissue
Unexpectedly, a distinct difference in C3d deposition was observed in the pre-reperfusion 
endomyocardial tissue of the various patient groups (Figure 4). C3d deposition was abundantly 
present in endomyocardial tissue of both patients with non-ischemic and ischemic heart 
failure in comparison to donor biopsies (both P = 0.02, Figure 5). This C3d deposition was, 
however, not correlated to preoperative NT-proBNP values (data not shown). No significant 
differences in endomyocardial C5b-9 deposition were observed between the groups 
(P = 0.06). Overall, endomyocardial tissue showed less C5b-9 deposition in all groups 
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figure 4. c3d and c5b-9 deposition in pre-reperfusion endomyocardial tissue. 
Early ischemic endomyocardial tissue of patients with non-ischemic heart failure (NIHF), ischemic 
heart failure (IHF), non-heart failure patients (NHF), and donors were stained for C3d and C5b-9. 
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figure 5. Quantification of complement deposition in endomyocardial tissue. 
C3d was abundantly present in tissue of both patients with non-ischemic (NIHF) and ischemic heart 
failure (IHF) compared with donor tissue (both P = 0.02). Similar endomyocardial C5b-9 deposition was 
observed between the groups (P = 0.06). Graph error bars represent mean ± SEM. 
Abbreviations: IHF, ischemic heart failure; NHF, non-heart failure; NIHF, non-ischemic heart failure. 
Plasma measurements
Assessment of complement depositions of C3d and C5b-9 in pre-reperfusion biopsies 
indicated clearly that the complement system was activated in the very early stages of 
ischemia. To assess also plasma complement activation in the reperfusion phase, terminal 
complement complex activation was evaluated by measuring the release of sC5b-9 from 
the heart. This sC5b-9 release was assessed in the simultaneously collected systemical and 
myocardial venous blood samples. In addition, C5a was measured to assess whether the 
more upstream complement cascade is activated without causing the formation of the 
sC5b-9 complex (Figure 6). 
No myocardial release or uptake of C5a or sC5b-9 in the early reperfusion phase
No significant differences in sC5b-9 or C5a were measured over the heart, indicating 
the absence of net release of both complement activation markers from the reperfused 
heart during the first 60 minutes of reperfusion (Table 2). This suggests that the observed 
complement deposition in myocardial tissue was generated already in the preoperative 
phase. 
Similar levels of C5a and sC5b-9 at baseline and 24 hours after reperfusion
Not only arteriovenous concentration differences were studied. Similar baseline systemic 
levels of C5a (P = 0.31) and sC5b-9 (P = 0.75) were observed between the three patient 
groups the day before surgery. Also at 24 hours after reperfusion, similar systemic levels of 
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and sC5b-9 returned even to baseline levels within 24 hours after reperfusion in all patient 
groups with the exception of slightly lower sC5b-9 values in patients with ischemic heart 
failure (P = 0.03). 
Figure 6. no local C5a and sC5b-9 release or uptake during the early myocardial reperfusion phase. 
No arteriovenous differences, expressed as mean ± SEM, were observed in all three patient groups: 
patients with non-ischemic heart failure (NIHF) [(A) = C5a, P = 0.20; (D) = sC5b-9, P = 0.30] and ischemic 
heart failure (IHF) [(B) = C5a, P = 0.051; (E) = sC5b-9, P = 0.08], and non-heart failure patients (NHF) [(C) 
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nIHF c5a (μg/mL*min) 2.20 (1.35-3.15) 2.29 (1.39-3.12) 0.09 0.20
C5b-9 (u/ml*min) 407.47 (242.44-536.83) 406.85 (181.22-621.05) -0.62 0.30
IHF c5a (μg/mL*min) 4.83 (3.20-6.24) 4.35 (2.84-6.90) -0.48 0.051
C5b-9 (u/ml*min) 271.32 (138.71-410.24) 269.24 (126.65-390.05) -2.08 0.08
nHF c5a (μg/mL*min) 3.31 (2.30-3.65) 3.32 (2.03-4.19) 0.01 0.12
C5b-9 (u/ml*min) 287.18 (247.76-332.85) 300.92 (222.07-355.85) 13.74 0.51
No release by the myocardium was observed for C5a or C5b-9 in patients with non-ischemic heart failure 
(NIHF), ischemic heart failure (IHF), and non-heart failure patients (NHF). A positive delta area under the 
curve (AUC) indicates a myocardial release of C5a or C5b-9, whereas a negative delta AUC represents a 
myocardial uptake. Means of the AUCs and interquartile ranges are shown. 
DISCuSSIon
It is generally accepted that complement plays a major role in myocardial I/R injury. However, 
since clinical trials consistently fail to show clinical relevant benefits of complement 
inhibitors, the role of complement activation in human myocardial I/R injury should be 
considered carefully. 
The present clinical study shows that myocardial C3d and C5b-9 depositions are already 
present in early left ventricular pre-reperfusion biopsies. Most abundant deposition was 
observed in patients with non-ischemic heart failure. Endomyocardial biopsies, on the other 
hand, show clear depositions for C3d in both patients with non-ischemic and ischemic heart 
failure. These abundant early endomyocardial C3d depositions might be an underlying 
mechanism of heart failure, since these biopsies were used as read-out for preoperative 
involvement of complement activation. In addition, when comparing the heart failure groups 
with the donor group, also early endomyocardial C5b-9 deposition seems higher in the 
heart failure groups although not significantly different. Using our model of arteriovenous 
measurements, our results strongly suggest that terminal complement activation is not 
involved in the acute phase following myocardial reperfusion. 
The observed myocardial and endomyocardial depositions of C3d and C5b-9 in our study 
are in line with previous human studies. However, these studies used autopsy or allograft 
tissue to investigate myocardial complement deposition. To our best knowledge, this is the 
first time that viable myocardial tissue is used to study myocardial and endomyocardial 
complement deposition. Nijmeijer et al. used autopsy tissue of patients who died as a result 
of an acute myocardial infarction.15 Depositions of C3d and C5b-9 in patients treated with 
reperfusion or suffering from reinfarction were compared with depositions of both markers 
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reperfusion therapy showed more depositions of these two complement activation markers. 
Unfortunately, no comparisons between their and our study could be made for activation 
of complement components in plasma, since no plasma measurements were performed in 
addition to immunohistochemistry. In a study of Jenkins et al. myocardial tissue, obtained 
by autopsy, was stained for C4d and C9 after myocardial infarction.16 Normal myocytes were 
non-reactive, whereas necrotic myocytes reacted strongly with the C4d and C9 antibodies. 
In our study, allograft tissue from donor hearts stained also negative for C3d and C5b-9. 
As a result of the clear complement depositions in pre-reperfusion biopsies in our 
study, we were interested in the myocardial release of complement components upon 
myocardial reperfusion. By measuring arteriovenous differences over the reperfused organ, 
we were able to obtain data on local release of sC5b-9 and C5a from the heart. However, 
arteriovenous concentration differences did not indicate a myocardial release or uptake of 
C5a or sC5b-9. 
Although no sC5b-9 or C5a release was observed in any of the tested groups, there was 
a remarkable increase in systemical sC5b-9 levels observed upon reperfusion in comparison 
to baseline, indicating activation of the immune system. This increase in complement 
components is in line with previous studies.5, 17, 18 Remarkably, C5a levels were relatively 
high in patients with ischemic heart failure (e causa ignota). There might be a less effective 
uptake and removal of C5a from plasma by granulocytes via cellular receptors such as 
leucocyte C5a receptors. There also might be a difference in carboxypeptidase N activity 
between the patient groups. This enzyme cleaves the COOH-terminal arginine from C5a 
forming C5a des arginine. This C5a/C5a(desArg) complex has been measured with our C5a 
assay. The systemic increase of C5a and C5b-9 is not related to release of both activation 
markers from the heart, since our arteriovenous measurements over the heart did not show 
such a release. The systemic increase might be explained by the use of CPB and the surgical 
injury itself. However, the exact source remains to be unravelled. Baseline levels were similar 
between heart failure patients and non-heart failure patients in our study. This is in contrast 
to a study of Yasuda et al., which showed increased levels of C3 split-products and sC5b-9 in 
patients with ischemic heart failure.19 The increased baseline levels in their study might be 
explained by the fact that their patients suffered an acute myocardial infarction before the 
plasma measurements. Our patients did not have an acute myocardial infarction prior to 
cardiac surgery and were classified as chronic heart failure patients. 
Despite the fact that in animal studies of myocardial I/R injury beneficial effects are 
observed following complement inhibition4, 8, 9, only few complement inhibitors reached 
clinical trials such as anti-C5 antibodies20, soluble complement receptor 1 (TP10)21 and C1-
esterase inhibitor.11 However, all consistently show minute and inconsistent effects of anti-
complement therapy in humans. These disappointing results raise the question whether 
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and adaptive immunity.22 Another explanation might be that there is a narrow window 
of clinical opportunity in humans when treatments can be therapeutically effective23, 
depending on timing, tissue penetration, patient characteristics, single versus multiple 
cycle administration and many others. Based on our results, it may be more beneficial to 
use complement inhibitors during the chronic state of heart failure by contributing to anti-
inflammatory processes instead of during reperfusion. Furthermore, it might be that in 
humans complement is not really a key mediator of reperfusion injury. This may well explain 
the unsuccessful outcomes of anti-complement therapy during the early reperfusion phase 
so far. 
Limitations
Our results show that terminal complement activation is not involved in the initiating phase 
of myocardial I/R injury. However, we only focused on the first 60 minutes of reperfusion and 
complement activation may result from other processes later in the cascade of I/R injury. 
This is confirmed in an animal study following renal I/R injury in which C3 deposition was 
present two hours after reperfusion although C6 and C9 depositions were present twelve 
hours after reperfusion.24 Complement might therefore have a role in repair or removal 
of damaged cells in the late reperfusion phase instead of an initiating role in the acute 
reperfusion phase. This concept matches the observed depositions of C5a and C5b-9 in 
patients with heart failure in our present study, who are already exposed to damage before 
surgery. In this study, only ischemic pre-reperfusion biopsies could be collected since most of 
the included heart failure patients were hemodynamically instable in the early reperfusion 
phase. Myocardial tissue obtained during human autopsy is known for excessive deposition 
of C5b-9.15 Therefore, biopsies of human myocardial allografts were preferred as control 
tissue. However, also in these biopsies some C5b-9 deposition might be observed as a result 
of the brain-death situation of the donor25 but due to ethical concerns no left ventricular 
biopsies were taken in healthy people. Therefore, biopsies of patients without heart failure 
were valuable as additional controls, although we can not exclude cellular changes based 
on their valvular disease. As the goal of this study was to assess the basic pathophysiological 
role of complement activation in the process of I/R injury instead of correlating findings 
to clinical outcome, small patient numbers were sufficient. However, some results were 
close to significant values which might be related to the small sample size. At last, aortic 
cross-clamping times and CPB times were different between the patient groups, although 
no correlations were observed between these durations and the measured complement 
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Conclusion
Our findings do not support a prominent role for terminal complement activation in the 
acute phase following myocardial reperfusion. This is of major importance for the focus on 
therapeutic interventions currently being explored for human myocardial I/R injury, since 
clinical anti-complement therapies have not led to appreciable clinical relevant beneficial 
effects so far. However, complement depositions of C3d and sC5b-9 were present before 
reperfusion in myocardial tissue, especially in patients with heart failure. This probably 
preoperative depositions might be an underlying mechanism of the syndrome of heart 
failure. Therefore, it may be more beneficial to use complement inhibitors during the 
chronic state of heart failure instead of during the acute phases of reperfusion.
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supplementary data, figure 1. Quantification of c5b-9 depositions in early and late pre-reperfusion 
myocardial tissue. 
The amount of C5b-9 was similar between early and late pre-reperfusion biopsies in all patient groups 
(Wilcoxon signed ranks test; non-ischemic heart failure (NIHF) P = 0.89, ischemic heart failure (IHF) 
P = 0.69, non-heart failure (NHF) P = 0.89, and donors P = 1.00). Graph error bars represent mean ± 
SEM. 
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AbStRACt
background: The pathophysiology of ischemia/reperfusion (I/R) injury is complex and 
poorly understood. Preclinical studies implicate platelets in the inflammatory response 
upon reperfusion. However, their role in clinical myocardial I/R is unknown. 
Methods: Patients undergoing scheduled I/R during mitral valve surgery were included. 
Paired arterial and myocardial venous blood samples, collected at timed intervals during 
the first hour post-reperfusion, allowed for cardiac-selective evaluation in time. We 
evaluated platelet counts, and established circulating markers of platelet activation (soluble 
P-selectin, RANTES, CXC chemokine ligand-8, and beta-thromboglobulin), and tested the 
responsiveness of platelets.
Results: In total, 39 patients were included: 20 patients with and 19 patients without left 
ventricular (LV) dysfunction. Platelet count was reduced at the start of reperfusion (P < 0.001), 
mainly due to hemodilution. Remarkably, reperfusion was not associated with myocardial 
release of platelet activation markers, except for minimal release of CXC chemokine ligand-8 
in patients with LV dysfunction (P = 0.02). Absent release of platelet activation markers can 
be accredited to a lack of platelet activation or to platelet desensibilisation. Therefore, a 
bedside platelet excitability assay was performed in which platelets were stimulated and 
their response measured, showing a reduced post-reperfusion responsiveness of platelets. 
Conclusions: Our studies indicate that platelets are not activated in early myocardial I/R 
injury in both patients with or without LV dysfunction. These findings suggest that platelets 
do not initiate the inflammatory response that is associated with I/R, indicating that 
preclinical evidence of platelet activation upon reperfusion can not directly be translated 
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IntRoDuCtIon
Ischemia/reperfusion (I/R) injury is the paradoxical increase of tissue damage upon 
reperfusion of ischemic tissue. This injury is an inherent component of cardiac surgery with 
artificial arrest and subsequent myocardial reperfusion. The pathophysiology of myocardial 
I/R injury is complex and incompletely understood. I/R is dominated by inflammation1, 2, but 
the mechanisms initiating these inflammatory responses are unknown. 
In addition to their well-defined role in hemostasis, platelets also serve as specialized 
cells of the innate immune system and modulators of inflammatory responses. Upon 
activation, platelets secrete various mediators into the circulation by exocytosis3, 4, such as 
leukotrienes, sP-selectin, beta-thromboglobulin (beta-TG), platelet-derived growth factor 
(PDGF), and RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted), 
which can all contribute to the inflammatory response upon reperfusion by recruitment and 
activation of leukocytes.5 Currently, preclinical evidence implies the activation of platelets as 
a major contributor to ischemia/reperfusion (I/R) injury.6-9
In contrast to ample preclinical data, involvement of platelets as key mediators in human 
I/R in general, and more specifically in myocardial I/R injury, is unclear with the current 
data.10-12 Given the lack of clinical data, we performed a prospective study that aimed to 
evaluate platelet activation during controlled human myocardial I/R. We used the approach 
of consecutive arteriovenous differences, which allowed for discrimination between 
systemic platelet activation (as consequence of the surgery and the use of cardiopulmonary 
bypass), and myocardial reperfusion-related activation of platelets in time. Results of these 




Myocardial I/R was studied in 39 patients with mitral regurgitation undergoing mitral valve 
surgery with aortic cross-clamping. Within this group, 20 patients had left ventricular 
(LV) dysfunction. These two clinical groups, patients with and without LV dysfunction, 
were studied separately, as I/R may be influenced by a preexisting heart condition. In 
patients without LV dysfunction (control subjects), the mitral regurgitation was caused by 
organic pathology, with a predominance of prolapse disease. All patients were scheduled 
for restrictive mitral annuloplasty (RMA) ring implantation, with or without additional 
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minimal invasive surgical procedures, emergency operations, and previous cardiac surgery. 
This study was approved by the local ethics committee, and written informed consent was 
obtained from each patient.
Surgical procedures 
All participating patients received standardized anesthetic procedures, according to a fast-
track protocol.13 Cardiac surgery was performed according to local standardized protocols. 
All surgical procedures were performed via a midline sternotomy under normothermic CPB 
(Jostra Maquet, Maquet, Hirrlingen, Germany) with intermittent antegrade warm-blood 
cardioplegia and heparin softline coating. A uniform CPB protocol was designed, excluding 
autologous priming and ultrafiltration. 
Arteriovenous measurements
Prior to surgery, a 5 French indwelling jugular vein catheter (PICC, Arrow International Inc., 
REF PS-01651, PA, USA) was inserted in the right atrium and placed in the coronary sinus by 
the surgeon. Since all patients underwent mitral valve surgery using a vertical transseptal 
incision, the coronary sinus could easily be cannulated during the surgical procedure. An 
arterial catheter was placed into the radial artery according to standard care. Arterial and 
myocardial venous blood samples were collected directly over the reperfused heart, that is 
from the radial artery (arterial) and coronary sinus (venous). These paired blood samples 
were obtained at 0, 15, 30, 45, and 60 minutes after reperfusion (after declamping of the 
aorta). Moreover, a systemic baseline sample was taken the day prior to surgery from the 
brachial vein. All samples were collected in pre-cooled tubes containing EDTA (BD Vacutainer, 
Plymouth, UK) and immediately placed in an ice water bath. In a pre-study evaluation, effects 
of storage conditions on platelet activation were analyzed. Blood samples were centrifuged 
(1,550 g, 10 min, 4°C) and the derived plasma was re-centrifuged (10,000 g, 4 min, 4°C) to 
obtain leukocyte and thrombocyte-free plasma. Aliquots were stored at -70°C until analysis.
Laboratory plasma measurements
Plasma measurements
Plasma levels of sP-selectin and RANTES were determined using a semi-automated enzyme-
linked immunosorbent assay (ELISA) on a TECAN Freedom Evo robot. ELISA plates (384 wells, 
Maxisorp, cat no. 460372) were coated overnight (4°C) with coating buffer. Established 
human ELISA antibody duosets were used (sP-selectin, duoset DY137, R&D systems; anti-
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beta-TG were measured manually with commercially available antibodies (human beta-TG, 
MAB393, R&D systems, Abingdon, UK). Plasma levels of CXC chemokine ligand-8 (CXCL-8) 
were measured on the Bio-Plex system according to manufacturer’s instructions (Biorad, 
Veenendaal, The Netherlands). 
Platelet counts
Baseline platelet counts (day before surgery) and platelet counts for the arterial and 
coronary sinus samples collected at 0, 30, and 60 minutes after reperfusion were assessed 
(Sysmex XE-2100, Sysmex Corporation, Kobe, Japan). 
Platelet activation and responsiveness
A novel bedside applicable assay was developed to explore more subtle changes in 
responsiveness of platelets. We determined the platelet responsiveness to agonists with 
serial dilutions of adenosine diphosphate (ADP), collagen-related peptide (C-RP), and 
trombin receptor-activating peptide (TRAP). Serial dilutions of ADP (125 μM, 31 μM, 8 μM, 
2 µM, 500 nM, 125 nM, 31 nM, and 8 nM) were prepared in HEPES buffered saline (HBS; 10 
mM HEPES, 150 mM NaCl, 1 mM MgSO4, 5 mM KCl, pH 7.4) with PE-labeled mouse anti-
human P-selectin antibodies (diluted 1: 25). Similarly, serial dilutions of C-RP (2.5 μg/mL, 
625 ng/mL, 156 ng/mL, 39 ng/mL 10 ng/mL, 2.5 ng/mL, 625 pg/mL, and 156 pg/mL) were 
prepared in HBS with PE-labeled mouse anti-human P-selectin antibodies (diluted 1:25). 
Furthermore, serial dilutions of TRAP (625 nM, 156 nM, 39 nM, 10 nM, 2.5 nM, 625 pM, 
156 pM, and 156 pM) were prepared in HBS with PE labeled mouse anti-human P-selectin 
antibodies (diluted 1: 25). 
The platelet activation test was initiated by addition of 5 μL fresh, citrate-anticoagulated, 
whole blood to each sample of the serial dilutions directly in the operating room. Samples 
as described above were used at various time points: baseline, and at 0, 30, and 60 minutes 
after reperfusion (both arterial and myocardial venous). After 20 minutes of incubation, the 
samples were fixed with 500 μL 0.2% formyl saline (0.2% formaldehyde in 0.9% NaCl, filtered 
through a 0.22 μm filter) and kept at 4°C until analyses. After an additional 1:4 dilution 
in 0.2% formyl saline, all samples were analyzed on a Beckman Coulter Cytomics FC500 
flow cytometer (Beckman and Coulter, Krefeld, Germany) the same day after processing 
to assess the activation state and responsiveness of platelets. Samples were analyzed on 
GP1b positivity (all platelets) and P-selectin positivity (activated platelets). Analysis involved 
assessment of the maximum percentage of activated platelets (% P-selectin positive) and 
their intensity of activation (mean fluorescence index; MFI). Each serial dilution resulted in 
a typical sigmoid shaped curve. In other words, the percentage activated platelets increased 
with the concentration of the agonist in this sigmoid shaped curve. As a result, two different 
quantitative values were derived from these curves: (1) the area under the curve (AUC) and 
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Statistical analysis
All statistical analyses were performed with the Statistical Package for the Social Sciences 
20.0 (SPSS Inc., Chicago, IL, US). Clinical characteristics were compared using the Chi-Square 
test for the categorical data and the Mann-Whitney U-test for the numerical data, expressed 
as medians and interquartile ranges or frequencies (Table 1). Baseline plasma measurements 
were compared using a Mann-Whitney U-test, and expressed as medians and interquartile 
ranges (Table 2). Area under the curves (AUCs) were calculated for the arterial and coronary 
sinus blood levels of all three platelet activation markers. Arteriovenous AUC’s and platelet 
counts were analyzed by a paired t-test, expressed as mean ± SEM. The excitability of 
platelets was evaluated in GraphPad Prism Software (Graphpad Software 5.01, Inc., San 
Diego, CA, USA) by the maximal MFI and AUC. The maximal MFI and AUC were analyzed 
by a Wilcoxon-signed rank test comparing baseline levels with levels early after reperfusion 
and arteriovenous differences at 0, 30, and 60 minutes after reperfusion. A P value < 0.05 
was considered significant. 
ReSultS
Patient population
This explorative study included 39 patients undergoing mitral valve surgery for severe mitral 
regurgitation. Clinical characteristics of patients with and without LV dysfunction are shown 
in Table 1. Two patients in the LV dysfunction group died: one patient died in hospital eight 
days after surgery as a result of ventricular fibrillation and the other patient died in hospital 
42 days after surgery as a result of therapy-resistant heart failure. 
Platelet activation and ischemia/reperfusion
No platelet activation in the reperfused heart
Patients with LV dysfunction show higher baseline values of sP-selectin (P = 0.03), and slightly 
higher values of RANTES (P = 0.06) as compared with patients without LV dysfunction, while 
the levels of CXCL-8 and the platelet-specific marker beta-TG were similar in the two groups 
(Table 2). Reperfusion was not associated with a myocardial release of sP-selectin, RANTES, 
or beta-TG in patients with LV dysfunction (P = 0.42, P = 0.51, and P = 0.67, respectively) 
as well as in patients without LV dysfunction (P = 0.07, P = 0.73, and P = 0.29, respectively; 
Figure 1). Myocardial release of CXCL-8 was observed in patients with LV dysfunction 
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table 1. clinical characteristics of patients with left ventricular dysfunction and controls.
all patients LV dysfunction Controls P value
n = 39 n = 20 n = 19
Clinical characteristics
   Age (years) 65 (57-74) 65 (57-72) 65 (55-76) 0.78
   Male gender (n) 24 (62%) 13 (65%) 11 (58%) 0.65
   body Mass Index (kg/m2) 27 (24-29) 28 (25-30) 26 (23-28) 0.20
   Systolic blood pressure (mmHg) 125 (115-140) 118 (105-130) 130 (120-144) 0.004*
   Diastolic blood pressure (mmHg) 70 (65-80) 65 (60-80) 75 (70-80) 0.03*
   Hemoglobin (mmol/l) 8.6 (8.1-9.2) 8.3 (7.8-9.0) 8.9 (8.5-9.5) 0.03*
   creatinine (μmol/L) 86 (74-103) 90 (74-109) 85 (74-98) 0.42
   nt-probnP (ng/l) 1242 (578-2295) 1954 (836-2610) 849 (90-1132) 0.003*
   Logistic EuroscoRE (%) 5.97 (3.07-9.79) 8.66 (5.97-14.09) 3.07 (1.51-6.22) < 0.001*
   nyha functional class 3 (2-3) 3 (3-3) 2 (1-2) < 0.001*
Comorbidities 
   Diabetes (n) 9 (23%) 7 (35%) 2 (11%) 0.07
   CoPD (n) 7 (18%) 5 (25%) 2 (11%) 0.24
   AF (n) 11 (28%) 6 (30%) 5 (26%) 0.80
Medication
   acE-inhibitors / aRBs (n, %) 27 (69%) 17 (85%) 10 (53%) 0.03*
   Beta-blockers (n, %) 28 (72%) 19 (95%) 9 (47%) 0.001*
   statins (n, %) 22 (56%) 16 (80%) 6 (32%) 0.002*
   Diuretics (n, %) 28 (72%) 19 (95%) 9 (47%) 0.001*
   Digoxins (n, %) 7 (18%) 4 (20%) 3 (16%) 0.73
Echocardiography
   lVeSV (ml) 92 (62-113) 110 (96-156) 62 (53-72) < 0.001*
   lVeDV (ml) 146 (135-194) 159 (139-218) 135 (128-154) 0.01*
   LVEf (%) 39 (32-54) 32 (26-33) 54 (49-60) < 0.001*
Surgical characteristics
   aortic cross-clamp time (min) 120 (94-159) 112 (88-182) 125 (105-155) 0.52
   cPB time (min) 178 (140-212) 197 (133-241) 176 (149-200) 0.54
   surgery time (min) 310 (255-352) 338 (277-389) 288 (247-319) 0.03*
Postoperative characteristics
   CPK directly in ICu (u/l) 613 (498-936) 656 (411-1425) 580 (500-899) 0.46
   CPK 6 hours in ICu (u/l) 850 (594-1304) 923 (596-1621) 736 (594-1269) 0.22
   CPK 12 hours in ICu (u/l) 971 (612-1519) 1117 (560-2101) 803 (630-1388) 0.25
   troponin t directly in ICu (ng/l) 1.07 (0.76-1.51) 1.07 (0.76-1.47) 1.07 (0.75-1.62) 0.67
   troponin t 6 hours in ICu (ng/l) 1.33 (0.82-1.78) 1.29 (0.83-1.91) 1.36 (0.76-1.81) 0.86
   troponin t 12 hours in ICu (ng/l) 0.91 (0.64-1.82) 0.91 (0.64-2.04) 0.92 (0.58-1.61) 0.51
   total ICu stay (hours) 24 (21-69) 57 (21-86) 22 (21-24) 0.01*
   total stay in hospital (days) 13 (10-19) 14 (10-26) 13 (10-17) 0.45
Medians and interquartile ranges are shown unless stated otherwise. * P values are given for the comparisons 
of patients with LV dysfunction and controls (patients without LV dysfunction). 
Abbreviations: ACE, Angiotensin Converting Enzyme; AF, Atrial Fibrillation; ARB, Angiotensin Receptor 
Blocker; CPK, creatine phosphokinase; COPD, Chronic Obstructive Pulmonary Disease; CPB, Cardiopulmonary 
Bypass; ICU, Intensive Care Unit; LVEDV, Left Ventricular End-Diastolic Volume; LVEF, Left Ventricular Ejection 
Fraction; LVESV, Left Ventricular End-Systolic Volume; NT-proBNP, N-Terminal-proB-type Natriuretic Peptide; 
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figure 1. no myocardial release of platelet activation markers upon reperfusion.
Arteriovenous differences were used to determine the myocardial release of soluble P-selectin, 
RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted) and beta-thromboglobulin 
(beta-TG). The differences in area under the curve of the arterial and myocardial venous curves 
were assessed to quantify the net release from the myocardium. No arteriovenous differences were 
observed in both patient groups, despite a myocardial release of CXC chemokine ligand-8 in patients 
with LV dysfunction. Of note, time point zero is several seconds after the release of the aortic cross-
clamp and not the baseline value (the day before surgery). Graph error bars indicate the standard 
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table 2. Baseline values of patients with left ventricular dysfunction and controls.
all patiens LV dysfunction Controls P value





















Higher baseline values of soluble P-selectin (sP-selectin) were found in patients with LV dysfunction 
compared with controls (patients without LV dysfunction). Details are noted as medians (interquartile 
ranges). * indicates level of significance (P < 0.05) reached. 
Abbreviations: Beta-TG, Beta-Thromboglobulin; CXCL-8, CXC Chemokine Ligand-8; LV, Left Ventricular; 
RANTES, Regulated upon Activation, Normal T-cell Expressed, and Secreted. 
Thrombocytes are not retained in the heart
Thrombocyte counts of arterial and myocardial venous blood samples were determined, 
as differences in these levels could strongly influence the above described plasma 
measurements of sP-selectin, RANTES, beta-TG, and CXCL-8. To evaluate thrombocyte 
retention, arterial and myocardial venous number of thrombocytes were measured directly 
upon reperfusion, and at 30 and 60 minutes after reperfusion. The number of thrombocytes 
was found to be 50% reduced in comparison to the levels observed the day before surgery 
(P < 0.001). The present practice of CPB, which entails the addition of ≥ 1.5L of non-hematic 
fluids to the patient’s blood volume, to prime the CPB circuit, frequently results in marked 
hemodilution. The reduction in number of thrombocytes can therefore be largely explained 
by hemodilution, since the hematocrit levels dropped with 36%. We did not observe 
differences in the number of arteriovenous thrombocytes within the first hour following 
reperfusion of the myocardium (Figure 2). In summary, thrombocyte counts were stable 
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Figure 2. thrombocytes are not retained in the heart.
(A) Thrombocyte counts were similar in arterial (A) and myocardial venous (V) blood collected 
at 0 (respectively A0 and V0, P = 0.38), 30 (respectively A30 and V30, P = 0.60), and 60 minutes 
(respectively A60 and V60, P = 0.96) after reperfusion. Upon reperfusion, the number of thrombocytes 
was significantly reduced in comparison to baseline (dark grey) as a result of hemodilution by use 
of cardiopulmonary bypass (P < 0.001). (B) Hematocrit levels decreased significantly after use of 
cardiopulmonary bypass compared with baseline (P < 0.001). Graph error bars indicate the standard 
error of the mean (SEM).
Platelet excitability assays  
A novel bedside assay was used to evaluate the responsiveness of platelets in the presence 
of various agonists. With this method, more subtle changes in platelet responsiveness 
may be induced when platelets pass through the heart. These results were in line with our 
arteriovenous measurements of plasma markers, which revealed a lack of platelet activation 
during reperfusion. After in vitro stimulation of arterial and myocardial venous blood 
with the platelet activation agonists ADP, C-RP, and TRAP, the maximum total percentage 
of activated platelets (AUC) and the maximal mean fluorescence index (MFI) of activated 
platelets were measured. Reduced responsiveness of platelets upon reperfusion was 
observed, as indicated by attenuated P-selection expression on platelets, as evidenced by 
the AUC (Figure 3) and maximal MFI (Figure 4). Our approach of consecutive arteriovenous 
differences to assess the myocardial reperfusion-related activation of platelets did show 
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Figure 3. Reduced responsiveness of platelets upon reperfusion as evidenced by the area under the 
curves.
Graphs represent the area under the curves (AUCs) for the serial dilution series of (A) adenosine 
diphosphate (ADP), (B) collagen-related peptide (C-RP), and (C) trombin receptor-activating peptide 
(TRAP) per time point early after reperfusion. The P-selection expression on platelets was markedly 
reduced directly after reperfusion in comparison to baseline (dark grey). No arteriovenous differences 
were found for the AUC in coronary sinus blood (respectively V0, V30, and V60) as compared with arterial 
blood (respectively A0, A30, and A60) the first hour after reperfusion. * indicates level of significance 
(P < 0.05) reached. Error bars indicate the standard error of the mean (SEM).  
Figure 4. Reduced responsiveness of platelets upon reperfusion as evidenced by the maximal 
median fluorescence intensity. 
Graphs represent the maximal median fluorescence intensity (max. MFI) for the serial dilution series 
of (A) adenosine diphosphate (ADP), (B) collagen-related peptide (C-RP), and (C) trombin receptor-
activating peptide (TRAP) per time point early after reperfusion. The max. MFI % P-selection expression 
on platelets was markedly reduced directly after reperfusion in comparison to baseline (dark grey). 
No arteriovenous differences were found for the max. MFI in coronary sinus blood (respectively V0, 
V30, and V60) as compared with arterial blood (respectively A0, A30, and A60) the first hour after 
reperfusion. * indicates level of significance (P < 0.05) reached. Error bars indicate the standard error 
of the mean (SEM).
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DISCuSSIon
Preclinical evidence implies activated platelets as a contributing factor to I/R injury.6-9 In 
contrast to these data, involvement of platelets as a factor in human I/R in general, and 
more specifically in myocardial I/R injury, currently remains unclear. Results of this clinical 
study show that platelet activation is minimal or even absent in myocardial I/R, in contrast 
to findings from preclinical models.6-9 In addition, a reduced responsiveness of platelets was 
observed upon myocardial reperfusion. 
Platelet activation upon myocardial reperfusion was studied in two separate patient 
groups, patients with and without LV dysfunction. This subdivision was made as patients 
with LV dysfunction may be more susceptible to myocardial I/R injury.14 Platelet activation 
was therefore expected to be more pronounced in patients with LV dysfunction. We 
observed higher levels of sP-selectin and modestly increased levels of RANTES at baseline 
(the day before surgery), yet the platelet specific marker beta-TG was similar between the 
two patient groups. As such, it is more likely that these elevated levels reflect preoperative 
endothelial cell activation in patients with LV dysfunction.15 
Cardiospecific platelet activation was measured by assessing arteriovenous differences 
of sP-selectin, RANTES, beta-TG, and CXCL-8. Of all measured factors, only CXCL-8 was found 
to be released from the reperfused heart in patients with LV dysfunction. Since the other 
platelet activation markers were not released by the reperfused heart, it is more likely 
that CXCL-8 is a component of an early pro-inflammatory response.16 The principal cellular 
sources of CXCL-8 are monocytes, macrophages, fibroblasts and endothelial cells.17 The 
absence of a detectable release of platelet activation markers in our study is in line with 
the study of Sbrana et al.18 Using fluorescence-activated cell sorting, Sbrana et al. did not 
observe platelet activation after cardiac surgery in either coronary sinus or peripheral blood. 
It must be noted however, that our study was restricted to a sample collection time shortly 
after reperfusion. I/R injury is generally considered an acute process, one that is initiated 
directly after reperfusion. We can not exclude the possibility of platelet activation during the 
later phases of myocardial I/R injury, nor in other organs.
The absence of platelet activation upon early reperfusion can potentially be accredited to 
either the absence of activation signals or to the desensibilisation of the platelets. Here, we 
detail excitability assays that were designed to evaluate the latter possibility, which revealed 
markedly reduced P-selectin expression on platelets directly upon reperfusion. These 
results suggest that activated platelets remain in the CPB, which could be an explanation 
for our inability to detect differences in arteriovenous concentrations of beta-TG, RANTES 
and sP-selectin. Of note, total number of platelets were equal in arterial and venous blood, 
indicating no adherence of platelets in the heart. One would then expect a measurable 
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Limitations
The absence of subgroup analyses for our studies due to the small sample size is a limitation 
of our study. Moreover, the observed reductions in thrombocyte counts were greater than 
could be explained by hemodilution alone, indicating a potential role for other mechanistic 
players in this process, such as an early mechanical disruption, and sequestration in 
organs.19, 20 The two patient groups were different at baseline, reflecting a more vulnerable 
population of patients with LV dysfunction. The universal use of CPB during on-pump cardiac 
surgery likely also influences the assessment of factors that indicate the degree of platelet 
activation, for example by hemodilution and the use of heparin.21 However, our results 
are in line with findings for kidney I/R in which the absence of platelet activation in early 
reperfusion injury was shown in both living and deceased donor kidney transplantation 
(personal communication, D.K. de Vries et al.).
Conclusion
This study identifies that platelets are not activated in human myocardial I/R injury after 
on-pump cardiac surgery. This suggests that platelets do not play a prominent role in the 
initiation of the acute inflammatory responses upon myocardial reperfusion. As a result, 
preclinical evidence can not directly be translated to the human situation in the context of 
platelet involvement. 
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AbStRACt
background: Post-cardiac surgery vasoplegia is a frequent complication of cardiac surgery. 
The pathophysiological mechanisms underlying this syndrome are currently unknown. We 
hypothesized that this vasoplegia reflects endothelial dysfunction, either as preexisting 
condition or as consequence of the surgical procedure (i.e. ischemia/reperfusion injury and 
surgical injury). 
Methods: To address these mechanisms, six established and distinct markers of endothelial 
cell activation were measured preoperatively and at various time points upon myocardial 
reperfusion. Post-cardiac surgery vasoplegia was defined as a mean arterial blood pressure 
< 60 mmHg with a cardiac index ≥ 2.2 L/min/m2 treated with continuous intravenous 
administration of norepinephrine. 
Results: Development of postoperative vasoplegia was associated with elevated baseline 
von Willebrand Factor propeptide levels (above 11.9 nM) as well as with baseline sP-selectin 
levels (above 64.4 ng/mL). In patients with vasoplegia (n = 15), no myocardial release of 
endothelial cell activation markers was observed upon reperfusion. In contrast, in patients 
without vasoplegia (n = 24), a myocardial release of von Willebrand Factor propeptide 
(P < 0.001), osteoprotegerin (P = 0.02), and interleukin-8 (P = 0.009) was demonstrated. 
Similar systemic levels of all markers were found upon reperfusion in both groups, except 
for higher sP-selectin levels in vasoplegia patients.
Conclusions: Preexisting low-grade endothelial cell activation, reflected by higher baseline 
von Willebrand Factor propeptide and sP-selectin levels, is a predisposing factor for post-
cardiac surgery vasoplegia. Myocardial release of various endothelial cell activation markers 
in patients without this vasoplegia may appear counterintuitive, but may reflect the more 
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IntRoDuCtIon
Vasoplegic syndrome occurs in 9 to 44% of the patients after cardiac surgery.1-4 This 
syndrome is characterized by profound loss of systemic vascular resistance, resulting in 
severe hypotension, high cardiac output, and metabolic acidosis reflecting inadequate 
tissue perfusion.5, 6 High levels of vasopressive agents are required to maintain an adequate 
blood pressure postoperatively. In a substantial proportion of the patients the vasoplegia 
appears refractory to these agents.7 It is hypothesized that the surgical trauma and use of 
cardiopulmonary bypass (CPB) activate vasoactive inflammatory mediators, neurohumoral 
factors, and the coagulation system. This activation results in a disbalance in the regulation 
of the vascular tone.1 Prolonged hypotension and the accompanying hypoperfusion 
subsequently lead to end-organ dysfunction. Consequently, this syndrome is associated 
with increased morbidity and mortality.1, 8
The pathophysiologic basis of this vasoplegia is unknown, and preventive or treatment 
strategies are lacking. We hypothesized that development of this syndrome could be caused 
by each or a combination of the following factors: preexisting endothelial dysfunction, 
endothelial dysfunction caused by myocardial ischemia/reperfusion (I/R) that occurs during 
surgery, and endothelial dysfunction caused by surgical injury including the use of CPB.9-11 To 
address these issues, we performed an explorative study and collected serial blood samples 
in patients scheduled for mitral valve surgery. This patient population was specifically 
selected since patients with and without left ventricular dysfunction both undergo this 
homogeneous procedure. Arteriovenous concentration differences were obtained over the 
reperfused heart by selective cannulation of the coronary sinus, the venous pool of the 
heart. In parallel, we collected arterial samples reflecting systemic changes. Endothelial cell 
activation was assessed with measurement of six established markers, and the results were 
linked to clinical outcome. 
MetHoDS
Patient population
In this 16 months prospective study, 40 patients undergoing cardiac surgery were included of 
which 20 patients had left ventricular dysfunction. All patients were scheduled for restrictive 
mitral annuloplasty (RMA) ring implantation with or without additional procedures. Exclusion 
criteria were perioperative corticosteroid treatment, active infection, minimal invasive 
surgical procedures, emergency operations, and previous cardiac surgery. Although there 
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used the definition of Colson et al.12 In the intensive care unit (ICU), dobutamine was used 
in order to obtain a cardiac index ≥ 2.2 l/min/m2 as assessed by thermodilution (pulmonary 
artery catheter). A mean arterial blood pressure < 60 mmHg with a cardiac index ≥ 2.2 
L/min/m2 defined post-cardiac surgery vasoplegia the first 12 hours at the ICU, and was 
treated with continuous intravenous administration of norepinephrine. 
Although post-cardiac surgery vasoplegia occurs more often in patients with low ejection 
fraction, it can also develop in patients with normal systolic function.13 In daily clinical practice, 
vasoplegia is frequently observed in patients with prolonged aortic cross-clamp time, 
such as valve repair. Therefore, it is essential to unravel the underlying pathophysiological 
mechanisms to prevent it in all patients undergoing cardiac valve surgery, with or without 
systolic dysfunction. This study was approved by our local ethics committee, and written 
informed consent was obtained from each patient.
Anesthesia and surgical procedures
All participating patients received standardized anesthetic procedures, according to a fast-
track protocol. A 5 French indwelling jugular vein catheter (PICC, Arrow International Inc., 
REF PS-01651, PA, USA) was inserted into the right atrium and placed in the coronary sinus 
by the surgeon. Since all patients underwent mitral valve surgery using a vertical transseptal 
incision, the coronary sinus could easily be cannulated during the surgical procedure. An 
arterial catheter was routinely placed in the radial artery. Cardiac surgery was performed 
according to local standardized protocols. All surgical procedures were performed via a 
midline sternotomy under normothermic CPB (Jostra Maquet, Maquet, Hirrlingen, Germany) 
with intermittent antegrade warm-blood cardioplegia and heparin softline coating. A 
uniform CPB protocol was designed, excluding autologous priming and ultrafiltration. 
Plasma measurements
Arteriovenous measurements 
Arterial (radial artery) and myocardial venous blood samples (coronary sinus) were collected 
simultaneously over the reperfused heart as described before.14, 15 With this approach, 
accurate and specific measurements of locally ongoing processes were assessed the first hour 
after reperfusion. These paired blood samples were obtained during the early reperfusion 
phase: 0, 15, 30, 45, and 60 minutes after start of reperfusion, i.e. after removing the aortic 
cross-clamp. Two additional samples were collected: at baseline (the day before surgery 
from the brachial vein) and one day post-reperfusion (radial artery). Samples were collected 
in pre-cooled EDTA-tubes, immediately placed on melting ice, centrifuged twice, and stored 
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Measurement of endothelial cell activation markers
Plasma levels of the following endothelial cell activation markers, released by Weibel-Palade 
bodies, were assessed: von Willebrand factor (vWF), von Willebrand Factor propeptide 
(vWFpp), osteoprotegerin (OPG), and angiopoietin-2 (Ang-2). These markers were selected 
as they are released from prestored pools, and thus provide an immediate read-out of 
endothelial cell activation. vWF, vWFpp, and OPG were determined using a semi-automated 
enzyme-linked immunosorbent assay on a TECAN Freedom Evo robot using the following 
commercial antibody duosets: rabbit anti-human vWF and peroxidise-conjugated rabbit anti-
human vWF, A00082 and P0226, Dako, Glostrup, Denmark; vWFpp rabbit-anti-propeptide 
and rabbit-anti-propeptide-biotine16; OPG, duoset DY805, R&D systems, Abingdon, UK. 
Plasma levels of Ang-2 were measured manually (human Ang-2, DY623, R&D systems, 
Abingdon, UK). Moreover, two other endothelial cell activation markers were measured: 
interleukin (IL)-8 and soluble P-selectin (sP-selectin). 
Plasma levels of IL-8 were measured with a custom made X-plex assay according to 
instructions of the manufacturer (Biorad, Veenendaal, The Netherlands). Plasma levels of 
sP-selectin were determined using a semi-automated enzyme-linked immunosorbent assay 
(ELISA) on a TECAN Freedom Evo robot. ELISA plates (384 wells, Maxisorp, cat no. 460372) 
were coated overnight (4°C) with coating buffer. Established human ELISA antibody duosets 
were used (sP-selectin, duoset DY137, R&D systems, Abingdon, UK).
Statistical analysis
Continuous data are presented as medians with 25th and 75th percentiles. Categorical data 
are expressed as frequencies and percentages. Patients were divided into two subgroups 
based on the occurrence of post-cardiac surgery vasoplegia during follow-up. Perioperative 
data were evaluated between these groups with a Mann Whitney U-test or Chi-square test 
whenever appropriate. In addition, receiver operating characteristic (ROC) curve analysis 
was performed to determine the sensitivity and specificity for various cut-off values of 
baseline log-transformed vWFpp and sP-selectin levels for the prediction of post-cardiac 
surgery vasoplegia. Area under the curve (AUC) was calculated for the measurements in 
arterial and myocardial venous blood samples the first hour after reperfusion, and compared 
using a paired t-test. Arterial AUCs were compared between the two patient groups with a 
unpaired t-test. All statistical analyses were performed with the Statistical Package for the 
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ReSultS
This explorative study included 40 patients undergoing mitral valve surgery for severe 
mitral regurgitation. One patient without preexisting heart failure was excluded since the 
left ventricular function was perioperatively worse than estimated on the preoperative 
echocardiogram. In the remaining population of 39 patients, 15 (38.5%) patients developed 
a post-cardiac surgery vasoplegia. In four of these patients the vasoplegia persisted up to 24 
hours after surgery. Two of these patients developed a more prolonged vasoplegia of more 
than 24 hours post-surgery. One patient in the vasoplegia group died 41 days after surgery 
as a result of therapy-resistant heart failure. One patient in the non-vasoplegia group, 
with a poor left ventricular function, died eight days after surgery as a result of ventricular 
fibrillation. Perioperative characteristics of the patient population are summarized in Table 
1. Detailed information about the surgical procedures is provided in the Supplementary 
data, Table 1.    
Association between vasoplegia, preoperative von Willebrand Factor propeptide, and 
soluble P-selectin levels
Baseline vWFpp levels (i.e. day before surgery) were elevated in patients with vasoplegia 
compared with non-vasoplegia patients (25.34 [IQR 14.85-48.37] vs 8.35 [IQR 6.57-11.09] 
nM, P = < 0.001). A correlation was observed between baseline vWFpp levels and vasoplegia 
(Spearman’s rho correlation coefficient; r = 0.63, P = < 0.001). According to ROC curve 
analysis, a cut-off value of 11.9 nM showed a good accuracy to identify vasoplegia (Figure 1). 
Baseline sP-selectin levels were also higher in patients with post-cardiac surgery vasoplegia 
compared with non-vasoplegia patients (75.95 [IQR 62.12-81.56] vs 54.04 [IQR 43.77-72.70] 
ng/mL, P = 0.006, respectively). A correlation was observed between baseline sP-selectin 
levels and vasoplegia (Spearman’s rho correlation coefficient; r = 0.45, P = 0.004). According 
to ROC curve analysis, a cut-off value of 64.4 ng/mL showed a good accuracy to identify 
vasoplegia (Figure 1). Baseline levels of vWF, OPG, Ang-2 and IL-8 were similar between the 
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table 1. Perioperative patient characteristics. 
all patients Vasoplegia no vasoplegia P value
n = 39 n = 15 n = 24
Clinical characteristics
   Age (years) 65 (57-74) 71 (57-77) 64 (56-71) 0.36
   Male gender (n) 24 (62%) 11 (73%) 13 (54%) 0.23
   body Mass Index (kg/m2) 27 (24-29) 27 (25-30) 27 (24-29) 0.48
   Systolic blood pressure (mmHg) 125 (115-140) 120 (105-130) 128 (120-140) 0.12
   Diastolic blood pressure (mmHg) 70 (65-80) 70 (60-80) 73 (65-80) 0.59
   Hemoglobin (mmol/l) 8.6 (8.1-9.2) 8.3 (7.8-9.2) 8.6 (8.3-9.3) 0.32
   creatinine (μmol/L) 86 (74-103) 93 (83-109) 81 (73-99) 0.19
   nt-probnP (ng/l) 1242 (578-2295) 1598 (660-2449) 898 (364-2257) 0.11
   Logistic EuroscoRE (%) 5.97 (3.07-9.79) 6.96 (5.58-14.20) 4.29 (2.08-7.75) 0.02*
   nyha functional class 3 (2-3) 3 (3-3) 3 (2-3) 0.01*
Comorbidities 
   Diabetes (n) 9 (23%) 4 (27%) 5 (21%) 0.44
   CoPD (n) 7 (18%) 3 (20%) 4 (17%) 0.79
   AF (n) 11 (28%) 6 (40%) 5 (21%) 0.20
Medication
   acE-inhibitors / aRBs (n, %) 27 (69%) 12 (80%) 15 (63%) 0.25
   Beta-blockers (n, %) 28 (72%) 14 (93%) 14 (58%) 0.02*
   statins (n, %) 22 (56%) 11 (73%) 11 (46%) 0.09
   Diuretics (n, %) 28 (72%) 13 (87%) 15 (63%) 0.10
   Digoxins (n, %) 7 (18%) 2 (13%) 5 (21%) 0.55
Echocardiography
   lVeSV (ml) 92 (62-113) 100 (92-120) 71 (57-102) 0.10
   lVeDV (ml) 146 (135-194) 156 (135-194) 143 (133-191) 0.57
   LVEf (%) 39 (32-54) 33 (30-38) 50 (32-59) 0.06
Surgical characteristics
   aortic cross-clamp time (min) 120 (94-159) 147 (115-186) 108 (89-151) 0.04*
   cPB time (min) 178 (140-212) 205 (154-252) 162 (135-198) 0.01*
   surgery time (min) 310 (255-352) 376 (275-406) 292 (226-322) 0.003*
Postoperative characteristics
   norepinephrine (µg/kg/min)
0-12 hours at the ICu









   Dobutamine (µg/kg/min)
0-12 hours at the ICu









   creatinine 24 hours after surgery  
       (μmol/L)
79 (64-105) 96 (70-140) 77 (58-96) 0.06
   total stay in ICu (hours) 24 (21-69) 47 (21-93) 22 (21-25) 0.07
   total stay in hospital (days) 13 (10-19) 15 (11-21) 13 (10-19) 0.35
Medians and interquartile ranges are shown unless stated otherwise. * P values are given for the comparisons 
of patients with and without post-cardiac surgery vasoplegia. 
Abbreviations: ACE, Angiotensin Converting Enzyme; AF, Atrial Fibrillation; ARB, Angiotensin Receptor 
Blocker; COPD, Chronic Obstructive Pulmonary Disease; CPB, Cardiopulmonary Bypass; ICU, Intensive Care 
Unit; LVEDV, Left Ventricular End-Diastolic Volume; LVEF, Left Ventricular Ejection Fraction; LVESV, Left 
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table 2. Baseline endothelial cell activation markers.
all patients Vasoplegia no vasoplegia P value
n = 39 n = 15 n = 24
vwF (nM) 45.62 (32.09-64.05) 47.54 (36.88-57.28) 43.09 (25.63-66.40) 0.77
vwFpp (nM) 10.11 (7.20-24.48) 25.34 (14.85-48.37) 8.35 (6.57-11.09) < 0.001*
oPg (pg/ml) 36.16 (19.09-53.49) 26.32 (15.53-45.99) 38.89 (24.57-60.11) 0.09
Ang-2 (ng/ml) 2.38 (2.08-3.07) 2.52 (2.06-3.54) 2.36 (2.05-2.83) 0.57
Il-8 (pg/ml) 8.44 (3.47-13.87) 8.33 (5.61-17.00) 8.44 (2.88-13.32) 0.45
sP-selectin (ng/mL) 62.71 (49.00-76.43) 75.95 (62.12-81.56) 54.04 (43.77-72.70) 0.006*
Medians and interquartile ranges are shown. * P values are given for the comparisons of patients with and 
without post-cardiac surgery vasoplegia. 
Abbreviations: Ang-2, Angiopoeitin-2; IL-8, Interleukin-8; OPG, Osteoprotegerin; sP-selectin, soluble 
P-selectin; vWF, von Willebrand Factor; vWFpp, von Willebrand Factor propeptide.
figure 1. von Willebrand factor propeptide and soluble P-selectin in patients with and without post-
cardiac surgery vasoplegia. 
Median and interquartile range concentrations of baseline (A) von Willebrand Factor propeptide 
(vWFpp) and (B) soluble P-selectin are shown in patients with and without vasoplegia. (C) Receiver 
operating characteristic (ROC) curve analysis demonstrated a sensitivity of 79% with a specificity of 80% 
to predict vasoplegia following cardiac surgery at a cut-off of log-transformed von Willebrand Factor 
propeptide of 1.08 at baseline (geometrical mean of 11.9 nM). (D) ROC curve analysis demonstrated a 
sensitivity of 67% with a specificity of 67% to predict vasoplegia following cardiac surgery at a cut-off 








































Preexisting endothelial cell activation predicts post-cardiac surgery vasoplegia  •  125
6
Myocardial release of von Willebrand Factor propeptide, osteoprotegerin, and 
interleukin-8 upon reperfusion
Arteriovenous differences between blood collected from the radial artery and coronary 
sinus were analyzed in patients with and without post-cardiac surgery vasoplegia. In patients 
with vasoplegia, no myocardial release of vWF, vWFpp, OPG, Ang-2, IL-8 or sP-selectin was 
observed (P = 0.46, P = 0.86, P = 0.18, P = 0.16, P = 0.22, and P = 0.53, respectively). In 
contrast, in patients without vasoplegia, a myocardial release of vWFpp (P < 0.001), OPG 
(P = 0.02), and IL-8 (P = 0.009) was observed. No myocardial release of vWF, Ang-2 or sP-
selectin was observed in this group (P = 0.60, P = 0.27, and P = 0.09, respectively). 
Systemical levels of endothelial cell activation markers 
In contrast to the preexisting differences of baseline vWFpp and sP-selectin between 
patients with and without vasoplegia, no differences were observed up to one hour after 
reperfusion comparing both patient groups for systemic levels of vWF (P = 0.96), vWFpp 
(P = 0.84), OPG (P = 0.80), Ang-2 (P = 0.81), and IL-8 (P = 0.16). However, sP-selectin levels 
were higher in patients who experienced post-cardiac surgery vasoplegia as compared with 
patients without this vasoplegia upon reperfusion (P = 0.03). Similar levels of all markers 
were found in both groups one day post-reperfusion: vWF (P = 0.52), vWFpp (P = 0.18), OPG 
(P = 0.51), Ang-2 (P = 0.40), IL-8 (P = 0.47), and sP-selectin (P = 0.16). Overall, reperfusion was 
characterized by a decrease in plasma vWF and Ang-2 levels, and increased levels of vWFpp, 
OPG, and IL-8. sP-selectin levels were relatively stable upon reperfusion as compared with 
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Figure 2. systemic and myocardial venous plasma concentrations of various endothelial cell 
activation markers. 
(A;B) von Willebrand Factor, (C;D) von Willebrand Factor propeptide, (E;F) osteoprotegerin, (G;H) 
angiopoeitin-2, (I;J) interleukin-8, and (K;L) sP-selectin at baseline, the first hour after reperfusion, 
and one day post-reperfusion in respectively patients with and without vasoplegia. Graph error bars 
indicate medians with interquartile ranges. 
DISCuSSIon
Our results show that preexisting low-grade endothelial cell activation is a predisposing 
factor for post-cardiac surgery vasoplegia, identified with elevated baseline vWFpp and 
sP-selectin levels. Effective treatment strategies for this vasoplegic syndrome are currently 
lacking although these markers may be of prognostic value. Moreover, these markers may be 
used as opportunity to develop preoperative interventions aimed at stabilizing the vascular 
tone. No myocardial release of endothelial cell activation markers was observed upon 
reperfusion in patients with vasoplegia. In contrast, patients without vasoplegia showed 
a myocardial release of vWFpp, OPG, and IL-8. This myocardial release of endothelial cell 
activation markers post-surgery in non-vasoplegia patients may appear counterintuitive, 
but may reflect the more prominent ability of the endothelium to respond to injury. The 
preexisting long-term demand of continuous systemic as well as myocardial endothelial cell 
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As indicated, elevated baseline levels of vWFpp were observed in patients who later 
developed post-cardiac surgery vasoplegia. vWF and vWFpp are stored in and released 
from activated Weibel Palade bodies, and are therefore markers of acute endothelial cell 
injury.17 vWF, in contrast to vWFpp, is a substrate for platelet aggregation.18 Moreover, the 
multimeric vWF is cleaved by a specific metalloproteinase (ADAMTS13, disintegrin-like 
and metalloproteinase with thrombospondin type I motifs 13), resulting in consumption 
of vWF.18, 19 As a result, plasma vWFpp levels reflect more directly vascular endothelial cell 
injury than that of vWF.18
Another difference between vWF and vWFpp was observed with measurement of 
arteriovenous concentrations differences upon reperfusion, to discriminate between 
myocardial and systemic release of endothelial cell activation markers. Our results indicate 
a myocardial release of vWFpp, but not vWF upon reperfusion in patients without post-
cardiac surgery vasoplegia. A possible hypothesis for this discrepancy is that the larger vWF 
molecules remain inside the heart, whereas vWFpp is systemically released. In line with 
our study, no myocardial release of vWF was observed in previous studies.20, 21 Moreover, 
differences in plasma kinetics between vWF and vWFpp were observed: vWF levels increase 
much slower but are more sustained compared with vWFpp. Our results regarding these 
biokinetic properties are in line with a previous in vivo study of experimental endotoxemia.16 
Under physiological conditions, the molar concentration of vWFpp in normal plasma is about 
one tenth of the concentration of mature vWF. Yet, under pathophysiological conditions the 
molar ratio of vWFpp to mature vWF can increase four- to fivefold compared with baseline, 
presumably due to compartmentalization and/or catabolism of the mature vWF. 
Limitations
This explorative study has some limitations. The small sample size might have limited the 
detection of minor differences, like a trend towards significance for elevated Ang-2 levels 
one day post-reperfusion in patients with vasoplegia (type II error). Moreover, no subgroup 
analysis could be performed neither correction for hemodilution was applied as a result 
of the small sample size. The differences at baseline between the groups, for example the 
higher logistic EuroSCORE and New York Heart Association (NYHA) class in patients with 
vasoplegia, reflect a more vulnerable patient population. Moreover, the mortality rate 
was low and not significantly different between patients with and without vasoplegia. This 
limits the potential for conclusions regarding the prognostic value of plasma concentrations 
of vWFpp and sP-selectin for clinical outcome. In addition, we decided to use a recent 
definition of Colson et al., although there is no consensus regarding the definition of post-
cardiac surgery vasoplegia in the current literature.12 Sun et al. described postoperative 
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resistance < 1400 dyne/s/cm5/m2, cardiac index ≥ 2.5 L/min/m2, and central venous pressure 
≥ 10 mmHg.22 Levin et al. used the amount of vasopressor support required to separate from 
the CPB as surrogate marker of vasoplegia.6 
Conclusion
Elevated baseline vWFpp and sP-selectin levels were measured in patients who develop post-
cardiac surgery vasoplegia in a later stage, reflecting a preexisting low-grade endothelial cell 
activation. These markers may be useful for the identification of patients at increased risk for 
developing vasoplegia postoperatively. In contrast to the preoperatively measured effects, 
no myocardial release of endothelial cell activation markers was observed upon reperfusion 
in patients with vasoplegia. In contrast, patients without vasoplegia showed a myocardial 
release of vWFpp, OPG, and IL-8. This myocardial release may appear counterintuitive, 
but may reflect the more prominent ability of the endothelium to respond to injury in this 
patient group. The preexisting long-term demand of continuous endothelial cell activation 
in patients with vasoplegia may result in no (additional) myocardial release of endothelial 
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Supplementary data, table 1. Surgical procedures.
Surgical procedures (no.) all patients Vasoplegia no vasoplegia
n = 39 n = 15 n = 24
corcap®, mVP, tVP, LV-lead +/- af-ablation 
CorCap®, MVP, lV-lead 
CorCap®, CAbg, MVP, lV-lead 
LV-reconstruction, caBG, mVP, tVP, Vt-ablation 
LV-reconstruction, caBG, mVP, LV-lead 
LV-reconstruction, mVP, tVP, Vt- and af ablation 
LV-reconstruction, mVP, tVP, LV-lead 
caBG, mVP, tVP, af-ablation 
CAbg, MVP +/- lV lead 
MVP/R, AVR 






































Abbreviations: AF, Atrial Fibrillation; CABG, Coronary Artery Bypass Grafting; LV, Left Ventricle/Ventricular; 
MVP/R, Mitral Valve Annuloplasty/Replacement; TVP, Tricuspid Valve Annuloplasty; VT, Ventricular 
Tachycardia.
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AbStRACt 
background: Systemic complications after cardiac surgery are common in heart failure 
patients. However, the pathophysiological mechanisms, such as a different local inflammatory 
response of failing hearts, remain in question. This study examines whether failing hearts 
respond differently to cardioplegic arrest and reperfusion compared with non-failing hearts 
(controls).
Methods and results: The inflammatory response was evaluated in samples collected 
simultaneously from the radial artery and coronary sinus, and in myocardial tissue of 62 
patients undergoing cardiac surgery. No myocardial release of inflammatory mediators was 
observed upon reperfusion in controls (n = 19). In contrast, in patients with heart failure, 
reperfusion was characterized by a myocardial release of several cytokines. Myocardial 
interleukin-6 was 115% increased in non-ischemic heart failure patients (n = 18, P = 0.002) 
as compared with a 117% increase in patients with ischemic heart failure (n = 25, P = 0.01). 
Furthermore, a myocardial release of monocyte chemoattractant protein-1 was observed in 
both patient groups: a 109% (P = 0.001) and 114% (P = 0.01) increase in patients with non-
ischemic heart failure and ischemic heart failure, respectively. Postoperative myocardial 
damage, expression of inflammatory mediators, and p65-nuclear factor-kappa B activity 
were similar in all patient groups. Inflammatory cell content was increased in early ischemic 
myocardial tissue in both heart failure groups compared with controls. 
Conclusions: Heart failure patients show a clear myocardial inflammatory response upon 
reperfusion, probably explained by degranulation of infiltrated inflammatory cells. Results 
in controls indicate that they better withstand cardioplegic arrest and reperfusion without 
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IntRoDuCtIon
Systemic complications after cardiac surgery, such as vasoplegia and infections, are common 
in patients with preexisting heart failure. These complications are a major contributor to 
morbidity and mortality. A remarkable observation is that these systemic complications 
appear to be independent of their pump failure itself.1 They merely seem to reflect 
a different response of the body to the surgical procedure. This response can be due to 
systemic alterations in the setting of heart failure or may reflect a different response of the 
failing heart to cardioplegic arrest and reperfusion. 
Ischemia/reperfusion (I/R) injury is the paradoxical increase of tissue damage upon 
reperfusion of ischemic tissue. This injury is an inherent component of cardiac surgery 
with artificial arrest and subsequent myocardial reperfusion. The pathophysiology of 
myocardial I/R injury is complex and not fully elucidated yet. Animal studies show that a 
complex cascade of events ultimately results in a myocardial inflammatory response upon 
reperfusion.2-4 Whether this can be extrapolated to the more complex situation in humans 
is unknown. 
In this clinical study, we evaluated whether failing hearts respond differently to 
cardioplegic arrest and reperfusion compared with non-failing hearts. The inflammatory 
response was studied in the two most common types of heart failure, non-ischemic and 
ischemic heart failure, and compared with patients without heart failure undergoing cardiac 
surgery. Release of various inflammatory mediators was sequentially measured after 
myocardial reperfusion in human cardiac surgery. Selective arteriovenous concentration 
differences could be obtained directly over the reperfused heart by cannulation of the 
coronary sinus (i.e. the venous pool of the heart). We evaluated which factors were released 




In this two-year prospective study, 62 patients were included: 43 patients with heart failure 
and 19 controls (Supplementary data, Figure 1). All heart failure patients were scheduled for 
restrictive mitral annuloplasty (RMA) ring implantation. Patients with non-ischemic heart 
failure (n = 18) also underwent a concomitant implantation of an external cardiac support 
device (CorCap cardiac support device, Acorn Cardiovascular, St. Paul, MN, USA). Patients 
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ventricular reconstruction surgery if they had a large area of anterior akinesia or dyskinesia 
(n = 11) in addition to RMA. Patients without heart failure, scheduled for reconstructive mitral 
valve surgery for degenerative, rheumatic, or cured endocarditis mitral valve pathology, 
were selected as controls. These controls were expected to have approximately the same 
aortic cross-clamp times as heart failure patients. Heart failure was preoperatively defined 
as an inadequate pump function of the heart with an echocardiographically estimated 
ejection fraction biplane below 35%5 and the presence of one or more clinical symptoms 
as classified by the New York Heart Association (NYHA). All controls had a moderate to 
normal pump function of the heart (defined as an ejection fraction biplane above 45%), no 
clinical signs of heart failure by physical examination, and did not use high doses of diuretics. 
Exclusion criteria were perioperative corticosteroid treatment, active infection, minimal 
invasive surgical procedures, emergency operations, and previous cardiac surgery. Patients 
were followed during total hospital stay, including hospital stay after discharge to a referring 
hospital. This study was carried out in accordance with the Declaration of Helsinki and 
approved by the local ethics committee. All patients provided written informed consent. 
Anesthesia and surgical procedures
All participating patients received standardized anesthetic procedures, according to a fast-
track protocol. A 5 French indwelling jugular vein catheter (PICC, Arrow International Inc., 
REF PS-01651, PA, USA) was inserted into the right atrium and placed in the coronary sinus 
by the surgeon. Since all patients underwent mitral valve surgery using a vertical transseptal 
incision, the coronary sinus could easily be cannulated during the surgical procedure. An 
arterial catheter was routinely placed in the radial artery. Cardiac surgery was performed 
according to local standardized protocols. All surgical procedures were performed via a 
midline sternotomy under normothermic cardiopulmonary bypass (CPB; Jostra Maquet, 
Maquet, Hirrlingen, Germany) with intermittent antegrade warm-blood cardioplegia and 
heparin softline coating. A uniform CPB protocol was designed, excluding autologous 
priming and ultrafiltration. 
Plasma measurements
Arteriovenous measurements 
Arterial (radial artery) and myocardial venous blood samples (coronary sinus) were collected 
simultaneously over the reperfused heart (Figure 1). With this approach, accurate and 
specific measurements of locally ongoing processes were assessed up to 24 hours after 
reperfusion. Arterial and myocardial venous blood samples were obtained during the early 
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aortic cross-clamp (early phase), and at 2, 4, 8, and 24 hours after reperfusion (late phase). 
In all patients, a baseline sample was taken the day before surgery from the brachial vein. All 
samples were collected in pre-cooled tubes containing EDTA (BD Vacutainer, Plymouth, UK) 
and immediately placed on melting ice. Blood samples were centrifuged within one hour 
after collection (1.550 g, 10 min, 4°C) and the derived plasma was re-centrifuged (10.000 g, 
4 min, 4°C) to obtain leukocyte and thrombocyte free plasma. Aliquots were stored at -70°C 
until analysis. 
Measurement of inflammatory mediators
A pilot study was performed in five heart failure patients (three patients with ischemic 
heart failure and two patients with non-ischemic heart failure) and five controls to identify 
detectable inflammatory mediators with the sensitive human 27-plex panel (Biorad, 
Veenendaal, The Netherlands). Based on the results of this pilot study, the following 12 
cytokines were measured in the complete cohort with a custom-made multiplex assay 
according to the instructions of the manufacturer (X-plex, Biorad, Veenendaal, The 
Netherlands): interleukin-1 receptor antagonist (IL-1ra), IL-6, IL-8, IL-9, IL-10, IL-16, IL-
18, granulocyte colony-stimulating factor (G-CSF), interferon-inducible protein-10 (IP-
10), monocyte chemoattractant protein-1 (MCP-1), regulated upon activation, normal 
T cell expressed and secreted (RANTES), and vascular endothelial growth factor (VEGF). 
Underlying mechanisms for the myocardial release of inflammatory mediators were 
investigated in the complete cohort. First, the possibility of passive secretion from damaged 
myocytes was looked for by measurement of troponin T. Next, we investigated whether 
active production and secretion by myocardial cells might be responsible for the release of 
inflammatory mediators by means of mRNA expression of various inflammatory mediators. 
Moreover, cellular activation was examined by assessing transcriptionally active nuclear 
factor-kappa B (NF-κB). Eventually, the possibility of release by infiltrating inflammatory 
cells was investigated. 
Myocardial damage
To assess myocardial damage, troponin T values were measured by a routine laboratory 
assay (Roche Diagnostics, Mannheim, Germany). Dissimilarity in myocardial damage 
between the groups could explain differences in the myocardial release of inflammatory 
mediators. Troponin T values were measured 45 minutes after reperfusion in coronary sinus 
blood. This time point lies within the range of the early reperfusion phase, where the most 
dominant myocardial release of inflammatory mediators was observed. After cardiac valve 
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Myocardial tissue samples
Through the mitral valve, an endomyocardial biopsy was obtained from a standardized 
location at the posterior wall of the left ventricle between the two papillary muscles, early 
after aortic cross-clamping. The late endomyocardial biopsy was collected on average 70 
minutes later from the same location just before release of the aortic cross-clamp (Figure 
1). Biopsies were divided and fixed in formalin or immediately snap-frozen in liquid nitrogen 
and stored at -70°C. Formalin-fixed, paraffin-embedded biopsies were cut into 5 µm thick 
sections with a microtome. 
Figure 1. schematic representation of the coronary sinus catheter and location of the biopsies.
This figure shows the position of the coronary sinus catheter and the location of the left ventricular 
biopsies.
RNA extraction and mRNA analysis
Total RNA was prepared from early and late endomyocardial biopsies. Total RNA extraction 
was performed using RNA-Bee (Campro Scientific, Veenendaal, The Netherlands) and glass 
beads. Subsequently, cDNA was prepared using a High Capacity RNA-to-cDNA Kit (Applied 
Biosystems Inc, Foster City, CA, USA). Taqman gene expression master mix, ABI 7500 Fast 
system and established primer/probe sets (Applied Biosystems Inc, Foster City, CA, USA) 
were used according to the manufacturer’s instructions to quantify IL-1ra (Hs00893626_m1), 
IL-6 (Hs00174131_m1), IL-8 (Hs00174103_m1), IL-10 (Hs00961622_m1), tumor necrosis 
factor (TNF)-α (Hs00174128_m1), IL-1β (Hs00174097_m1), matrix metallopeptidase 
(MMP)-9 (Hs00957562_m1), cluster of differentiation (CD)68 (Hs00154355_m1) and MCP-1 
(Hs00234140_m1). Glyceraldehyde phosphate dehydrogenase (GAPDH; VIC labelled) was 
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Analysis of intramyocardial p65-nuclear factor-κB activity
To assess the role of NF-κB as transcription factor controlling the expression of genes 
involved in immune responses, p65-NF-κB activity was quantified in paired early and 
late endomyocardial biopsies of five patients of each patient group. Myocardial p65-NF-
κB activity was determined as described previously by Kleemann et al.6, using a TransAM 
transcription factor assay kit (no. 40097, Active Motif Europe, Rixensart, Belgium). The 
assays were performed according to the instructions of the manufacturer. Myocardial tissue 
homogenates were prepared using the Nuclear Extract Kit (no. 40010, Active Motif Europe, 
Rixensart, Belgium). Equal amounts of protein (6 μg/well) of these homogenates were used 
to determine the amount of active p65-NF-κB.
Immunohistochemical analysis of left ventricular tissue
Formalin-fixed, paraffin-embedded microtome sections were deparaffinized and rehydrated 
before staining for CD3, CD68, myeloperoxidase (MPO), and human leucocyte antigen (HLA)-
DR. Some stainings required the use of a protein retrieval: an EDTA buffer solution for CD3 and 
CD68 (pH = 9.0), and a citrate buffer solution (pH = 6.0) for HLA-DR. Sections were incubated 
overnight with the primary antibody raised against CD3 (1:200, Abcam, Cambridge, MA, 
USA), CD68 (1:4000, DAKO, Glostrup, Denmark), MPO (1:5000, DAKO, Glostrup, Denmark), 
and HLA-DR (1:200, DAKO, Glostrup, Denmark) for staining of T-lymphocytes, macrophages, 
polymorphonuclear neutrophils, and activated leukocytes, respectively. Subsequently, 
envision and 3,3’-diaminobenzidine tetrahydrochloride as a chromogen for detection were 
applied. Slides were counterstained with Mayer’s hematoxylin to allow morphological 
analysis. The number of positive cells was quantified in five views (original magnifications 
x200; AxioVision software, version 4.4.1.0 Carl Zeiss MicroImaging Inc, Gottingen, Germany). 
The number of cells over five calibrated grid areas per view was counted using ImageJ Cell 
Counter® by an independent blinded observer. 
Statistical analysis
Continuous variables were analyzed using the Kruskal-Wallis test with post-hoc analyses 
with Mann-Whitney U-tests whenever appropriate. The significant Kruskal-Wallis offers 
protection against an inflated α-error rate when performing multiple comparisons. 
Furthermore, Benjamini-Hochberg correction was used to correct for multiple comparisons. 
If values were not significant after this correction, NS was placed in the text after the 
unadjusted P value. The area under the curve (AUC) was calculated for the arterial and 
venous curves of the plasma measurements for the early and late reperfusion phase. A 
delta AUC was calculated (venous minus arterial) and the null hypothesis (delta AUC is 0) 
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groups analysis of variance (ANOVA). The Wilcoxon signed rank test was used to analyze 
differences between early and late ischemic biopsies for the mRNA analysis and NF-κB 
activity. All statistical tests were performed using SPSS statistical analysis software version 
17.0 (SPSS Inc, Chicago, IL, USA). A P value < 0.05 was considered significant. Graph error 
bars represent the mean ± standard error of the mean (SEM) unless stated otherwise. 
ReSultS
General findings
Patient characteristics are summarized in Table 1. A similar gender distribution was observed 
in all groups (P = 0.43). In two controls, a mitral valve replacement had to be done; a repair 
was not possible due to extensive calcifications. Moreover, one patient was scheduled for a 
mitral valve repair in combination with a left ventricular reconstruction procedure. Although 
included, this patient did not undergo this valve repair since there was no longer any mitral 
regurgitation after the reconstruction procedure. Two patients died during follow-up in 
hospital: one patient with non-ischemic heart failure died unexpectedly eight days after 
surgery as a result of ventricular fibrillation. The other patient, with ischemic heart failure, 
died 41 days after ventricular reconstruction surgery as a result of therapy-resistant heart 
failure. Baseline levels of all inflammatory mediators were comparable in all patient groups 
(Supplementary data, Table 1), of which controls generally showed the lowest baseline 
levels of pro-inflammatory mediators. Systemic levels of inflammatory mediators, i.e. 
concentrations in arterial blood samples, were similar during the first hour after reperfusion 
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figure 2. Illustration of our analysis method in patients with non-ischemic heart failure.
Arteriovenous differences were used to determine the release of inflammatory markers upon 
reperfusion. The difference in the area under the curve of the arterial and myocardial venous curves 
was assessed to quantify the net release from the myocardium. A significant myocardial release of 
interleukin-6 (IL-6) as well as monocyte chemoattractant protein-1 (MCP-1) was observed in patients 
with non-ischemic heart failure upon reperfusion. Graph error bars represent the mean ± SEM. 
figure 3. myocardial release of inflammatory mediators in patients with heart failure.
Various inflammatory mediators were released by the myocardium in patients with non-ischemic 
and ischemic heart failure upon early reperfusion. No significant myocardial release was observed in 
controls. Graph error bars represent the mean ± SEM. 
Abbreviations: Co, Controls; G-CSF, Granulocyte-Colony Stimulating Factor; IHF, Ischemic Heart Failure; 
IL, Interleukin; IL-1ra, Interleukin-1 receptor antagonist; IP-10, Interferon-inducible Protein-10; MCP-
1, Monocyte Chemoattractant Protein-1; NIHF, Non-Ischemic Heart Failure; RANTES, Regulated upon 
Activation, Normal T cell Expressed and Secreted; VEGF, Vascular Endothelial Growth Factor.
Myocardial release of inflammatory mediators in patients with preexisting heart failure
Arteriovenous differences were used to determine the myocardial cytokine and chemokine 
release upon reperfusion. The differences in the AUC of the arterial and venous curves 
were assessed to quantify the net release from the myocardium. Our analysis method is 
illustrated in Figure 2. Both heart failure groups showed a significant myocardial release of 
various cytokines upon early reperfusion. As shown in Figure 3, early myocardial reperfusion 
of patients with non-ischemic heart failure was associated with a release of IL-1ra (P = 
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(P = 0.04, NS). In patients with ischemic heart failure, early reperfusion was characterized by 
a more limited number of inflammatory markers that were released: IL-6 (P = 0.01), MCP-
1 (P = 0.01) and VEGF (P = 0.004). This inflammatory response was not observed during 
the late reperfusion phase. The early cytokine response was exclusive for heart failure 
patients, since controls did not show a significant myocardial release of any of the measured 
inflammatory mediators upon early and late reperfusion.
Similar postoperative myocardial damage
To assess whether variation in myocardial damage is the cause for the observed differences 
in cytokine release between the groups, troponin T values were measured 45 minutes after 
reperfusion. No differences were observed between the patient groups (P = 0.67). The 
median and interquartile range of troponin T was 1.24 μg/L (0.93 to 1.49) in patients with 
non-ischemic heart failure, 1.36 μg/L (0.83 to 2.49) in patients with ischemic heart failure, 
and 1.25 μg/L (0.83 to 1.60) in controls. A number of patients with ischemic heart failure 
underwent a ventriculotomy in the setting of their surgical ventricular reconstruction which 
might explain the higher range of troponin T values.
Similar expression of inflammatory mediators during ischemia
A subsequent analysis of inflammatory mediators in mRNA extracts of endomyocardial 
tissue showed no differences at baseline in all groups (early endomyocardial biopsies; 
Supplementary data, Table 2), except for a small difference in MMP-9 expression in patients 
with non-ischemic heart failure and controls (P = 0.01). More importantly, there were no 
differences in inflammatory gene expression in early versus late endomyocardial biopsies in 
all patient groups (Supplementary data, Table 3). This indicates that transcriptional changes 
are not responsible for the increased cytokine release in heart failure patients.
Similar p65-nuclear factor-kappa B activity during ischemia
Since transcription of cytokines itself did not change, NF-κB was measured as many of 
the myocardial released inflammatory mediators are under transcriptional control of this 
regulator. Myocardial NF-κB activity was compared between the groups using homogenates 
of paired endomyocardial tissue samples collected in the early and late ischemic period. 
Baseline values of NF-κB activity were similar between the groups (P = 1.00). No increase 
in NF-κB activity was observed in early versus late endomyocardial biopsies (P = 0.23, 
P = 0.14, and P = 0.89 for patients with non-ischemic heart failure, ischemic heart failure, 
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More tissue macrophages and neutrophils in heart failure patients 
Immunohistochemical stainings were performed to evaluate whether differences in 
inflammatory cell content caused differences in cytokine release between the groups. 
There was a significant difference in CD68-positive and MPO-positive cells between the 
groups in the early biopsies (Figure 4A). Post-hoc comparisons indicated that the amount 
of macrophages was 3.8 times higher in patients with non-ischemic heart failure relative to 
controls (P = 0.002; Figure 4B). Also the neutrophil content was 2.7 times higher in patients 
with non-ischemic heart failure compared with controls (P = 0.006; Figure 4C). T-lymphocytes 
(CD3) were sparsely present in all patient groups, with non-ischemic heart failure patients 
showing most T-lymphocytes (P = 0.04, NS). The content of activated leukocytes (HLA-DR) 
was 3.5 times higher in patients with non-ischemic heart failure as compared with both 
ischemic heart failure and control patients, although not significant (P = 0.06). No significant 
changes in macrophage or neutrophil content were observed between the early and late 
biopsies (Supplementary data, Figure 4).
Figure 4. Macrophage and neutrophil contents. 
(A) Early ischemic endomyocardial biopsies of patients with non-ischemic heart failure (NIHF) 
[A and D], ischemic heart failure (IHF) [B and E] and controls (Co) [C and F] were stained for cluster 
of differentiation 68 (CD68) and myeloperoxidase (MPO). Representative images are shown. Original 
magnifications x200. (B) Macrophage content was higher in patients with non-ischemic heart failure 
compared with controls, P = 0.002. (C) Neutrophil content was higher in patients with non-ischemic 
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DISCuSSIon
Since heart failure patients experience various systemic complications postoperatively, we 
evaluated which inflammatory mediators are released by the myocardium and whether 
failing hearts differ from non-failing hearts in their local inflammatory responses. Besides the 
expected systemic inflammatory response in all patients, our results show that patients with 
preexisting heart failure have a different and more pronounced myocardial inflammatory 
response after cardiac surgery than controls. Myocardial IL-6 and MCP-1 were released in 
both non-ischemic and ischemic heart failure patients. Furthermore, IL-10, G-CSF, and IL-18 
were released in patients with non-ischemic heart failure whereas patients with ischemic 
heart failure showed a release of VEGF. This myocardial release of various inflammatory 
mediators may cause systemic complications with a resultant increase in morbidity and 
mortality. 
Release of inflammatory mediators 
Baseline values of the inflammatory markers were not statistically different, although 
a trend was observed for higher levels in patients with preexisting heart failure. Various 
previous studies showed higher cytokine values in patients with heart failure.7, 8 However, 
the opposite has been described as well by Vanderheyden et al.9 They showed a higher 
TNF-α and IL-6 expression in patients with aortic stenosis with normal ejection fraction 
compared with patients with dilated cardiomyopathy. 
In our study, a difference in the myocardial inflammatory response between the two 
most common types of heart failure was observed, comparing non-ischemic and ischemic 
heart failure patients. Patients with non-ischemic heart failure showed a more diverse and 
pronounced release of inflammatory mediators than patients with ischemic heart failure. 
The myocardial inflammatory response is, however, specific for patients with heart failure, 
as controls did not show a myocardial release of inflammatory mediators. This may indicate 
that controls are able to cope with the stress associated with tissue reperfusion.
Mechanisms of the myocardial inflammatory response
Mechanisms underlying the observed myocardial inflammatory response in patients with 
heart failure were analyzed in more detail. Since troponin T values were similar between the 
groups, passive secretion of inflammatory mediators via myocardial damage is unlikely to 
be a possible cause of the differences. Secondly, similar expression of several inflammatory 
mediators was observed during ischemia between the groups. This suggests that the release 
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for the myocardial response in heart failure patients. Moreover, no cellular activation by 
means of NF-κB activity was observed during ischemia. NF-κB activity was already high at 
baseline in patients with ischemic heart failure, which might explain why NF-κB activity 
could not increase further during cardioplegic arrest. A more likely explanation for the 
myocardial release of inflammatory mediators is the observed difference in tissue content of 
inflammatory cells. Macrophages and neutrophils can release inflammatory mediators such 
as IL-6, IL-10, IL-18, G-CSF and MCP-1,10, 11 which were found to be elevated in our study. 
Since no changes in transcription of these cytokines were observed and that is likely to take 
longer, degranulation of pre-stored cytokine pools is the likeliest explanation.12, 13 The post-
reperfusion accumulation and activation of neutrophils in the post-ischemic myocardium in 
the first hours after initiation of myocardial reperfusion have been described in animals.14 
However, we observed increased amounts of infiltrated neutrophils and macrophages 
already during early ischemia. This may suggest pre-ischemic presence of higher amounts 
of inflammatory cells in the failing heart. During reperfusion, these tissue inflammatory cells 
and their released chemoattractants may amplify the influx of more inflammatory cells into 
the myocardium, thereby contributing to damage. 
Clinical implications
It is evident that the clinical prognosis after cardiac surgery is influenced by the balance 
between pro- and anti-inflammatory mediators. Elevated levels of various pro-inflammatory 
cytokines are associated with adverse events after cardiac surgery.15 For example, high 
circulating IL-6 levels correlate with hepatic and renal dysfunction.16 It has been shown 
that IL-6, IL-8, and MCP-1 showed higher peaks and persisted longer in patients with a 
complicated course after cardiac surgery in comparison with patients with an uneventful 
recovery.10 In our study, no significant correlations were found between any of the measured 
inflammatory mediators and intensive care unit or hospital stay. 
The increased inflammatory cell content and release of inflammatory mediators in 
patients with heart failure stresses the potential of preoperative anti-inflammatory therapy 
to attenuate the inflammatory response postoperatively. This could contribute to fewer 
systemic complications and therefore to a more widespread use of cardiac surgical procedures 
in patients with heart failure. Yet, clinical trials of anti-inflammatory therapies have failed 
to show a benefit in patients with heart failure.17 We should therefore be cautious when 
intervening with cytokine pathways. In addition to the detrimental role of inflammatory 
mediators, some also appear to have protective effects depending on the presence of 
responsive cells, the timing, and combination of released cytokines. For example, both 
receptors of TNF have disparate and opposing effects in mice with heart failure.18 TNFR1 
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it has been shown that the role of IL-6 is not straightforward either.19 A renal release of IL-6 
was observed upon reperfusion in human kidney transplantation, but neutralization of IL-6 
in mice undergoing renal I/R injury resulted in aggravation of tissue injury. Therefore, further 
clinical studies are needed to determine the possibilities of preoperative anti-inflammatory 
therapy in patients with heart failure undergoing cardiac surgery. To stress the multifactorial 
approach of treating patients with heart failure even more, bone marrow dysfunction due 
to inflammation20, renal insufficiency, and hemodilution also plays a major role in addition 
to myocardial and systemic inflammatory responses. 
Limitations
Since the aim of this study was to identify differences in the release of inflammatory 
mediators between the groups instead of correlating findings to clinical outcome, small 
patient numbers were sufficient. However, this small sample size might have limited the 
detection of minor differences (type II errors). The three patient groups are inherently 
heterogeneous regarding clinical characteristics. No adjustment for these inevitable 
differences were made. One might consider the collection of pre-reperfusion biopsies 
only as a limitation. However, a post-reperfusion biopsy could not be collected since most 
of the included heart failure patients were hemodynamically unstable during the early 
reperfusion phase. Lifting the heart, to take a biopsy, was considered unsafe. However, 
human vital myocardial tissue is not often studied since most previous studies used post-
mortem biopsies. Moreover, there were also inter-group differences in aortic cross-clamp 
times. However, no strong relationships between aortic cross-clamp times and plasma levels 
of inflammatory mediators were observed. In addition, patients with non-ischemic heart 
failure had the shortest aortic cross-clamp times, but showed the most diverse release of 
inflammatory mediators upon reperfusion. Finally, our explorative study was not designed 
to evaluate inflammatory markers in relation to clinical endpoints. Larger, preferably 
multicenter, studies are therefore essential. 
Conclusions
Patients with heart failure show a clear myocardial inflammatory response upon reperfusion. 
This can be explained by degranulation of preoperatively infiltrated inflammatory cells in 
myocardial tissue of failing hearts. In contrast, results in control patients indicate that they 
can better withstand cardioplegic arrest and subsequent reperfusion without a myocardial 
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supplementary data, figure 1. flowchart of patient inclusion.
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supplementary data, figure 2. arterial levels of inflammatory mediators.
Logarithmic AUCs of systemic (that is, arterial) inflammatory mediators were similar between patients 
with non-ischemic heart failure, ischemic heart failure, and controls except for interleukin-1 receptor 
antagonist, interleukin-6, and granulocyte-colony stimulating factor during the first hour after 
reperfusion (IHF versus NIHF: IL-1ra P = 0.03; IL-6 P = 0.006; G-CSF P = 0.005; IHF versus Co: IL-1ra 
P = 0.004; IL-6 P = 0.009; G-CSF P = 0.002). Graph error bars represent the mean ± SEM. 
Abbreviations: AUC, Area Under the Curve; Co, Controls; G-CSF, Granulocyte-Colony Stimulating Factor; 
IHF, Ischemic Heart Failure; IL, Interleukin; IL-1ra, Interleukin-1 receptor antagonist; IP-10, Interferon-
inducible Protein-10; MCP-1, Monocyte Chemoattractant Protein-1; NIHF, Non-Ischemic Heart Failure; 
RANTES, Regulated upon Activation, Normal T cell Expressed and Secreted; VEGF, Vascular Endothelial 
Growth Factor.
supplementary data, figure 3. no differences in nf-κB activity during ischemia.
No significant increase in nuclear factor-kappa B (NF-κB) activity was observed in early versus late 
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Supplementary data, Figure 4. Macrophage and neutrophil contents.
Endomyocardial biopsies of patients with non-ischemic heart failure (NIHF), ischemic heart failure 
(IHF), and controls (Co) were stained for (A) cluster of differentiation 68 (CD68) and (B) myeloperoxidase 
(MPO). No significant differences in inflammatory cell content were observed between early and late 
pre-reperfusion biopsies. Graph error bars represent the mean ± SEM. 









Il-1ra 69.85 (26.72-117.56) 95.84 (34.46-155.40) 45.00 (22.85-158.39) 0.72
Il-6 7.67 (4.97-13.98) 11.10 (4.68-17.15) 7.12 (1.52-11.76) 0.43
Il-8 9.19 (6.98-13.76) 9.58 (6.51-19.43) 6.77 (3.04-15.72) 0.45
Il-9 3.35 (0.44-8.25) 1.39 (0.91-14.19) 3.78 (1.60-21.32) 0.47
Il-10 3.69 (1.74-7.39) 2.29 (1.69-7.20) 3.05 (1.02-5.66) 0.94
Il-16 93.73 (54.35-146.46) 96.66 (41.35-170.83) 133.22 (21.36-237.52) 0.86
Il-18 75.98 (37.28-131.77) 61.86 (30.52-144.80) 60.65 (18.04-83.47) 0.26
g-CSF 34.58 (14.42-50.99) 38.33 (21.82-56.44) 24.21 (6.78-39.85) 0.21
IP-10 736.81 (308.66-1039.02) 581.81 (324.59-959.91) 456.10 (135.92-794.17) 0.28
MCP-1 19.80 (12.26-23.20) 20.36 (12.82-36.78) 19.96 (7.19-32.22) 0.95
RAnteS 416.53 (157.88-787.20) 219.50 (121.65-728.99) 211.46 (64.07-1067.45) 0.52
VegF 5.00 (3.63-13.07) 10.02 (5.00-19.85) 5.38 (3.14-23.69) 0.32
Baseline values of the inflammatory mediators were not statistically different in patients with non-ischemic 
heart failure, ischemic heart failure, and controls. Medians ± interquartile ranges are shown. 
Abbreviations: Co, Controls; G-CSF, Granulocyte-Colony Stimulating Factor; IHF, Ischemic Heart Failure; 
IL, Interleukin; IL-1ra, Interleukin-1 receptor antagonist; IP-10, Interferon-inducible Protein-10; MCP-
1, Monocyte Chemoattractant Protein-1; NIHF, Non-Ischemic Heart Failure; RANTES, Regulated upon 
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Supplementary data, table 2. Baseline myocardial gene expression of inflammatory markers.
Δct (median, interquartile range) Kruskal-wallis
nIHF (n = 7) IHF (n = 8) Co (n = 7) P value
Il-1ra 8.85 (8.05 to 9.04) 4.80 (3.05 to 8.91) 6.16 (3.16 to 9.07) 0.20
Il-6 4.86 (2.99 to 6.83) 2.84 (-3.20 to 4.62) 1.28 (-2.32 to 2.97) 0.14
Il-8 3.84 (2.68 to 5.89) 2.76 (1.19 to 6.15) 4.68 (2.49 to 6.22) 0.88
Il-10 9.90 (4.95 to 11.75) 10.34 (6.59 to 11.78) 7.56 (5.06 to 10.17) 0.52
tnf-α 6.89 (6.63 to 8.25) 7.42 (3.94 to 8.84) 4.96 (4.00 to 5.74) 0.19
IL-1β 8.49 (6.25 to 8.53) 5.77 (4.83 to 8.68) 5.24 (4.55 to 8.65) 0.41
MMP-9 7.09 (6.24 to 8.55) 4.26 (2.80 to 7.08) 4.93 (3.38 to 6.05) 0.047*
CD68 4.89 (4.28 to 5.22) 2.81 (1.29 to 5.25) 2.49 (1.09 to 2.97) 0.13
MCP-1 6.11 (5.54 to 6.46) 2.91 (2.34 to 7.09) 3.25 (2.35 to 3.53) 0.16
mRNA expression was analyzed in endomyocardial tissue of patients with non-ischemic heart failure, 
ischemic heart failure, and controls. Levels of mRNA expression were determined using Ct values, i.e. number 
of cycles at which the fluorescent signal reaches a fixed threshold. ΔCt was calculated according to the 
formula: Ct target gene - Ct housekeeping gene. High ΔCt values reflect low mRNA expression levels. *Matrix 
metallopeptidase 9 expression was significantly different in early endomyocardial biopsies of patients with 
non-ischemic heart failure and controls (P = 0.01). 
Abbreviations: CD68, Cluster of Differentiation 68; Co, Controls; IHF, Ischemic Heart Failure; IL, Interleukin; 
IL-1ra, Interleukin-1 receptor antagonist; MCP-1, Monocyte Chemoattractant Protein-1; MMP, Matrix 
Metallopeptidase; NIHF, Non-Ischemic Heart Failure; TNF, Tumor Necrosis Factor.
supplementary data, table 3. Log relative changes in gene expression of inflammatory markers. 




nIHF (n = 7) IHF (n = 8) Co (n = 7)
Il-1ra 0.08 (-0.13 to 0.25) 0.74 (-0.98 to 1.84) 0.34 (-0.23 to 0.86) 0.63
Il-6 1.15 (0.07 to 1.88) 0.66 (-0.02 to 2.06) 0.45 (-0.09 to 1.27) 0.39
Il-8 0.45 (0.04 to 1.02) 1.52 (-0.67 to 1.99) 0.85 (-0.12 to 1.27) 0.57
Il-10 0.03 (-1.53 to 0.43) 0.49 (0.12 to 0.85) 0.40 (-0.47 to 0.90) 0.20
tnf-α 0.13 (-0.08 to 0.44) 0.03 (-0.08 to 0.42) 0.003 (-0.22 to 0.14) 0.23
IL-1β -0.12 (-0.62 to 0.26) 0.28 (0.05 to 1.13) 0.33 (-0.48 to 0.54) 0.20
MMP-9 0.48 (0.39 to 0.61) 0.25 (-0.58 to 1.09) 0.18 (0.03 to 0.70) 0.41
CD68 0.05 (-0.15 to 0.21) 0.25 (-0.61 to 0.80) -0.03 (-0.31 to 0.10) 0.48
MCP-1 0.30 (-0.12 to 0.46) 0.99 (-0.64 to 1.56) 0.21 (0.12 to 0.42) 0.85
Similar log relative changes in gene expression of inflammatory markers were observed in early versus late 
endomyocardial biopsies of patients with non-ischemic heart failure, ischemic heart failure, and controls. 
For each sample, ΔΔCt was calculated according to the formula: ΔCt target gene late biopsy − ΔCt target 
gene early biopsy. 
Abbreviations: CD68, Cluster of Differentiation 68; Co, Controls; IHF, Ischemic Heart Failure; IL, Interleukin; 
IL-1ra, Interleukin-1 receptor antagonist; MCP-1, Monocyte Chemoattractant Protein-1; MMP, Matrix 
Metallopeptidase; NIHF, Non-Ischemic Heart Failure; TNF, Tumor Necrosis Factor.
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AbStRACt
background: Mitral valve repair in patients with functional mitral regurgitation (FMR) has 
been associated with beneficial left ventricular (LV) reverse remodeling. Recently, galectin-3 
emerged as a marker of myocardial inflammation and fibrosis which may influence LV 
remodeling after surgery. The aim of the current study was to evaluate the association 
between preoperative galectin-3 levels, and LV reverse remodeling in heart failure patients 
with significant FMR who underwent mitral valve repair.
Methods and Results: In total, 42 heart failure patients (66 ± 10 years, 69% male) were 
evaluated. Plasma galectin-3 levels were assessed preoperatively. Two-dimensional 
echocardiographic parameters were measured at baseline, and at six and twelve months 
after surgery. LV reverse remodeling was defined as a decrease in LV end-systolic volume 
≥ 15% at six months follow-up. In total, 57% of the patients showed LV reverse remodeling. 
Patients with LV reverse remodeling showed significantly lower preoperative galectin-3 
levels (17.5 ± 5.6 vs. 23.7 ± 9.9 ng/mL, P = 0.009) compared with patients without LV 
reverse remodeling. In addition, patients with galectin-3 ≤ 18.2 ng/mL had a six-fold higher 
probability of showing LV reverse remodeling after surgery as compared with patients with 
levels > 18.2 ng/mL (odds ratio 6.58, 95% confidence interval 1.32 – 33.33, P = 0.02).
Conclusions: High preoperative plasma galectin-3 is independently associated with the 
absence of LV reverse remodeling after mitral valve repair. Galectin-3 may be useful to 
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IntRoDuCtIon
Surgical mitral valve repair in patients with heart failure, and moderate to severe functional 
mitral regurgitation (FMR) has been associated with improvement in clinical symptoms, left 
ventricular (LV) reverse remodeling and better prognosis.1-4 In particular, the occurrence of LV 
reverse remodeling has important prognostic implications, since the absence of significant 
LV reverse remodeling or the presence of progressive LV dilatation after surgical mitral valve 
repair has been associated with recurrence of mitral regurgitation and worse prognosis.2 
The incidence of favorable LV reverse remodeling ranges between 40% and 52% of the 
patients, according to different series.1, 3, 5 Preoperative LV dimensions have been associated 
with the extent of LV reverse remodeling after mitral valve repair.2 In particular, in patients 
with LV end-diastolic dimension > 65 mm, the presence of LV reverse remodeling after 
mitral valve repair is less frequent as compared with patients with smaller LV dimensions.2 
This suggests that a severely dilated left ventricle may not show reverse remodeling after 
restoration of valvular function and volume load. Therefore, additional surgical procedures 
have been proposed to improve the outcomes of patients with FMR and severe LV dilatation 
undergoing mitral valve repair.2 Detailed knowledge of the pathophysiological mechanisms 
underlying LV reverse remodeling after mitral valve repair may prompt the search for novel 
(surgical) therapies that lead to improved outcomes. 
Recently, it has been demonstrated that galectin-3, a novel biomarker in patients 
with heart failure, plays a key role in myocardial fibrosis processes that may influence LV 
remodeling after surgery.6-8 In animal models, intrapericardial infusion of galectin-3 has 
been associated with increased deposition of collagen I and induction of LV dysfunction.9 
However, whether galectin-3 is associated with LV reverse remodeling after mitral valve 
repair remains unexplored. Therefore, the aim of the present study was to evaluate the 
association between preoperative galectin-3 levels and LV reverse remodeling in non-
ischemic and ischemic heart failure patients with moderate to severe FMR who underwent 
mitral valve repair. 
MetHoDS
Patient population
In total, 42 patients were included to participate in this two-year prospective observational 
study: 18 patients with non-ischemic heart failure and 24 patients with ischemic heart 
failure. Patients with heart failure and significant FMR who underwent surgical mitral valve 
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pressure, New York Heart Association (NYHA) functional class, quality of life score (according 
to the Minnesota Living with Heart Failure Questionnaire), six-minute walk test (6-MWT), 
medical treatment, and co-morbidities. In addition, common laboratory parameters were 
assessed, including hemoglobin, C-reactive protein, and creatinine. Glomerular filtration 
rates (GFRs) were calculated according to the Modification of Diet in Renal Disease formula, 
and renal dysfunction was defined as recommended by the National Kidney Foundation 
and the Kidney Disease Outcomes Quality Initiative Guidelines (estimated GFR (eGFR) < 60 
mL/min/1.73m2).10 Moreover, logistic EuroSCOREs were calculated in all patients to assess 
the peri-operative risk. All patients had NYHA function class II-IV heart failure symptoms, 
moderate to severe FMR, and reduced LV ejection fraction (LVEF < 60%).11 
One day before surgery, venous galectin-3 levels were determined in resting conditions. 
Moreover, two-dimensional (2D) echocardiography was performed before surgery and 
repeated before hospital discharge, and six and twelve months after surgery. Clinical and 
echocardiographic data were collected at the departmental Cardiology Information System 
(EPD-Vision®, Leiden University Medical Centre) and the echocardiography database, 
respectively, and retrospectively analyzed. 
This study complied with the Declaration of Helsinki, was approved by our local ethics 
committee, and written informed consent was obtained from all patients.
Echocardiography
Images were acquired at rest with the patient in the left lateral decubitus position using a 
commercially available system (Vivid 7 and E9, General Electric-Vingmed, Horten, Norway). 
Data acquisition was performed with a 3.5-MHz transducer in the parasternal and apical 
views. M-mode and 2D images were obtained and saved in cine-loop format. Data analysis 
was performed offline (EchoPAC version 111.0.0; General Electric-Vingmed, Horten, 
Norway). LV end-systolic volumes and end-diastolic volumes were measured in the apical 
2- and 4-chamber views using the biplane Simpson’s method and the LVEF was calculated.12 
LV volumes were indexed to body surface area. The intra-observer agreement for LV end-
systolic and end-diastolic volume, and LVEF were 7.0 ± 10.1 mL, 7.4 ± 11.2 mL, and 1.9 
± 4.4%, respectively. The inter-observer agreement for LV end-systolic and end-diastolic 
volume, and LVEF were 11.3 ± 13.9 mL, 12.9 ± 14.7 mL, and 2.5 ± 4.9%, respectively.13 
LV reverse remodeling was defined as a reduction in LV end-systolic volume of ≥ 15% at 
six months follow-up (or at twelve months follow-up when not available).3, 4 Baseline LV 
volumes and LVEF were measured in all patients. In patients who underwent concomitant 
LV reconstruction surgery, LV end-systolic volumes were also measured before hospital 
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Severity of FMR was assessed using a multiparametric approach, including the effective 
regurgitant orifice area and regurgitant volume calculated with the proximal isovelocity 
surface area method.14 Color Doppler images were obtained using a Nyquist limit of 30-60 
cm/s and a color gain that just removes random color speckle from non-moving areas.14, 15 
In addition, LV sphericity index was calculated at end-systole and end-diastole as 
the ratio between the LV-short-axis diameter and the LV long-axis diameter in the apical 
4-chamber view.16, 17 Moreover, maximal left atrial volume was measured according to the 
biplane Simpson’s technique in the apical 2-chamber and 4-chamber views and indexed to 
the body surface area, as recommended.12
Finally, systolic pulmonary artery pressure was assumed by adding the right ventricular 
pressure to the right atrial pressure. Right ventricular pressure was estimated by calculating 
the systolic pressure gradient between the right ventricle and right atrium by the maximum 
velocity of the regurgitant jet using the modified Bernoulli equation.18 Right atrial pressure 
was estimated by measuring the diameter and the inspiratory collapse of the inferior vena 
cava, as recommended.18
 
Measurement of circulating levels of galectin-3 
Plasma galectin-3 levels were measured in samples collected the day before surgery using 
a commercially available enzyme-linked immunosorbent assay (BG Medicine, Waltham, 
MA, USA). The lower detection limit was 1.13 ng/mL.19 The assay has been optimized and 
standardized, and intra- and inter-assay variation have been reported.19 In addition, no 
potential interference was found for commonly used cardiovascular medications with this 
galectin-3 assay.20 
Measurement of N-terminal pro-brain natriuretic peptide
Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were determined 
in samples collected the day before surgery by using proBNP and proBNP II kits from 
Roche Diagnostics on a Modular Analytics E170 analyser (Roche Diagnostics, Mannheim, 
Germany). A sandwich-type quantitative immunoassay was performed using antibodies 
against epitopes in the N-terminal part of proBNP. The lower detection limit was 5 ng/L. 
Total coefficients of variance at low concentrations (77 ng/L) and high concentrations (2,170 
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Surgical procedures 
All surgical procedures were performed via a midline sternotomy under normothermic 
cardiopulmonary bypass with intermittent antegrade warm-blood cardioplegia and heparin 
softline coating. An external cardiac support device (CorCap cardiac support device, Acorn 
Cardiovascular, St. Paul, MN, USA) was placed in patients with non-ischemic heart failure 
and a LV end-diastolic diameter > 65 mm, measured on the preoperative echocardiographic 
examination. Patients with ischemic heart failure underwent a coronary artery bypass 
grafting procedure based on the preoperative coronary angiogram, and were considered 
eligible for ventricular reconstruction as described by Dor et al. if akinesia or dyskinesia 
was present in a large area of the anterior LV wall.21, 22 Mitral valve repair was considered 
successful if there was no residual mitral regurgitation, and if a leaflet coaptation height of 
≥ 8 mm at the A2-P2 level was achieved as measured directly after the surgical procedures.23 
Statistical analysis
Continuous data are presented as the mean ± standard deviation or standard error of the 
mean, or median with 25th and 75th interquartile ranges, where appropriate. Categorical 
data are expressed as frequencies and percentages. Changes in LV volumes and EF during 
follow-up in the overall population were assessed by linear mixed models. Patients were 
divided into two subgroups based on the occurrence of LV reverse remodeling during 
follow-up. Clinical and echocardiographic differences at baseline were evaluated between 
these subgroups with the unpaired Student’s t-test and χ2 test. For this analysis, galectin-3, 
NT-proBNP, C-reactive protein, creatinine, and eGFR values were log-transformed to obtain 
a Gaussian distribution. Statistical tests that required normality (or rather symmetry) 
were applied on these transformed data. Thereafter, data were back-transformed to the 
original data scales, and expressed as means with confidence intervals (CIs). Subsequently, 
differences in changes in LV volumes and EF over time between patients with LV reverse 
remodeling, and patients without were analyzed with linear mixed models. Moreover, to 
assess the association between baseline log-transformed galectin-3 levels and changes in 
LV volumes during follow-up, correlation analysis was performed using Pearson correlation 
coefficients. Again, after performing the statistical tests, data were back-transformed to the 
original scales. 
In addition, receiver operating characteristic (ROC) curve analysis was performed to 
determine the sensitivity and specificity for various cut-off values of baseline galectin-3 
levels for the prediction of LV reverse remodeling. Finally, univariate and multivariate 
logistic regression analyses were performed to identify independent baseline clinical and 
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follow-up. All significant univariate variables (P < 0.05) were included in a multivariate logistic 
regression model. To avoid multicollinearity between univariate predictors, a correlation 
coefficient of < 0.7 was set.24 
All statistical tests were two-sided, a P value < 0.05 was considered statistically significant. 




In total, 42 heart failure patients with moderate to severe FMR (mean age 66 ± 10 years, 69% 
men) were evaluated. Baseline characteristics of the patient population are summarized in 
Table 1. The mean galectin-3 level was 20.1 ± 7.9 ng/mL, which is comparable to previously 
published heart failure cohorts. All patients underwent surgical mitral valve repair; 18 
patients also received an external cardiac support device and 24 patients underwent 
concomitant ventricular reconstruction surgery (n = 10), and/or coronary artery bypass 
surgery (n = 14). Tricuspid valve annuloplasty, aortic valve replacement, and ablation 
procedures were additionally performed if indicated (Table 2). 
Surgical outcomes
There were no intra-operative deaths. Early mortality (30-day mortality and in-hospital 
mortality when length of stay after surgery was > 30 days) was 4.8% (two patients). One 
patient with non-ischemic heart failure died eight days after surgery as a result of ventricular 
fibrillation. The other patient with ischemic heart failure died 41 days after surgery as a 
result of refractory heart failure after ventricular reconstruction surgery.
Time course of New York Heart Association functional class, left ventricular volumes, and 
ejection fraction
Within the first six months after surgery, two patients died of a cardiac cause as discussed 
above. Moreover, 2D echocardiography was not available at six and twelve months follow-
up in three patients. As a result, echocardiography at six and/or twelve months follow-up 
was available in 37 patients (88%). Of these patients, 28 patients had an echocardiogram 
at both six and twelve months follow-up, four patients only had an echocardiogram at 6 
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n = 42 n = 21 n = 16
Clinical characteristics
   Age (years) 66 ± 10 64 ± 11 66 ± 8 0.50
   Male gender 29 (69%) 16 (76%) 11 (69%) 0.61
   body surface area (m2) 2.02 ± 0.21 2.08 ± 0.21 1.98 ± 0.20 0.16
   Ischemic etiology 24 (57%) 12 (57%) 8 (50%) 0.67
   Systolic blood pressure (mmHg) 117 ± 16 118 ± 15 114 ± 18 0.55
   Diastolic blood pressure (mmHg) 70 ± 11 71 ± 10 71 ± 13 0.94
   Logistic EuroscoRE (%) 10.0 ± 5.8 10.1 ± 6.4 8.8 ± 3.8 0.45
   nyha functional class 2.9 ± 0.3 2.9 ± 0.4 2.9 ± 0.3 0.45
   Qol score 28 ± 15 26 ± 13 32 ±17 0.33
   6Mwt (m) 381 ± 109 395 ± 122 380 ± 76 0.73
Comorbidities 
   Diabetes 11 (26%) 7 (33%) 3 (19%) 0.32
   CoPD 7 (17%) 3 (14%) 3 (19%) 0.72
   AF 10 (24%) 4 (19%) 5 (31%) 0.39
Laboratory tests
   Galectin-3 (ng/mL) 18.9 [17.1 – 20.9] 16.8 [14.9 – 18.9] 22.4 [19.1 – 26.3] 0.009
   nt-probnP (pg/ml)    1,408 [1,054 – 1,882] 1,108 [750 – 1,636] 1,826 [1,164 – 2,864] 0.12
   Hb (mmol/l) 8.7 ± 0.9 8.8 ± 0.8 8.7 ± 0.9 0.87
   CRP (mg/l)    2.4 [0.3 – 17.6] 2.3 [1.8 – 3.1] 2.3 [ 1.8 – 3.1] 0.98
   creatinine (μmol/L)    65 [59 – 72] 86 [77 – 95] 105 [89 – 123] 0.04
   egFR (ml/min/1.73m2) 92 [85 – 99] 74 [65 – 83] 56 [47 – 67] 0.01
   egFR < 60 ml/min/1.73m2 14 (33%) 4 (19%) 9 (56%) 0.02
Medication 
   ACe-inhibitors / ARbs 38 (91%) 19 (91%) 15 (94%) 0.72
   beta-blockers 39 (93%) 20 (95%) 15 (94%) 0.84
   statins 33 (78%) 17 (81%) 12 (75%) 0.66
   Diuretics 38 (91%) 19 (91%) 15 (954%) 0.72
   Digoxins 6 (14%) 2 (10%) 4 (25%) 0.21
Echocardiography
   lVeSV (ml/m2) 73 ± 26 156 ± 56 143 ± 41 0.44
   lVeDV (ml/m2) 102 ± 30 105 ± 31 105 ± 33 0.99
   LVEf (%) 30 ± 6 29 ± 7 30 ± 6 0.59
   lV sphericity index end-diastole 58 ± 8 58 ± 8 58 ± 9 0.39
   lV sphericity index end-systole 53 ± 9 58 ± 9 58 ± 10 0.85
   lAVI (ml/m2) 41 ± 16 40 ± 12 44 ± 20 0.99
   SPAP (mmHg) 33 ± 16 33 ± 16 34 ± 16 0.65
   Mean MR grade 3.0 ± 0.4 3.1 ± 0.4 3.1 ± 0.4 0.82
   eRoA (cm2) 0.27 ± 0.11 0.26 ± 0.09 0.29 ± 0.14 0.43
   R Vol (ml/beat) 41 ± 14 39 ± 13 44 ± 17 0.32
Data are presented as mean ± standard deviation, mean [confidence interval] or as number (percentage). 
P values are given for the comparisons of patients with and without LV reverse remodeling.
Abbreviations: 6MWT, six-Minute Walk Test; ACE, Angiotensin Converting Enzyme; AF, Atrial Fibrillation; 
ARB, Angiotensin Receptor Blocker; COPD, Chronic Obstructive Pulmonary Disease; CRP, C-Reactive Protein; 
eGFR, estimated Glomerular Filtration Rate; EROA, Effective Regurgitation Orifice Area; Hb, Hemoglobin; 
IQR, Interquartile Range; LAVI, Left Atrial Volume Index; LV, Left Ventricular/Ventricle; LVEDV, Left Ventricular 
End-Diastolic Volume; LVEF, Left Ventricular Ejection Fraction; LVESV, Left Ventricular End-Systolic Volume; 
MR, Mitral Regurgitation; NT-proBNP, N-Terminal Pro-brain Natriuretic Peptide; NYHA, New York Heart 
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Echocardiographic characteristics of the total patient population at baseline, and at six 
and twelve months follow-up are summarized in Figure 1. A significant decrease in LV end-
systolic (baseline: 73 ± 4 mL/m2; six months: 55 ± 4 mL/m2; twelve months: 54 ± 4 mL/m2, 
P < 0.001), and end-diastolic volumes (baseline: 102 ± 5 mL/m2; six months: 84 ± 5 mL/m2; 
twelve months: 85 ± 5 mL/m2, P < 0.001) was observed over time. These changes resulted 
in a significant improvement in LVEF from 30 ± 1% at baseline to 34 ± 1% at six months 
follow-up, and to 37 ± 2% at twelve months follow-up (P = 0.005 for trend over time). In 
patients with concomitant LV reconstruction or use of Corcap cardiac support device, the 
time evolution of LV volumes is provided in the Supplementary data, Tables 1 and 2.
Importantly, these LV volumetric and functional improvements were accompanied by 
improvements in NYHA functional class (baseline: 2.9 ± 0.0, six months: 1.9 ± 0.1, twelve 
months: 2.0 ± 0.1, P < 0.001). 
Patients with left ventricular reverse remodeling vs. non-left ventricular reverse remodeling
Patients were divided into two subgroups based on the occurrence of LV reverse remodeling 
at six months follow-up (or, when not available, at twelve months follow-up). LV reverse 
remodeling (reduction in LV end-systolic volume ≥ 15%) was observed in 21 patients (57%). 
The differences in baseline characteristics between patients with and without LV reverse 
remodeling are shown in Table 1. Patient groups were comparable in terms of clinical 
characteristics, comorbidities, medical treatment, and echocardiographic characteristics. 
However, patients who showed LV reverse remodeling also demonstrated a better 
preservation of renal function compared with patients who did not show LV reverse 
remodeling. In addition, patients showing LV reverse remodeling had significantly lower 
baseline galectin-3 levels compared with patients without LV reverse remodeling (16.8 [14.9 
– 18.72] versus 22.4 [19.1 – 26.31] ng/mL, P = 0.009). 
In both patient groups, significant improvements in NYHA functional class were observed, 
albeit that this improvement was more pronounced in patients with LV reverse remodeling: 
from 2.9 ± 0.1 at baseline to 1.6 ± 0.2 and 1.9 ± 0.2 (P < 0.001) at six and twelve months, 
respectively, in patients with LV reverse remodeling versus from 2.9 ± 0.1 to 2.2 ± 0.2 and 2.2 
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figure 1. Echocardiographic data in heart failure patients. 
Time course of (A) LV end-systolic volumes (LVESV), (B) LV end-diastolic volumes (LVEDV), and (C) 
LV ejection fractions (LVEF) in heart failure patients who underwent mitral valve repair. Data are 
presented as mean ± standard error of the mean. * P < 0.05 compared with baseline. 
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Association between preoperative galectin-3 and LV reverse remodeling
A significant correlation was observed between baseline galectin-3 levels and changes in LV 
end-systolic volume after mitral valve repair (r = 0.47, P = 0.003, Figure 2).
Figure 2. correlation between baseline log-transformed galectin-3 levels and changes in LV end-
systolic volume after mitral valve repair. 
Five patients with high log-transformed galectin-3 levels (≥ 2.9; geometrical mean of ≥ 18.2 ng/mL) 
showed significant LV reverse remodeling (≥ 25% reduction): three patients underwent coronary 
artery bypass grafting and two patients received an external cardiac support device in addition to 
their mitral valve repair.
According to the ROC curve analysis, galectin-3 levels at baseline showed a modest 
accuracy to predict LV reverse remodeling, with an area under the curve (AUC) of 0.77. The 
highest sensitivity and specificity could be demonstrated at a cut-off value of galectin-3 of 
18.2 ng/mL (Figure 3).
Univariate and multivariate logistic regression analyses were performed to evaluate 
the association between LV reverse remodeling and galectin-3 (Table 3). The final 
multivariate model included galectin-3 ≤ 18.2 ng/mL and eGFR < 60 mL/min/1.73 m2. In 
this model, galectin-3 ≤ 18.2 ng/mL (odds ratio 6.58, 95% confidence interval 1.32 – 33.33, 
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figure 3. Prediction of LV reverse remodeling with galectin-3 levels. 
Receiver operating characteristic (ROC) curve analysis demonstrated a sensitivity of 67% with a 
specificity of 81% to predict LV reverse remodeling following mitral valve repair at a cut-off of log-
transformed galectin-3 of 2.9 at baseline. This level corresponds to a non log-transformed value of 
18.2 ng/mL. 







n = 42 n = 21 n = 16
CorCap® 18 9 8
LV reconstruction 10 5 4
caBG (mean number of grafts) 24 (2.5) 13 (2.3) 7 (2.4)
Mitral valve annuloplasty 42 21 16
tricuspid valve annuloplasty 22 12 9
aortic valve replacement 2 0 2
af ablation 8 4 4
Vt ablation 5 1 3
CRt 27 15 10
Abbreviations: AF, Atrial Fibrillation; CABG, Coronary Artery Bypass Grafting; CRT: Cardiac Resynchronization 
Therapy; LV, Left Ventricular/Ventricle; VT, Ventricular Tachycardia.
table 3. Determinants of left ventricular reverse remodeling after mitral valve repair.
Univariate analysis         Multivariate analysis
oR 95% cI P value oR 95% cI P value
Galectin-3 ≤ 18.2 ng/mL 8.70 1.84 – 40.00 0.006 6.58 1.32 – 33.33 0.02
egFR < 60 ml/min/1.73m2 0.18 0.04 – 0.80 0.02 0.28 0.06 – 1.37 0.12
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DISCuSSIon
The present study demonstrates that lower preoperative galectin-3 levels are independently 
associated with LV reverse remodeling after mitral valve repair in heart failure patients with 
moderate to severe FMR. Heart failure patients with a galectin-3 level ≤ 18.2 ng/mL had a 
six-fold higher probability of showing LV reverse remodeling as compared with patients with 
a galectin-3 value > 18.2 ng/mL.
Left ventricular remodeling after mitral valve repair in heart failure patients  
The incidence of LV reverse remodeling after mitral valve repair in patients with heart failure 
and FMR still remains relatively low.1-4 Several pathophysiological factors are involved in the 
LV reverse remodeling process after surgical mitral valve repair. A previous study has shown 
that preoperative LV dimensions are predictive of LV reverse remodeling after mitral valve 
repair, suggesting that very distorted and diseased left ventricles may no longer recover 
after restoration of mitral valve function, and additional surgical procedures may be needed 
(such as CorCap® devices).2 In addition, LV fibrosis and inflammation may also be important 
determinants of LV reverse remodeling after mitral valve repair.8, 25, 26 In patients with mitral 
valve regurgitation, Oral et al. showed that preoperative levels of tumor necrosis factor-α 
were significantly associated with changes in LV volumes following surgery, emphasizing the 
role of inflammation in LV remodeling.27 Reduction in LV dimensions after surgical mitral 
valve repair has been largely associated with improved outcome. Therefore, understanding 
the underlying pathophysiological determinants of LV remodeling may be an important clue 
to provide tailored surgical strategies to improve the outcome of heart failure patients with 
FMR. In particular, evaluation of biomarkers associated with LV remodeling, such as the 
β-galactoside-binding lectin galectin-3, may provide further insight into this field. 
Galectin-3: a marker of inflammation, fibrosis, and cardiac remodeling
Recently, galectin-3 emerged as a novel biomarker in patients with heart failure.6, 7 Galectin-3 
is secreted by activated macrophages and involved in various physiological and pathological 
processes.6, 7, 9 Preclinical studies provide evidence on the association between inflammation, 
fibrosis, and cardiac remodeling, with galectin-3 as the main underlying pathophysiological 
factor.9 Patients with heart failure show increased levels of galectin-3 compared with the 
general population, and several studies demonstrated the prognostic value of elevated 
galectin-3 levels in this population.19, 28-32 In addition, Lok et al. recently observed in 240 
chronic heart failure patients that baseline galectin-3 values were independently correlated 
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association between galectin-3 and occurrence of LV reverse remodeling after heart failure 
therapies (including surgical mitral valve repair) remains unknown.  
Galectin-3: a marker of left ventricular reverse remodeling after mitral valve repair 
The present study provides additional information on the association between baseline 
galectin-3 levels and LV reverse remodeling in patients with non-ischemic and ischemic 
heart failure, and moderate to severe FMR undergoing mitral valve repair. As hypothesized, 
one of the major findings was an independent association between preoperative galectin-3 
levels and LV reverse remodeling during follow-up. We observed that a cut-off value of 18.2 
ng/mL best predicted LV reverse remodeling. This value is very close to the 17.8 ng/mL 
cut-off value in the Food and Drug Administration (FDA) label, that was set to prognosticate 
stable heart failure patients. Patients with low preoperative values of galectin-3 more 
frequently showed LV reverse remodeling compared with patients with high preoperative 
levels of galectin-3. This suggests that patients without LV reverse remodeling may have had 
an enhanced inflammatory and pro-fibrotic status compared with patients who did show LV 
reverse remodeling. Therefore, galectin-3 levels may be an important marker of LV reverse 
remodeling after surgical mitral valve repair, possibly via modulation of fibrosis. 
Current guidelines provide recommendations on medical, device-based, and surgical 
therapies of patients with heart failure.33 In addition, identification of patients who will 
benefit from those therapies, specifically device-based and surgical therapies, is paramount. 
Evaluation of the pathological substrate (LV volumes and EF, extent and location of scar, 
and LV dyssynchrony) has been proposed to improve selection of patients for specific 
therapies. In this regard, heart failure patients undergoing surgical mitral valve repair and LV 
reconstruction surgery may benefit from a thorough pre-procedural evaluation to anticipate 
to the therapy outcomes. In this regard, the results of the present hypothesis-generating 
evaluation points towards the relevance of assessing LV fibrosis and inflammatory activity 
in these patients, by measuring, for example, galectin-3 levels. Moreover, measurement of 
galectin-3 levels may potentially be helpful in the selection of patients who will benefit from 
transcatheter valve repair in terms of LV reverse remodeling.34, 35 The present results should 
be considered hypothesis-generating and must be confirmed in larger trials or registries 
before being implemented in daily clinical practice. 
Limitations
Some limitations should be acknowledged. The present study has an observational design 
and has a relatively small sample size with various etiologies of heart failure and treatment 
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performing subgroup analyses and evaluating the impact of galectin-3 levels on long-term 
prognosis. Furthermore, no follow-up galectin-3 assessments were available, which could 
have clarified further the relationship between this biomarker and LV geometry. Finally, our 
echocardiographic follow-up period was limited to twelve months after surgery, although 
we can not exclude that the process of LV reverse remodeling takes longer.3
Conclusion
In conclusion, preoperative plasma galectin-3 is independently associated with LV reverse 
remodeling after mitral valve repair for FMR in heart failure patients. Therefore, measuring 
plasma galectin-3 may be useful for the identification of patients who will respond to 
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supplementary data, table 1. time course of left ventricular volumes and ejection fractions in 











lVeSV (ml/m2) 76 ± 12 45 ± 3 38 ± 3 † 39 ± 4 † 0.03
lVeDV (ml/m2) 105 ± 12 68 ± 4 61 ± 5 †‡ 63 ± 6 † 0.002
LVEf (%) 30 ± 3 34 ± 3 37 ± 2 40 ± 4 0.32
Data are presented as mean ± standard error of the mean. 
P values are given for the overall change over time. 
† P < 0.05 compared with pre-surgery measurements (adjusted for multiple comparisons). 
‡ P < 0.05 compared with before discharge measurements (adjusted for multiple comparisons).
Abbreviations: LVEDV, Left ventricular End-Diastolic Volume; LVEF, Left Ventricular Ejection Fraction; LVESV, 
Left Ventricular End-Systolic Volume.
supplementary data, table 2. time course of left ventricular volumes and ejection fractions in 
patients who underwent an external cardiac support device implantation in addition to mitral valve 










lVeSV (ml/m2) 76 ± 6 74 ± 6 66 ± 6 †‡ 65 ± 7 †‡ 0.005
lVeDV (ml/m2) 105 ± 8 105 ± 8 95 ± 8 96 ± 8 0.04
LVEf (%) 29 ± 1 30 ± 1 31 ± 2 32 ± 2 0.13
Data are presented as mean ± standard error of the mean. 
P values are given for the overall change over time. 
† P < 0.05 compared with pre-surgery measurements (adjusted for multiple comparisons). 
‡ P < 0.05 compared with before discharge measurements (adjusted for multiple comparisons).
Abbreviations: LVEDV, Left ventricular End-Diastolic Volume; LVEF, Left Ventricular Ejection Fraction; LVESV, 
Left Ventricular End-Systolic Volume.
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AbStRACt
background: Inflammation is considered a key mediator of complications after cardiac surgery. 
Sevoflurane has been shown to quench inflammation and to provide cardioprotection in 
preclinical studies. Clinical studies using sevoflurane confirm this effect on inflammation but 
fail to show a clinical benefit. This paradox may indicate that the contribution of inflammation 
to postoperative squalae is less than commonly thought or, alternatively, that doses used 
in clinical studies are too low. To test the latter we evaluated the effect of intramyocardial 
sevoflurane delivery. 
Methods: Selective myocardial sevoflurane delivery was performed during aortic cross-
clamping in patients undergoing mitral valve surgery (n = 11). Results were compared with 
a control group not receiving sevoflurane (n = 10). A reference group (n = 5) was added 
to evaluate the effects of systemic sevoflurane delivery. Paired arterial and myocardial 
venous blood samples were collected at various time points after reperfusion. Inflammatory 
mediators and myocardial cell damage were studied.  
Results: Selective (myocardial) and systemic sevoflurane delivery effectively suppressed 
surgery-related inflammatory responses including postoperative C-reactive protein (P = 0.01 
and P = 0.04, respectively). Intramyocardial delivery was superior to systemic delivery in 
attenuation of interleukin-6 and interleukin-8 (both P = 0.001). Sevoflurane treatment did 
not reduce postoperative myocardial damage as assessed by troponin T, creatine kinase, 
and creatine kinase-MB levels (P = 0.87, 0.38, and 0.17, respectively).
Conclusions: This clinical proof-of-concept study shows that intramyocardial delivery of 
sevoflurane is superior to its systemic delivery with respect to attenuation of the systemic 
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Introduction
A pronounced inflammatory response following on-pump cardiac surgery is linked to 
postoperative circulatory failure. Moreover, this response is considered a major contributor 
to postoperative morbidity and mortality.1, 2 Consequently, it has been suggested that anti-
inflammatory strategies, attenuating this response, are of benefit. 
The hypothesized anti-inflammatory potential and tissue protective properties of 
sevoflurane, a frequently used volatile anesthetic, have been firmly established in preclinical 
studies.3-6 The anti-inflammatory potential of sevofluane has been confirmed in several clinical 
studies, including patients undergoing cardiac surgery with the use of cardiopulmonary 
bypass (CPB).7, 8 Yet, in contrast to animal studies, clinical studies do not show an overt 
cardioprotective or clinical benefit of volatile anesthetics such as sevoflurane.9-13
Absence of this clinical benefit in humans may suggest that the contribution of the 
inflammatory response to perioperative sequelae is less pronounced than commonly 
thought. Alternative explanations are apparent fundamental differences in the inflammatory 
response between rodent models and patients14 or sevoflurane levels established in clinical 
studies are simply too low to show a clinical benefit. As such, it can not be excluded that 
clinical benefits are observed at higher concentrations. Although systemic toxicity limits the 
dosing, high local concentrations can be established during local, direct administration to 
an organ at risk. This approach is well achievable in the clinical context of cardiac surgery 
during which sevofluane can be directly delivered to the heart in the cardioplegia solution 
used during on-pump cardiac surgery.15, 16 
In this proof-of-concept study, we tested whether sevoflurane-enriched warm blood 
cardioplegia solution attenuates postoperative inflammatory responses and myocardial 
cell damage. In order to differentiate between local and systemic effects we applied the 
technique of selective arteriovenous concentration differences over the reperfused heart. 
This set-up allows for independent evaluation of local and systemic effects.
MetHoDS
Patient characteristics 
Twenty-one patients scheduled for elective mitral valve surgery were included in this 
prospective interventional study. Eleven patients received intramyocardial sevoflurane 
(experimental group) and ten patients were included as controls. Randomization was 
accomplished through use of sealed envelopes. Participating patients were blinded for 
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Because of unanticipated systemic effects in the sevofluane treated group, we performed 
an additional reference experiment in five other patients in whom sevoflurane (0.5%) was 
delivered systemically. All patients had severe mitral regurgitation due to degenerative 
mitral valve disease. Exclusion criteria were left ventricular dysfunction (ejection fraction 
below 35%), minimal invasive or emergency procedures, previous cardiac surgery and the 
use of ketamine, aprotinin, corticosteroids, and volatile sevoflurane perioperatively. This 
single center study was approved by the ethics committee of the Leiden University Medical 
Center and each patient provided written informed consent. Moreover, this study was 
registered in the Nederlands Trial Register (NTR2089). 
Anesthesia and surgical procedures
All patients received standardized anesthetic procedures according to a fast-track protocol. In 
detail, all patients were premedicated with oral lorazepam 1-2 mg the evening and morning 
before surgery. The anesthetic regimen consisted of a continuous target controlled infusion 
of propofol (with targets adjusted between 1.6 and 2 μg/mL to maintain a bispectral index 
value between 40-60), remifentanil (guided by hemodynamic responses on stimuli) and 
sufentanil 0.1 μg/kg/hour. If necessary, inotropes (dobutamine, norepinephrine, enoximone 
or in combination) were used. All patients underwent mitral valve repair according to 
standard operating techniques including an annuloplasty as part of their repair procedure, 
except for one patient in which a repair was not possible due to extensive calcifications. 
Surgery was executed via a median sternotomy with normothermic CPB (Jostra Maquet, 
Maquet, Hirrlingen, Germany) and intermittent antegrade warm-blood cardioplegia. 
Delivery of sevoflurane
A standardized CPB protocol was used in all patients. After aortic and bicaval cannulation, 
normothermic CPB was initiated. The CPB system was coated with a heparin-free bioinert 
coating and a Kids D-100 oxygenator (Sorin group, Mirandola, Italia) was added to maintain 
pO2 and pCO2 concentrations within the normal range (15-20 kPa and 4.5-6.0 kPa, 
respectively). The CPB system was primed with 1300 mL priming volume consisting of 1000 
mL Voluven® 6%, 100 mL Mannitol 20% and 200 mL Ringer solution. In addition, a loading 
dose of 5000 IU of heparin was added. 
While administrating intermittently an antegrade warm-blood cardioplegia solution with 
a flow of approximately 450 mL/min, a gas flow of 1000 mL/min was given with an oxygen 
concentration of 21% and around 100 mL/min carbon dioxide. In the experimental group, 
sevoflurane 2% was administrated directly to the heart by addition of sevoflurane to this 
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and repeated every 15-20 minutes. In the reference group, a time frame and concentration 
was chosen to approximate the systemic exposure of myocardial sevoflurane delivery: 0.5 
L/min (cardioplegia flow) * 2% sevoflurane * 3 minutes (maximal duration of cardioplegia) 
= 4.5 L/min (blood flow) * 0.5% sevoflurane * 1.33 minutes (80 seconds). Sevoflurane 
was administrated in between two gifts of cardioplegia solution. With this perfusion 
technique, sevoflurane could not enter the coronary circulation. Exclusion criteria in all 
three patient groups were pulsatile flow, autologous priming, and ultrafiltration, since these 
measurements might influence the levels of inflammatory mediators. Heparin was reversed 
using protamine sulphate. Aspirated chest suction blood was collected in an autotransfusion 
reservoir (BT894, Dideco, Mirandola, Italy) before heparinization and after administration 
of protamine, and returned to the patient only after having been washed, using an Electa 
Concept (Dideco, Mirandola, Italy). 
Sample collection
A baseline sample was taken the day before surgery from the brachial vein. Arterial and 
myocardial venous blood samples were collected simultaneously over the reperfused heart 
resulting in accurate, and specific measurements of locally ongoing processes in the early 
(0, 15, 30, 45, and 60 minutes after reperfusion) and late reperfusion phase (2, 4, 8, 16, and 
24 hours after reperfusion), as described recently.17, 18
Inflammatory mediators
Multiplex analysis was used to evaluate arterial and myocardial venous cytokine patterns. 
Based on a previous study18, 12 cytokines were measured with a sensitive custom made 
multiplex assay according to the manufacturers’ instructions (X-plex, Biorad, Veenendaal, 
The Netherlands): IL-1 receptor antagonist (IL-1ra), IL-6, IL-8, IL-9, IL-10, IL-16, IL-18, 
granulocyte colony-stimulating factor (G-CSF), interferon-inducible protein-10 (IP-10) also 
know as C-X-C motif chemokine 10 (CXCL10), monocyte chemoattractant protein-1 (MCP-
1), regulated upon activation, normal T cell expressed and secreted (RANTES) also know as 
chemokine ligand 5 (CCL5) and vascular endothelial growth factor (VEGF).
Intramyocardial p65-nuclear factor-kappa B activity
The nuclear factor (NF)-κB family member p65 controls the transcription of various genes 
central to inflammation and immunity. Unfettered activation of NF-kB is associated with 
various inflammatory diseases.19 To quantify p65-NF-κB activity in myocardial tissue, paired 
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Myocardial p65-NF-κB activity was determined as described previously, using a TransAM 
transcription factor assay kit (DNA binding ELISA) (no. 40097, Active Motif Europe, Rixensart, 
Belgium).20 
Myocardial cell damage
Three established blood markers of myocardial cell damage were measured at baseline 
(brachial vein), at 2, 4, 8, 16, and 24 hours after reperfusion (radial artery), and at 3 and 
5 days after surgery (brachial vein). The markers of interest were high sensitive cardiac 
troponin T (hs cTnT; fifth generation, cat no 05092744190), creatine kinase activity (CK; cat 
no 12132672216) and creatine kinase-MB subfraction activity (CK-MB; cat no 12132893216). 
All reagents were purchased from Roche Diagnostics (Mannheim, Germany) and all analyses 
were done in EDTA plasma on Roche automated clinical chemistry analyzers. CK reference 
values at 37 °C are < 167 U/L for women and < 190 U/L for males; CK-MB reference values 
at 37 °C are < 24 U/L. For hs cTnT the 99th percentile, which is per definition the upper 
reference limit of a normal population, is 0.014 μg/L. 
Statistical analysis
Comparisons between continuous variables were made by means of the Mann-Whitney 
U-test. Categorical variables were analyzed with a Chi-square test. The area under the curve 
(AUC) was calculated for the arterial and venous curves of the plasma measurements for the 
early and late reperfusion phases. A delta AUC was calculated (venous minus arterial) and 
the null-hypothesis (delta AUC is 0) was tested by a paired t-test. Arterial AUCs were also 
compared separately using an unpaired t-test. AUCs of the three markers of myocardial cell 
damage were calculated, and compared with a Kruskal-Wallis test. All statistical tests were 
performed using SPSS statistical analysis software version 20.0 (SPSS Inc, Chicago, IL, USA). 
A P value < 0.05 was considered statistically significant. 
ReSultS
Patient characteristics
Baseline patient characteristics and perioperative data are summarized in Tables 1 and 2, 
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Age (years) 61 (53-74) 59 (50-76) 69 (65-76)
gender (no. of male) 7 5 5
body Mass Index (kg/m2) 25.46 (23.88-29.59) 25.92 (21.36-30.11) 27.08 (26.58-27.47)
Systolic blood pressure (mmHg) 140 (115-155) 136 (120-141) 140 (140-140)
new york heart association class 2 (1-2) 2 (2-2) 2 (2-2)
Logistic EuroscoRE (%) 2.40 (1.51-5.39) 2.08 (1.51-6.28) 4.61 (2.25-5.14)
creatinine (μmol/L) 87 (74-101) 91 (78-109) 114 (84-118)
c-reactive protein (mg/L) < 3 (< 3-7.00) < 3 (< 3-4.50) < 3 (< 3-< 3)
Hemoglobin (mmol/l) 9.2 (8.6-9.5) 8.7 (8.5-9.2) 9.5 (9.1-9.9)
Diabetes mellitus (no. of patients) 1 (IDDM) 1 (IDDM) 1 (NIDDM)
coPD (no. of patients) 2 0 0
caD (no. of patients) 4 2 3
medication (no. of patients)
























Values are expressed as medians and interquartile ranges, or number of patients. 
Abbreviations: ACE, Angiotensin Converting Enzyme; Ang II, Angiotensin-II; CAD, Coronary Artery Disease; 
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aortic cross-clamp time (min) 144 (80-172) 130 (104-147) 151 (140-153)
cPB time (min) 178 (123-203) 172 (131-197) 201 (186-217)
Duration of surgery (min) 303 (232-360) 294 (237-328) 335 (296-337)
Performed procedures (n)
only mVP (+ ablation)
mVP + tVP (+ ablation)
mVP + caBG (+ ablation)
MVP + tVP + CAbg
MVP + Morrow procedure















Ventilation time (hours) 7 (6-10) 8 (6-11) 8 (4-12)
CRP (mg/l) 
Day after surgery









Day one after surgery










total ICu stay (hours) 21 (19-24) 22 (21-24) 22 (20-26)
total stay in hospital (days) 9 (7-12) 12 (10-16) 9 (8-13)
Values are expressed as medians and interquartile ranges. 
Abbreviations: CABG, Coronary Artery Bypass Grafting; CPB, Cardiopulmonary Bypass; ICU, Intensive Care 
Unit; MVP, Mitral Valve Annuloplasty; MVR, Mitral Valve Replacement; TVP, Tricuspid Valve Annuloplasty. 
Inflammatory responses   
Sevoflurane and the surgery-induced inflammatory response
Baseline inflammatory parameters were similar in the sevoflurane and control group 
(Supplementary data, Table 1). Surprisingly, selective myocardial sevoflurane delivery via the 
cardioplegia solution (that is, prior to reestablishment of coronary blood flow) attenuated 
the systemic surgery-related inflammatory response as indicated by lower systemic (arterial) 
IL-6 (P = 0.03), IL-8 (P = 0.009), IL-16 (P = 0.007), IL-18 (P < 0.001), and CXCL10 (P = 0.001) 
levels during the first 60 minutes of reperfusion. This attenuation was even observed prior 
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figure 1. attenuation of systemic levels of several cytokines by intramyocardial delivery of 
sevoflurane. 
Levels of interleukin (IL)-6, IL-8, IL-16, IL-18, and C-X-C motif chemokines 10 (CXCL10) were already 
attenuated the moment of reperfusion after intramyocardial delivery of sevoflurane (iSevoflurane). 
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These early systemic effects may be explained by sevoflurane entering the systemic 
circulation via aspiration of sevoflurane-enriched blood by the cardiotomy sucker. We 
therefore included a third group, a reference group, in which sevoflurane (0.5%) was 
intermittently administrated systemically in a scheme that mimicked myocardial delivery. 
Results of this systemic administration of sevoflurane also resulted in attenuation of the 
inflammatory response (Figure 2). However, lower systemic levels of IL-6 and IL-8 (both P = 
0.001) and the delayed (that is, 2-24 hours after reperfusion) systemic attenuation of CCL5 
(P = 0.004) and IL-18 (P < 0.001) by intramyocardial delivery of sevoflurane suggest that 
intramyocardial delivery is more effective than systemic delivery. 
figure 2. Interleukin-6 and interleukin-8 levels the first hour after reperfusion. 
Concentrations of interleukin (IL)-6 and IL-8 were lower in patients who received sevoflurane 
intramyocardially (□) compared with the reference group (▲) (both P = 0.001). Controls (■) showed 
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Attenuation of inflammatory cytokines and chemokines was followed by reduced 
postoperative CRP levels 24 hours after surgery after intramyocardial and systemic delivery 
of sevoflurane (P = 0.01 and P = 0.04, respectively). CRP levels were not significantly different 
at 48 hours, although a trend towards lower levels in the sevoflurane groups was observed 
(P = 0.21 intramyocardial sevoflurane versus controls; P = 0.45 systemic sevoflurane versus 
controls; Figure 3). 
 
figure 3. c-reactive protein levels before and after cardiac surgery.
C-reactive protein (CRP) levels were attenuated significantly the first day after surgery in patients 
treated with sevoflurane (light: intramyocardial sevoflurane; dark: reference group) compared with 
controls (blanco). Medians and interquartile ranges are shown.
Sevoflurane and the myocardial reperfusion-related inflammatory response 
Arteriovenous concentration differences were assessed to selectively evaluate the 
myocardial reperfusion-related inflammatory response. Neither myocardial delivery nor 
systemic sevoflurane delivery influenced the immediate myocardial inflammatory response 
following reperfusion. In other words, during the first hour of reperfusion none of the 
inflammatory mediators were released by the myocardium. Cardiac selective sevoflurane 
delivery attenuated IL-6 and MCP-1 release 2-24 hours after reperfusion (P = 0.004, P = 0.03, 
respectively).
Since IL-6 and MCP-1 are under transcriptional control of NF-κB, myocardial NF-κB 
activity was measured in biopsies of the left ventricle to evaluate the effects of sevoflurane 
on protein level. Time points between aortic cross-clamping and collection of the pre-
reperfusion biopsy and reperfusion versus collection of the post-reperfusion biopsy were 
similar in the intramyocardial group (times of biopsies: 6.71 ± 10.23 min and 29.25 ± 10.26 
min, respectively), reference group (5.00 ± 3.35 min and 29.83 ± 9.37 min, respectively), 
and controls (9.33 ± 10.63 min and 28.63 ± 7.76 min, respectively). Baseline values of NF-
κB activity were similar in the three patient groups (P = 0.64). In addition, similar NF-κB 
activity was observed in pre- versus post-reperfusion biopsies in the intramyocardial group 
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Sevoflurane and clinical parameters
Sevoflurane treatment did not influence plasma creatinine values, ventilation time, or 
intensive care unit (ICU) length of stay (Table 2). Cardioprotective effects were evaluated by 
measuring plasma hs cTnT, CK and CK-MB (Figure 4). None of the myocardial cell damage 
markers were influenced by sevoflurane treatment (P = 0.87, 0.38, and 0.17, respectively).
figure 4. three biomarkers of postoperative myocardial cell damage.
Similar myocardial cell damage was observed in patients who received sevoflurane intramyocardially 
(□), the reference group (▲), and control patients (■): (A) high sensitive cardiac troponin T (hs cTnT; 
P = 0.87), (B) creatine kinase activity (CK; P = 0.38), and (C) creatine kinase-MB subfraction activity (CK-MB, 
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DISCuSSIon
Our results show that intramyocardial and systemic sevoflurane delivery effectively suppress 
surgery-related inflammatory responses. Sevoflurane did not influence the immediate 
myocardial inflammatory response following myocardial reperfusion, yet it did reduce the 
late myocardial inflammatory response. This suggests that the effects of sevoflurane are 
at the level of gene transcription and/or via an effect on cellular influx. However, effects 
exerted by sevoflurane are insufficient to result in a clinical benefit. 
The observed comprehensive attenuation of systemic inflammation is in line with an 
earlier study of Nader et al. in patients undergoing coronary artery bypass grafting.15, 16 
Their results with respect to cardioprotective effects were ambiguous with lower troponin 
I levels measured by a conventional assay but similar CK-MB concentrations. Findings of 
our evaluation with regard to myocardial cell damage, measured by state-of-the-art assays, 
were highly consistent with a clear increase in myocardial cell damage upon surgery but 
absence of sevoflurane-mediated cardioprotection.
The observed early systemic attenuating effects of selective myocardial delivery 
of sevoflurane on inflammatory markers during on-pump cardiac surgery may appear 
counterintuitive but is most likely explained by contamination of the circulating blood via 
the cardiotomy sucker. Therefore, a reference group was included in whom sevoflurane 
was intermittently administered to the systemic circulation. Observed effects suggest that 
sevoflurane has a strong anti-inflammatory potential that is already apparent after repeated 
brief exposure to low levels (as caused by spill-over from the cardioplegia solution). 
Clear anti-inflammatory effects but absence of clinical benefits question whether an 
inflammatory response is beneficial and necessary for tissue repair, or that it is detrimental 
and aggravates tissue injury. It has been shown that IL-6, IL-8 and MCP-1 showed higher 
peaks and persisted longer in patients with a complicated course after cardiac surgery in 
comparison with patients with an uneventful recovery.21 In addition to the detrimental 
role of inflammatory mediators, some also appear to have protective effects depending 
on the presence of responsive cells, the timing, and combination of released cytokines. 
For example, both receptors of tumor necrosis factor (TNF) have disparate and opposing 
effects in mice with heart failure. TNFR1 exacerbates and TNFR2 ameliorates NF-κB 
activation and inflammation.22 In renal I/R injury, it has been shown that the role of IL-6 is 
not straightforward either. A renal release of IL-6 was observed upon reperfusion in human 
kidney transplantation, but neutralization of IL-6 in mice undergoing renal I/R injury resulted 
in aggravation of tissue injury.23  
The slow weaning of the systemic effects and the delayed suppression of the post-
reperfusion myocardial inflammatory response suggest that the effects of sevoflurane are 








































190  •  Chapter 9
earlier preclinical findings.5, 24 Reduced systemic inflammation was followed by reduced CRP 
levels at 24 hours, showing that the anti-inflammatory effect is relevant. CRP levels were not 
statistically different anymore at 48 hours after surgery, presumably because of weaning of 
the sevoflurane effects. 
The absence of beneficial effects on myocardial cell damage markers do not indicate a 
protective effect of sevoflurane on myocardial ischemia/reperfusion injury. This observation 
follows findings of other large clinical trials who failed to show a clinical benefit of 
sevoflurane.13, 25 Results of these previous clinical studies may very well be related to the 
extent and degree of myocardial ischemia between the different studies, the differences in 
cardioplegic strategy, the possible interference of other drugs, the presence of co-existing 
diseases, the timing and duration of the administration of volatile anesthetics, and gaps in 
our understanding of inflammation and its regulation.26, 27
Limitations
The sample size of our proof-of-concept study was sufficient to identify differences in the 
release of inflammatory mediators between the patient groups, although patient numbers 
were too small to find a clear clinical benefit in relation to mortality and morbidity. However, 
other studies have repeatedly and consistently fail to show a clinical benefit. A greater 
number of patients were on statins and aspirin in the experimental group, although this 
did not influence inflammation at baseline. Furthermore, it is possible that changes in 
transcription take longer than the on average 30 minutes after reperfusion when collecting 
these biopsies, explaining similar p65-NF-κB activity in myocardial homogenates.28 
Conclusion 
This clinical proof-of-concept study shows that intramyocardial delivery of sevoflurane is 
superior to its systemic delivery with respect to attenuation of the systemic inflammatory 
response. However, these findings were not followed by beneficial clinical outcomes, 
suggesting that the association between systemic inflammation and postoperative outcome 
may be more complex than commonly thought.
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Il-1ra 50.10 (18.90-91.24) 68.66 (46.70-131.49) 0.25
Il-6 4.57 (3.07-13.72) 5.42 (2.28-9.51) 0.92
Il-8 6.61 (2.80-13.50) 8.23 (6.11-12.94) 0.40
Il-9 0.45 (0.10-5.14) 1.11 (0.10-8.02) 0.80
Il-10 4.76 (1.64-5.63) 1.85 (1.27-4.41) 0.26
Il-16 141.09 (60.38-285.80) 158.25 (143.53-175.76) 0.44
Il-18 82.74 (35.66-95.05) 85.03 (69.05-126.73) 0.32
g-CSF 30.73 (11.32-51.29) 20.97 (19.40-56.30) 1.00
CXCl10 357.42 (200.08-567.96) 577.18 (428.80-940.24) 0.07
MCP-1 20.21 (12.97-43.68) 21.47 (18.11-38.66) 0.73
CCl5 227.64 (56.26-379.55) 200.41 (98.88-389.87) 0.57
VegF 3.42 (0.69-14.48) 5.90 (0.76-16.29) 0.70
Values are expressed as medians and interquartile ranges (all pg/mL). 
Abbreviations: CCL 5, Chemokine Ligand 5; CXCL10, C-X-C motif Chemokine 10; G-CSF, Granulocyte-Colony 
Stimulating Factor; IL, Interleukin; IL-1ra, IL-1 receptor antagonist; MCP-1, Monocyte Chemoattractant 
Protein-1; VEGF, Vascular Endothelial Growth Factor. 
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AbStRACt
background: The pathophysiology of ischemia/reperfusion (I/R) injury is dominated by an 
inflammatory response. In the identification of new therapeutic agents, the role of individual 
cytokines may be essential. Interleukin (IL)-9 is a pleiotropic cytokine recently identified to 
be involved in various immune responses. In this study, the role of IL-9 in renal I/R injury 
was assessed. 
Methods: We performed repeated direct measurements of arteriovenous IL-9 concentration 
differences over the reperfused graft in human kidney transplantation. 
Results: Substantial renal IL-9 release was observed from deceased donor kidneys (P = 
0.006). In contrast, living donor kidneys, which have a more favourable clinical outcome, did 
not release IL-9 during early reperfusion (P = 0.78). Tissue expression of IL-9 did not change 
upon reperfusion in both living and deceased human donor kidneys. To assess the role of 
IL-9 in I/R injury, an experimental study comprising IL-9 inhibition in mice undergoing renal 
I/R was performed. Although there was no difference in kidney function, structural damage 
was significantly aggravated in anti-IL-9 treated mice. 
Conclusions: Deceased donor grafts show a substantial IL-9 release upon reperfusion 
in clinical kidney transplantation. However, inhibition of IL-9 aggravated kidney damage, 
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IntRoDuCtIon
Ischemia/reperfusion (I/R) injury is an inevitable consequence of organ transplantation and 
a major determinant of patient and graft survival. I/R injury induces delayed graft function, 
which complicates around 20%1, 2 of deceased donor kidney transplantations and has a 
major influence on graft function and survival.3 The pathophysiology of I/R injury is complex 
and incompletely understood, although both preclinical4-6 and clinical studies7-9 have shown 
that inflammation is an important mediator of I/R injury. The exact functions of the various 
cytokines involved in regulating the complex inflammatory events after I/R injury are not 
fully unraveled yet.10 Insight in the role of individual cytokines may be essential in the 
identification of new therapeutic agents. 
Interleukin (IL)-9 is a pleiotropic cytokine recently discovered to be involved in various 
immune responses. Studies on the etiology of asthma and allergies have demonstrated an 
evident pro-inflammatory role of IL-9.11, 12 IL-9 is produced by T helper cells13, regulatory T 
cells14, and mast cells15 and is able to modulate their production of various other cytokines.12 
In a preceding study, we described for the first time a renal release of IL-9 after kidney 
transplantation.10 
The aim of the present study was to explore the potential pathophysiological role of 
IL-9 in renal I/R injury. IL-9 release during reperfusion of both living and deceased human 
donor kidney grafts was assessed, and the effects of IL-9 inhibition on renal I/R injury were 
evaluated in an animal experiment.
MetHoDS 
Patient population
Twenty-four patients undergoing renal allograft transplantation were included; of these, 
eight patients received a kidney from a living donor and sixteen patients received a 
kidney from a deceased donor (nine brain-dead donors and seven cardiac-dead donors). 
Kidney transplantations were performed according to the local standardized protocol.16 
In living donors open nephrectomy was performed and Custodiol® histidine–tryptophan–
ketoglutarate solution (Tramedico, Weesp, The Netherlands) was used for cold perfusion 
and storage of the kidney. Brain-dead and cardiac-dead donor kidneys were perfused and 
stored with either University of Wisconsin solution or Custodiol® histidine–tryptophan–
ketoglutarate solution. The immunosuppressive regimen was based on induction therapy 
with basiliximab on day 0 and 4; and tacrolimus or cyclosporine A in addition with 
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patients receiving a left kidney were included. Patient and graft characteristics and ischemia 
times are summarized in the Supplementary data, Table 1. The postoperative course was 
uneventful in all patients. One-year patient and graft survival was 100%. The study protocol 
was approved by the local ethics committee, and informed consent was obtained from each 
patient.
Interleukin-9 plasma measurements in arteriovenous samples
Arterial and renal venous blood samples were obtained during human kidney transplantation 
as described previously.16 In short, blood aliquots were sampled at 30 seconds, 3, 10, and 
30 minutes after reperfusion via a catheter placed in the renal vein. Paired arterial blood 
samples were obtained at 0, 3, 10, and 30 minutes after reperfusion. The same method 
was used to obtain a control arterial and venous blood sample during donor nephrectomy 
prior to the induction of renal ischemia. All samples were collected in tubes containing EDTA 
(BD Vacutainer, Plymouth, UK) and centrifuged twice (1550 g, 20 min, 4°C) to deplete it of 
leukocytes and thrombocytes. Plasma was aliquotted and stored at –70°C until analysis. IL-9 
was measured in a custom-made multiplex assay in accordance with the manufacturer’s 
instructions (X-plex, Biorad, Veenendaal, The Netherlands). 
Immunohistochemical evaluation of interleukin-9 source in human kidney biopsies
A renal cortical biopsy was obtained before transplantation, after cold storage of a 
deceased donor graft. Kidney tissue was fixed in formalin for 24 hours and then embedded 
in paraffin for light microscopy. Longitudinal sections of 4 μm were prepared. After EDTA-
retrieval, IL-9 deposition was assessed using a human IL-9 mAb in a 1:100 dilution (cat. no. 
507602, Biolegend, Cambridge, UK). Staining was visualized using Nova RED (Vector Labs, 
Peterborough, UK). Sections were counterstained with hematoxylin (Merck, Darmstadt, 
Germany). 
Interleukin-9 expression in human kidney biopsies
A renal cortical biopsy was obtained before transplantation after cold storage, and a post-
reperfusion biopsy was collected 45 minutes after reperfusion. Biopsies were immediately 
snap frozen in liquid nitrogen and stored at –70°C. Total RNA was extracted from renal 
tissues using RNAzol (Campro Scientific, Veenendaal, The Netherlands) and glass beads.17 
The integrity of each RNA sample was examined by Agilent Lab-on-a-chip technology using 
the RNA 6000 Nano LabChip kit and a bioanalyzer 2100 (Agilent Technologies, Amstelveen, 
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if samples showed intact 18S and 28S rRNA bands, and displayed no chromosomal peaks 
or RNA degradation products (RNA Integrity Number > 8.0).18 Subsequent microarray 
analysis was performed using Illumina whole-genome gene expression BeadChips (Illumina 
BeadArray®, San Diego, CA, USA) according to instructions of the manufacturer at Service XS 
(Leiden, The Netherlands). IL-9 expression data were obtained from this array. 
Animals and surgical procedures
Male BALB/c Jico mice (Charles River, L’Arbresle, France) of 8 weeks old (20-30 g) were 
divided into the following four groups: (1) I/R pre-treated with anti-IL-9 antibody (Ab) 
(n = 12); (2) I/R pre-treated with control Ab (n = 12); (3) sham-operated, pre-treated with 
anti-IL-9 Ab (n = 4), and (4) sham-operated pre-treated with control Ab (n = 4). Monoclonal 
anti-IL-9 Ab (no. 504802, clone D9302C12, BioLegend, San Diego, CA, USA) or isotype 
control IgG (no. 400916, clone HTK888, BioLegend, San Diego, CA, USA) was administered 
at 1 and 2 days before surgery. At 2 days before surgery, 2 ug/g body weight anti-IL-9 Ab or 
its equivalent of isotype control Ab was administered by i.p. injection, followed by 4 ug/g 
body weight the day before surgery. This dosage is based on previous research in which a 
significant effect of anti-IL-9 treatment was observed after administration of a similar dose 
of the antibody.19 Mice were anesthetized with isoflurane. Bilateral kidney ischemia was 
induced by clamping the renal artery and vein for 35 minutes, followed by reperfusion. 
In the sham group, identical surgical procedures were used, except that clips were not 
applied.16 Kidney function was measured by plasma urea concentration (Reflotron®, Roche 
diagnostics, Almere, The Netherlands) the day before administration of antibodies (day -3), 
day of surgery (day 0), and the two consecutive days after surgery (day 1 and 2). Two days 
after surgery, mice were killed and kidneys retrieved. Mice were maintained on standard 
diet and given water ad libitum throughout the whole experimental period. The study was 
approved by the veterinary authorities of our institute. 
Histological evaluation of murine kidney tissue
The mouse kidneys were fixed in formalin for 24 hours and then embedded in paraffin for 
light microscopy. Longitudinal sections of 4 μm were prepared and stained with periodic 
acid-Schiff (PAS). The degree of tissue injury was scored by two blinded observers. Kidney 
injury was scored semi-quantitatively using the amount of proximal tubule necrosis (score 
0–3), band necrosis of the cortex and the medulla (score 0–3), and protein casts in the 
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Data collection and statistical analysis
Clinical donor data were retrieved from the Eurotransplant database. Delayed graft function 
was defined as the need for dialysis within the first week after transplantation. Statistical 
analysis was performed using SPSS 16.0 statistical analysis software (SPSS Inc, Chicago, IL, 
USA). Patient characteristics were compared by paired t-test and are expressed as mean 
± standard deviation (SD). Area under the curve (AUC) was calculated for the arterial and 
venous curve of the human plasma measurements for the total reperfusion period of 30 
minutes. The delta AUC was calculated (venous minus arterial) and the null-hypothesis 
(delta AUC is 0) was tested by a Wilcoxon signed rank test. Urea concentrations were 
compared using a Mann Whitney U-test, Wilcoxon signed rank test or Kruskal-Wallis test 
where appropriate. Histological score was tested by the Mann Whitney U-test. P value 
< 0.05 was considered significant.
ReSultS
Interleukin-9 is released from deceased donor kidneys during reperfusion
Living donor kidneys released no IL-9 during the first thirty minutes after reperfusion 
(P = 0.78, n = 8, Figure 1A). In contrast, deceased donor kidneys, which generally show 
more dysfunction after transplantation, released a vast amount of IL-9 during the first thirty 
minutes after reperfusion (P = 0.006, n = 16, Figure 1B). More specifically, only brain-dead 
donor kidneys showed a significant release of IL-9 (P = 0.04, n = 9). However, cardiac-dead 
donors showed the same trend (P = 0.07, n = 7), and therefore deceased donor data are 
clustered. IL-9 release was specific for I/R, as control measurements over the non-ischemic 
kidney in the donor did not show a transrenal difference in IL-9 levels (P = 0.89, data not 
shown). This indicates that IL-9 release is not a consequence of manipulation of the kidney 
during surgery or a reaction to anesthetics. 
Source of human interleukin-9 release is mainly tubular epithelial cells
The source of IL-9 released from deceased donor kidneys could be local resident cells or 
circulating cells. An immunohistochemical staining of IL-9 was performed on renal biopsy 
tissue from a deceased donor graft, which showed that local stores of IL-9 are present in the 
kidney. IL-9 signals were present predominantly in renal tubular epithelial cells and also in 
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figure 1. arterial and renal venous plasma concentrations of interleukin-9 during the first 30 minutes 
of reperfusion. 
(A) No significant release of interleukin-9 (IL-9) from living donor grafts was observed (P = 0.78, n = 8); 
(B) IL-9 was released significantly from deceased donor grafts (P = 0.006, n = 16). 
Figure 2. typical example of interleukin-9 staining in deceased donor kidney biopsy collected before 
transplantation. 
Interleukin-9  signal was positive in renal tubular epithelial cells, macrophages, and dendritic cells. 








































202  •  Chapter 10
No change in human renal interleukin-9 expression after reperfusion
No differences in IL-9 RNA expression were observed between pre- and post-reperfusion 
biopsies in living (P = 0.89, Figure 3A) as well as deceased donor kidneys (P = 0.59, Figure 
3B). In addition, similar baseline expression of IL-9 in living and deceased donor kidneys was 
observed (P = 0.57). 
Figure 3. Interleukin-9 expression in human kidney biopsies. 
Interleukin-9 (IL-9) expression in human pre- and post-transplantation biopsies of (A) living donor 
kidneys; and (B) deceased donor kidneys. There was no difference in IL-9 RNA expression between 
pre- and post-reperfusion biopsies in living and deceased donor kidneys (P = 0.89 and P = 0.59, 
respectively) nor in baseline IL-9 expression between both donor types (P = 0.57).
Anti-interleukin-9 treatment does not prevent functional and structural kidney ischemia/
reperfusion injury
Given the dominance of IL-9 release from deceased donor kidneys, we hypothesized that 
IL-9 is critical in the initiation of I/R injury. Therefore, mice were treated with anti-IL-9 
Ab or isotype control Ab before renal I/R. All mice survived the end of the experiment. 
Baseline urea concentrations were identical in all animals (Figure 4). In both anti-IL-9 
Ab and isotype control Ab treated mice that underwent renal I/R, urea concentration 
was significantly raised at 1 and 2 days after reperfusion as compared with baseline (all, 
P = 0.002). As expected, urea of sham-operated animals, both anti-IL-9 Ab and isotype 
control Ab pre-treated, did not change after surgery as compared with baseline (all, P = 
NS). Urea concentration was similar in anti-IL-9 treated and control Ab treated mice at day 1 
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figure 4. Plasma urea levels after murine renal ischemia/reperfusion. 
Plasma urea levels measured at baseline (day -3), at the day of surgery (day 0), and two consecutive 
days after surgery (day 1 and 2). Plasma urea levels were similar in anti-IL-9 Ab treated mice compared 
with isotype control Ab treated mice after I/R at day -3 (P = 0.77), day 0 (P = 0.69), day 1 (P = 0.91), and 
day 2 (P = 0.53). The median and interquartile range are plotted. 
Structural kidney damage was moderate to severe in all kidneys that underwent I/R, 
whereas kidneys of sham-operated mice showed normal histology. Kidney injury was 
scored on several characteristics and then quantified. There was significantly more 
structural damage in kidneys of anti-IL-9 Ab treated mice than in the control Ab treated 
group after I/R. In detail, anti-IL-9 Ab treated mice showed more proximal tubule necrosis 
(P = 0.02), band necrosis of the cortex and medulla (P = 0.01) and protein casts in the tubules 
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Figure 5. PAS-staining of murine kidney biopsies. 
Representative PAS-stained kidney sections harvested 2 days after surgery of (A) mice that received 
anti-IL-9 Ab before renal I/R; (B) mice that received control Ab before kidney I/R; and (C) sham-
operated mice that received anti-IL-9 or control Ab treatment before surgery (no difference). Original 
magnification x200. Mice receiving anti-IL-9 Ab before I/R had evident protein casts and tubule 
necrosis, more than isotype controle Ab treated mice. Sham-operated mice receiving either anti-IL-9 
Ab or control Ab had no PAS-positive deposits and no structural kidney damage. (D) Semi-quantitative 
histological damage score for the severity of kidney damage is shown. Damage was scored (0-3) 
on presence of proximal tubule necrosis (PTN), band necrosis (BN) and protein casts (PC). Kidneys 
of all mice that underwent kidney I/R showed moderate to severe damage. There were significant 
differences between anti-IL-9 Ab-treated and isotype control Ab-treated groups (PTN, P = 0.02; BN, 
P = 0.01; PC, P = 0.005). Kidneys of sham-operated mice scored 0 for all measures. Median and 
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DISCuSSIon
In this study it is shown that IL-9 is released exclusively from human deceased donor grafts 
directly after reperfusion. Since deceased donor grafts are clinically more affected by I/R 
injury, we hypothesized that IL-9 is a mediator of renal I/R injury. In a subsequent mouse 
experiment, inhibition of IL-9 did not influence kidney function after I/R and even aggravated 
structural kidney injury. 
IL-9 was released instantly after reperfusion from deceased donor grafts and its release 
persisted during the next thirty minutes. The substantial and immediate character of this 
IL-9 release suggests a pre-stored pool, since no change in IL-9 expression in kidney tissue 
upon reperfusion was observed. Pre-transplantation infiltrated cells are probably not 
involved, since baseline biopsies showed no difference between human living and deceased 
donor IL-9 expression, although there was a vast difference in cellular infiltrate before 
transplantation.10 Immunohistochemical staining of IL-9 showed its presence in tubular 
epithelium and resident macrophages and dendritic cells. These cells are likely responsible 
for secretion of their pre-stored IL-9. 
IL-9 is considered a pro-inflammatory cytokine, although as yet little is known about 
its exact functions. Preclinical studies have shown that IL-9 promotes mast cell growth and 
plays a crucial role in the nephroprotective effects of regulatory T cells.12, 20 In addition, a 
potential role in the stimulation of erythropoiesis has been suggested21, 22, as well as an 
antiapoptotic effect.23 The observation in our study that IL-9 was released exclusively from 
deceased donor kidneys, in which tissue damage is most severe, argues for an active role 
of IL-9 in initiating I/R injury. Therefore, the effect of IL-9 inhibition on kidney I/R injury was 
assessed in a mouse experiment. Remarkably, results showed aggravated structural kidney 
damage after I/R in anti-IL-9 Ab treated animals. When extrapolating these findings, it can 
be suggested that IL-9 plays a regulating role in clinical renal I/R injury or can be an initial 
trigger for salvaging or limiting injury. 
Although no previous data are available regarding the role of IL-9 in I/R injury, the few 
studies on allograft rejection after transplantation are conflicting. An association between 
IL-9 and acute, eosinophil-driven rejection has been suggested by Poulin et al. in mismatched 
heart allografts.24 However, no involvement of IL-9 was observed in rejection on a longer 
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Limitations
Our arteriovenous sampling time was limited to thirty minutes after reperfusion, the time 
needed to complete the operative procedure. Deceased donor kidney grafts showed an 
extensive release of IL-9 within the studied timeframe; therefore it is highly unlikely that 
living donor kidney grafts will start releasing IL-9 after the studied period. Finally, one might 
argue that a mouse model of renal I/R injury can only approximate the human situation. 
Nevertheless, the effects of IL-9 inhibition could be accurately assessed in our animal 
experiment and a negative effect of anti-IL-9 treatment was indeed observed. 
Conclusion
This study shows a substantial and exclusive release of IL-9 from deceased donor grafts 
in human kidney transplantation, while living donor kidneys, which generally have a more 
favourable clinical outcome, did not release IL-9 during early reperfusion. The source of 
released IL-9 was its pre-stored pool in renal tubular cells. Experimental inhibition of IL-9 
in mice aggravated kidney damage after I/R injury. All together, these results suggest a 








































The role of interleukin-9 in renal ischemia/reperfusion injury  •  207
10
ReFeRenCeS
 1.  Koning OH, Ploeg RJ, van Bockel JH, Groenewegen M, van der Woude FJ, Persijn GG, Hermans J. Risk 
factors for delayed graft function in cadaveric kidney transplantation: a prospective study of renal 
function and graft survival after preservation with University of Wisconsin solution in multi-organ 
donors. Transplantation 1997; 63:1620-1628.
 2.  Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications 
for renal allograft survival. Transplantation 1997; 63:968-974.
 3.  Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR. Association between delayed graft function 
and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant 2009; 
24:1039-1047.
 4.  Burne MJ, Elghandour A, Haq M, Saba SR, Norman J, Condon T, Bennett F, Rabb H. IL-1 and TNF 
independent pathways mediate ICAM-1/VCAM-1 up-regulation in ischemia reperfusion injury. J Leukoc 
Biol 2001; 70:192-198.
 5.  Patel NS, Chatterjee PK, Di Paola R, Mazzon E, Britti D, De Sarro A, Cuzzocrea S, Thiemermann C. 
Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/
reperfusion. J Pharmacol Exp Ther 2005; 312:1170-1178.
 6.  Jo SK, Sung SA, Cho WY, Go KJ, Kim HK. Macrophages contribute to the initiation of ischaemic acute 
renal failure in rats. Nephrol Dial Transplant 2006; 21:1231-1239.
 7.  Nijboer WN, Schuurs TA, van der Hoeven JA, Leuvenink HG, van der Heide JJ, van Goor H, Ploeg RJ. 
Effects of brain death on stress and inflammatory response in the human donor kidney. Transplant Proc 
2005; 37:367-369.
 8.  Stangl M, Zerkaulen T, Theodorakis J, Illner W, Schneeberger H, Land W, Faist E. Influence of brain death 
on cytokine release in organ donors and renal transplants. Transplant Proc 2001; 33:1284-1285.
 9.  Jassem W, Koo DD, Muiesan P, Cerundolo L, Rela M, Fuggle SV, Heaton ND. Non-heart-beating 
versus cadaveric and living-donor livers: differences in inflammatory markers before transplantation. 
Transplantation 2003; 75:1386-1390.
 10.  de Vries DK, Lindeman JH, Ringers J, Reinders ME, Rabelink TJ, Schaapherder AF. Donor brain death 
predisposes human kidney grafts to a proinflammatory reaction after transplantation. Am J Transplant 
2011; 11:1064-1070.
 11.  Soussi-Gounni A, Kontolemos M, Hamid Q. Role of IL-9 in the pathophysiology of allergic diseases. J 
Allergy Clin Immunol 2001; 107:575-582.
 12.  Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 2010; 
10:683-687.
 13.  Gessner A, Blum H, Rollinghoff M. Differential regulation of IL-9-expression after infection with 
Leishmania major in susceptible and resistant mice. Immunobiology 1993; 189:419-435.
 14.  Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, Scott ZA, Coyle AJ, Reed JL, van Snick 
J, Strom TB, Zheng ZZ, Noelle RJ. Mast cells are essential intermediaries in regulatory T-cell tolerance. 
Nature 2006; 442:997-1002.
 15.  Stassen M, Arnold M, Hultner L, Muller C, Neudorfl C, Reineke T, Schmitt E. Murine bone marrow-
derived mast cells as potent producers of IL-9: costimulatory function of IL-10 and kit ligand in the 
presence of IL-1. J Immunol 2000; 164:5549-5555.
 16.  de Vries DK, Lindeman JH, Tsikas D, de Heer E, Roos A, de Fijter JW, Baranski AG, van Pelt J, Schaapherder 
AF. Early renal ischemia-reperfusion injury in humans is dominated by IL-6 release from the allograft. 








































208  •  Chapter 10
 17.  Haslinger B, Kleemann R, Toet KH, Kooistra T. Simvastatin suppresses tissue factor expression and 
increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial 
cells. Kidney Int 2003; 63:2065-2074.
 18.  Kleemann R, Verschuren L, van Erk MJ, Nikolsky Y, Cnubben NH, Verheij ER, Smilde AK, Hendriks HF, 
Zadelaar S, Smith GJ, Kaznacheev V, Nikolskaya T, Melnikov A, Hurt-Camejo E, van der Greef J, van 
Ommen B, Kooistra. Atherosclerosis and liver inflammation induced by increased dietary cholesterol 
intake: a combined transcriptomics and metabolomics analysis. Genome Biol 2007; 8:200-215.
 19.  Jones TG, Hallgren J, Humbles A, Burwell T, Finkelman FD, Alcaide P, Austen KF, Gurish MF. Antigen-
induced increases in pulmonary mast cell progenitor numbers depend on IL-9 and CD1d-restricted NKT 
cells. J Immunol 2009; 183:5251-5260.
 20.  Eller K, Wolf D, Huber JM, Metz M, Mayer G, McKenzie AN, Maurer M, Rosenkranz AR, Wolf AM. IL-9 
production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced 
immune suppression. J Immunol 2011; 186:83-91.
 21.  Lu L, Leemhuis T, Srour EF, Yang YC. Human interleukin (IL)-9 specifically stimulates proliferation of 
CD34+++DR+ CD33-erythroid progenitors in normal human bone marrow in the absence of serum. Exp 
Hematol 1992; 20:418-424.
 22.  Donahue RE, Yang YC, Clark SC. Human P40 T-cell growth factor (interleukin-9) supports erythroid 
colony formation. Blood 1990; 75:2271-2275.
 23.  Fontaine RH, Cases O, Lelievre V, Mesples B, Renauld JC, Loron G, Degos V, Dournaud P, Baud O, Gressens 
P. IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis. Cell 
Death Differ 2008; 15:1542-1552.
 24.  Poulin LF, Richard M, Le Moine A, Kiss R, McKenzie AN, Goldman M, Renauld JC, van Snick J, Braun MY. 
Interleukin-9 promotes eosinophilic rejection of mouse heart allografts. Transplantation 2003; 76:572-
577.
 25.  Li XC, Schachter AD, Zand MS, Li Y, Zheng XX, Harmon WE, Strom TB. Differential expression of T-cell 
growth factors in rejecting murine islet and human renal allografts: conspicuous absence of interleukin 








































The role of interleukin-9 in renal ischemia/reperfusion injury  •  209
10
Supplementary data, table 1. transplantation and outcome characteristics in living donor and 
deceased donor kidney transplantation.
lD DD P value
n = 8 n = 16
Recipient age (years)
   Mean ± SD
41.1 ± 10.5 54.6 ± 12.2 0.02
Recipient gender
   (% male)
38 56 0.39
Donor age (years) 
   Mean ± SD 
43.9 ± 10.6 53.5 ± 16.1 0.14
Donor gender 
   (% male)
75 44 0.15
Preservation fluids HTK (n = 8) UW (n = 11)
HTK (n = 5)
0.001
CIt (min.)
   Mean ± SD
179.1 ± 18.6 1117.7 ± 299.1 < 0.001
wIt (min.)
   Mean ± SD
34.0 ± 6.3 33.5 ± 6.1 0.85
Abbreviations: CIT, Cold Ischemia Time; DD, Deceased Donor; HTK, Histidine–Tryptophan–Ketoglutarate; LD, 
Living Donor; UW, University of Wisconsin; WIT, Warm Ischemia Time. 
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End-stage heart failure is a challenging syndrome with growing incidence and prevalence. 
There is even a steady increase in the number of heart failure patients that reach an 
advanced state of the disease due to improved survival after acute myocardial infarction 
and improvements in the treatment of heart failure itself. In a substantial proportion of 
these patients, medical therapy for the treatment of heart failure is insufficient despite 
advances in medical treatment. Surgical procedures may provide an opportunity for 
additional treatment. Nowadays, the gold-standard therapy in end-stage heart failure 
is cardiac transplantation. However, there is a persistent shortage of organs available for 
transplantation. Therefore, surgical treatments, aimed to improve the cardiac function 
and clinical status of the patient, are therefore of great clinical interest.1 Although surgical 
techniques for end-stage heart failure are improving, perioperative morbidity and mortality 
remain high as outlined in a review by George et al.2 
In this thesis it has been shown that the observed postoperative complications are only 
partially explained by the preoperative high-risk state of these heart failure patients or the 
low cardiac output state. We suggest that postoperative complications are also a reflection 
of the preexisting autonomic dysregulation in this patient group. We hypothesized that the 
heart induces processes, such as an inflammatory response, which account for postoperative 
difficulties with major consequences for the myocardium but also for other organs. Such an 
effect could result in secondary systemic injury and a vicious circle of circulatory compromise 
due to the preexisting pump failure, leading to increased morbidity and mortality . 
Although generally assumed, the impact of preexisting heart failure on these 
postoperative complications has never been substantiated. Hence, the impact was 
evaluated in this thesis in Chapter 2. As confirmed, patients with heart failure experience 
more frequently complications related to their pump failure, resulting in the use of high 
dosages of inotropic support and various mechanical assist devices. However, complications 
not related to pump failure per se, such as prolonged mechanical ventilation, sepsis, and 
vasoplegia, were also more often observed in patients with heart failure. Overall, organ 
dysfunction, such as circulatory, renal and pulmonary failure, was more common in heart 
failure patients after cardiac surgery compared with patients without heart failure. This 
adverse postoperative course in these patients might reflect a systemic dysregulation 
related to the syndrome of heart failure and can not be directly attributed to the preexisting 
pump failure. Such an effect could result from a different response to ischemia/reperfusion 
(I/R) after heart failure surgery. This is however difficult to differentiate from the cardiac 
response to injury as a result of the surgical procedure and use of cardiopulmonary bypass. 
As such, arteriovenous measurements were used to discriminate between myocardial and 
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In the consecutive chapters of this thesis, perioperative pathophysiological mechanisms 
were studied in depth in patients with and without heart failure. The aim of this thesis 
was to systematically evaluate the pathophysiology of human myocardial I/R injury, using 
cardiac valve surgery as a planned model of clinical I/R. This model provides the opportunity 
to collect blood samples upon the release of the aortic cross-clamp, the moment of 
reperfusion, from the radial artery and coronary sinus. This approach allows to measure the 
release of I/R markers exclusively from the heart. 
Oxidative and nitrosative damage after I/R injury were studied in depth since preclinical 
studies implicate reactive oxygen and nitrogen species (RONS) as key initiators of I/R injury, 
as outlined in Chapter 3.3-5 Indeed, redox stress does occur during reperfusion as shown 
by Nrf2 activation, the master regulator of the antioxidant stress response. However, the 
generated RONS apparently do not induce tissue damage in human I/R since none of the 
damage markers – malondialdehyde, 15(S)-8-iso-prostaglandin F2α, nitrite, and nitrate – 
were released upon myocardial reperfusion. Organ specificity was excluded by including 
measurements over the kidney. Findings for all conditions were highly consistent and 
release of markers of oxidative damage was not observed. These observations suggest an 
efficient endogenous anti-oxidant system, providing an explanation for the limited efficacy 
of antioxidant therapy in human I/R.6 
In Chapter 4 the activation of the complement cascade after cardiac valve surgery was 
evaluated since clinical studies showed minute and inconsistent effects of anti-complement 
therapy in contrast to preclinical studies.7-9 Our results showed that endomyocardial C3d 
and C5b-9 depositions were already present in early ischemic biopsies and most abundant in 
patients with heart failure compared with patients without heart failure. These depositions 
might be related to the syndrome of heart failure. Remarkably, no myocardial release of C5a 
or sC5b-9 was observed upon reperfusion in patients with and without heart failure. These 
results suggest that the contribution of complement activation to human I/R may be less 
than commonly thought and may explain why anti-complement therapy in humans showed 
minute and inconsistent effects so far.  
A possible role of platelet and endothelial cell activation was studied in Chapters 5 
and 6. Results do not support preclinical evidence that platelets are involved in human 
myocardial I/R injury. The activation of platelets was impaired mainly as a result of 
cardiopulmonary bypass-related hemodilution. Moreover, activated platelets remained 
inside the cardiopulmonary bypass circuit. Endothelial cell activation markers were analyzed 
in patients with and without post-cardiac surgery vasoplegia. We observed that patients 
who develop this vasoplegia have higher preoperative von Willebrand Factor propeptide 
and soluble P-selectin levels, reflecting a systemic low-grade endothelial cell activation, 
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In Chapter 7 the inflammatory response was evaluated in patients with and without 
heart failure after cardioplegic arrest and reperfusion. Failing hearts showed a different 
and more pronounced myocardial inflammatory response upon reperfusion than patients 
without heart failure, which may be associated with the systemic complications as outlined 
in Chapter 2. This response can be explained by degranulation of preoperatively infiltrated 
inflammatory cells in myocardial tissue of failing hearts. Directly upon reperfusion, 
various cytokines and chemokines were released by the myocardium. However, it remains 
questioned whether this response is beneficial and necessary for tissue repair, or that it 
is detrimental and aggravates tissue injury. Currently, anti-inflammatory drugs, such as 
corticosteroids, have not lead to improved clinical outcomes.10-12 
The role of galectin-3, a marker of myocardial inflammation and fibrosis, has been 
described in relation to left ventricular reverse remodeling after mitral valve repair in 
patients with non-ischemic and ischemic heart failure in Chapter 8. Results show that low 
preoperative levels of this marker are associated with left ventricular reverse remodeling six 
months after surgery. Therefore, measurement of baseline galectin-3 may be useful for the 
identification of patients who will respond to additional (surgical) therapy with the aim to 
achieve beneficial left ventricular reverse remodeling after heart failure surgery. 
Translation of findings of the above mentioned pathophysiological mechanisms to practical 
applications is essential to enhance human health. Therefore, the intramyocardial delivery 
of sevoflurane was studied in detail in Chapter 9. Previous studies have shown that systemic 
administration of sevoflurane has led to differential clinical benefits.13-16 Our study shows 
that intramyocardial delivery of sevoflurane during mitral valve surgery attenuates the 
systemic pro-inflammatory response upon myocardial reperfusion. However, administration 
of sevoflurane to low-intermediate risk patients undergoing relatively complex valve surgery 
does not seem to result in less myocardial cell damage. We can not exclude a cardioprotective 
effect of sevoflurane in more extreme conditions. Again, it remains questioned whether 
attenuation of the pro-inflammatory responses is beneficial and necessary for tissue repair, 
or that it is detrimental and may aggravate tissue injury. 
The final chapter of this thesis, Chapter 10, describes the role of interleukin (IL)-9 in 
renal I/R injury. Bedside results showed that deceased donor grafts release a substantial 
amount of IL-9 upon reperfusion in kidney transplantation. The source of this released IL-9 
originated from pre-stored pools in renal tubular cells. However, bench results showed that 
inhibition of IL-9 aggravated kidney damage. IL-9 may therefore play a regulating role in 
clinical renal I/R injury or can be an initial trigger for salvaging or limiting injury. A murine 
renal I/R model was chosen since tissue damage due to I/R was more homogenous in this 
model compared with a myocardial model. In addition, the read-out of renal tissue damage 








































216  •  Chapter 11
Conclusion 
The main challenge of this thesis was to evaluate whether the reperfused heart induced 
systemic effects postoperatively, contributing to morbidity and mortality after cardiac surgery. 
We identified preexisting processes in patients with heart failure, such as complement 
activation and influx of inflammatory cells in the myocardium. These changes in their turn 
altered the post-reperfusion response of the myocardium after cardiac surgery. Moreover, 
preexisting low-grade endothelial cell activation predicted the development of post-cardiac 
surgery vasoplegia. No evidence was found for oxidative damage after reperfusion in contrast 
to the current theory. As expected, targeting the inflammatory response with sevoflurane 
resulted in attenuation of pro-inflammatory markers, although no cardioprotective effects 
were observed. A stepwise approach in future research via preclinical to clinical studies, and 
vice versa, is necessary to ensure the integration of advancements in pathophysiological 
science with clinical trials.  
Future perspectives
Instead of fundamentally different processes following myocardial reperfusion, preexisting 
mechanisms may contribute to a great extent to different post-reperfusion responses in 
patients with heart failure. Morbidity and mortality after cardiac surgery are therefore 
more likely related to the preexisting systemic dysregulation associated with the syndrome 
of heart failure. Still, many questions are unanswered and new questions arise every day. 
Despite continuing advances in unravelling the underlying pathophysiological mechanisms 
of clinical myocardial I/R in patients with heart failure, therapeutic modalities did not show 
favourable effects or still have to reach human clinical trials as outlined in the introduction 
of this thesis. 
Although beyond the scope of this thesis, the old saying ‘prevention is better than cure’ 
is applicable to almost all patients with heart failure. Primary prevention would still be the 
most simple and safe solution. However, due to improvements in secondary and tertiary 
prevention after myocardial infarction and diagnosis of heart failure itself, there is a steady 
growth of heart failure patients that reach advanced stages of heart failure. As outlined 
in this thesis, preexisting processes are present in patients with end-stage heart failure. 
Cardiac surgery in these heart failure patients can easily lead to dysregulation of their tightly 
regulated homeostasis. Therefore, preoperative interventions with the aim to optimize 
their preexisting processes, such as neurohumoral responses, inflammatory pathways, and 
responsiveness of the vascular beds, might lead to improved outcome after cardiac surgery, 
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When heart failure is diagnosed and surgical indications are present, it might be beneficial 
to perform cardiac surgery in an early stage of the disease. Neurohumoral responses – aimed 
at maintaining arterial and venous pressure, and increased blood volume – are less prominent 
in early stages. These neurohumoral mechanisms are compensatory to a certain extent, but 
can also aggravate the syndrome of heart failure by increasing ventricular afterload and 
preload. This ultimately leads to pulmonary or systemic congestion, and edema. However, 
timing of surgery has never been linked to the neurohumoral status of patients. After cardiac 
surgery, a study of Schenk et al. has shown an improvement in neuroendocrine activity a 
year after left ventricular reconstruction in patients with congestive heart failure.17 
Interestingly, as outlined in Chapter 7, patients with preexisting heart failure do have 
a different and more pronounced myocardial inflammatory response upon reperfusion 
compared with patients without heart failure. In our study, only circulating inflammatory 
markers and tissue inflammatory cells were evaluated; pathway analysis of pre- and 
post reperfusion myocardial tissue in patients with preexisting heart failure would reveal 
additional information. Of note, the application of a common inflammatory pathway may 
be inappropriate, because of the various etiologies underlying heart failure. Unravelling 
the complexities of these myocardial inflammatory pathways would be crucial for future 
studies focussed on anti-inflammatory therapies.18,19 Furthermore, experimental studies 
in myocardial infarction models have shown that inflammatory cell subsets could promote 
either pro-inflammatory and matrix-degrading effects or pro-angiogenetic and reparative 
effects.20-22 Consequently, future anti-inflammatory strategies should therefore reduce the 
deleterious effects of the inflammatory response while maintaining its favourable functions 
to reduce the risk of heart failure after myocardial infarction.19 
Another major clinical issue, most likely related to pronounced inflammatory responses, 
is the (sometimes therapy-resistant) post-cardiac surgery vasoplegia. This syndrome is 
most frequently observed in patients with preexisting heart failure and is characterized by 
severe refractory hypotension, metabolic acidosis, and extremely low peripheral vascular 
resistance. Of note, this is in contrast to the outpatient clinic in which end-stage heart 
failure patients benefit from medical treatment that lowers the peripheral resistance. In 
heart failure patients, the (responsiveness of the) vascular system seems to be permanently 
altered. More precisely, patients suffering from heart failure seem to display an altered 
vasoresponsiveness to exogenous (adrenergic) stimuli, which might be explained by chronic 
endogenous adrenergic stimulation and downregulation or desensibilisation of vascular 
adrenergic receptors.23,24 Indeed, chronic heart failure patients usually need more support 
with vasopressor agents after cardiac surgery as compared with patients without heart 
failure.25 The maintenance of an adequate blood pressure is often problematic during the 
early postoperative phase, despite pharmacological adrenergic stimulation. This response 
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needs of the completely (nonresponsive) vasoplegic vascular system. Prolonged hypotension 
and the accompanying hypoperfusion subsequently lead to end-organ dysfunction that 
constitutes the main category of complications in this patient population.26 Understanding 
of the vascular responsiveness after cardiac surgery in detail might yield therapeutic options 
or preventive strategies leading to safer surgical interventions and improvement in outcome 
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Hartfalen is een aandoening waarbij de pompfunctie van het hart verminderd is. Het hart 
is niet meer in staat voldoende bloed uit te pompen om aan de behoeften van weefsels te 
voldoen. Er zijn 2 vormen van hartfalen. De eerste vorm is systolisch hartfalen waarbij de 
hartspier niet krachtig genoeg samentrekt en er dus minder bloed rond wordt gepompt 
dan normaal. De tweede vorm is diastolisch hartfalen waarbij de hartspier onvoldoende 
ontspant, zodat het hart zich minder goed kan vullen met bloed en er derhalve ook minder 
bloed beschikbaar is om rond te pompen. Hartfalen kan verschillende oorzaken hebben, 
zoals een hartinfarct, langdurig hoge bloeddruk, een hartklepaandoening, ritmestoornissen 
of een hartspierziekte. Hartfalen ontstaat meestal geleidelijk. Het hart probeert initieel te 
compenseren voor de verminderde pompfunctie door bijvoorbeeld harder te werken. Op 
een gegeven moment is het hart verzwakt en treden er klachten op zoals vermoeidheid, 
kortademigheid bij geringe inspanning, en opgezette benen en enkels. Als het hart eenmaal 
pompkracht heeft verloren, is het moeilijk dit volledig te herstellen. De behandeling 
van hartfalen is initieel gericht op het achterhalen en behandelen van de onderliggende 
oorzaak. Indien de oorzaak niet kan worden behandeld, is de levensverwachting beperkt. 
Een behandeling met geneesmiddelen is vaak noodzakelijk om het hart te ontlasten en 
de pompkracht te vergroten met als doel de klachten te verminderen. De geleidelijke 
verslechtering van het hartfalen kan leiden tot het punt dat deze onbehandelbaar wordt: 
eindstadium van hartfalen. 
Het eindstadium van hartfalen is een uitdagend syndroom met een toenemend aantal 
(nieuwe) patiënten per jaar. Er is sprake van een gestage groei van het aantal patiënten 
met hartfalen die uiteindelijk een gevorderd stadium van de ziekte bereikt. Dit is het gevolg 
van een verbeterde overlevingskans na een acuut hartinfarct en door verbeteringen in de 
behandeling van hartfalen zelf. Ondanks vooruitgang in de medicamenteuze behandeling is 
er een toenemende groep patiënten met hartfalen waarbij medicamenteuze ondersteuning 
alleen onvoldoende is. Chirurgische procedures in combinatie met medicamenteuze 
therapie bieden een mogelijke behandeling voor deze patiëntgroep. Een harttransplantatie 
is op dit moment de gouden standaard voor de behandeling van patiënten met eindstadium 
hartfalen. Een chronisch tekort aan donororganen maakt dat hartchirurgische behandelingen 
gericht op het behoud van het eigen hart van grote klinische waarde en interesse zijn.1 
Alhoewel chirurgische technieken voor patiënten met hartfalen zijn verbeterd, blijven 
sterfte en complicaties rondom deze hartoperaties hoog, zoals beschreven in een review 
door George et al.2 
In dit proefschrift is beschreven dat complicaties na hartfalen chirurgie maar deels verklaard 
kunnen worden door het preoperatief hoge risico van deze patiënten als gevolg van het 
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één minuut kan rondpompen). Wij suggereren dat complicaties na hartfalen chirurgie 
een reflectie zijn van de al vóór de operatie bestaande dysregulatie in deze patiëntgroep. 
Wij veronderstellen dat het hart bepaalde processen induceert, zoals een inflammatoire 
respons (een reactie op een schadelijke prikkel leidend tot onder andere celbeschadiging, 
vaatverwijding en vochtophoping). De geïnduceerde processen zijn verantwoordelijk voor 
postoperatieve moeilijkheden met grote consequenties voor het hart, maar ook voor 
andere organen. Zo’n effect kan resulteren in secundaire systemische schade en een vicieuze 
cirkel van beperkte circulatie als gevolg van het pre-existente pompfalen bij patiënten met 
hartfalen, resulterend in verhoogde sterfte en complicaties. 
Alhoewel de impact van pre-existent hartfalen op deze postoperatieve complicaties 
algemeen aanvaard is, is de impact ervan nooit geobjectiveerd. Derhalve werd de impact 
geëvalueerd in Hoofdstuk 2. De resultaten bevestigen dat patiënten met hartfalen vaker 
complicaties ervaren die gerelateerd zijn aan hun pompfalen. Meer specifiek betreft dit de 
behoefte aan hogere dosering inotropica en mechanische ondersteuning om de werking 
van de hartspier te versterken. Daarentegen werden langdurige mechanische beademing, 
sepsis en vasoplegie (afgenomen vaattonus) – complicaties die niet perse gerelateerd zijn 
aan pompfalen – ook vaker geobserveerd. In het algemeen trad orgaandysfunctie, zoals hart, 
long- en nierfalen, vaker op na een hartoperatie bij patiënten met hartfalen. Dit nadelige 
postoperatieve beloop in deze patiëntgroep zou een systemische dysregulatie kunnen 
reflecteren, welke gerelateerd is aan het syndroom van hartfalen en niet direct toegewezen 
kan worden aan het al bestaande pompfalen. Zo’n effect kan veroorzaakt worden door een 
verschillende reactie van patiënten met hartfalen op ischemie/reperfusie (I/R) ten opzichte 
van patiënten zonder hartfalen. I/R is de weefselschade die optreedt als gevolg van het 
weer opnieuw van bloed voorzien van het hart, nadat dit een periode geen bloed heeft 
gehad. Dit is bijvoorbeeld het geval als er een hartoperatie wordt uitgevoerd waarbij het 
hart stil moet worden gelegd en deze functie tijdelijk wordt overgenomen door een hart-
longmachine. Deze reactie van het hart op I/R is daarentegen lastig te onderscheiden van 
de reactie van het hart op de schade als gevolg van de operatie en het gebruik van de hart-
longmachine. Derhalve werd in dit proefschrift gebruik gemaakt van metingen voor en na 
het hart (arterioveneuze metingen) om onderscheid te kunnen maken tussen mediatoren 
die vrijkwamen uit het hart of vrijkwamen uit het lichaam. 
In de opeenvolgende hoofdstukken van dit proefschrift werden pathofysiologische 
mechanismen bestudeerd bij patiënten met en zonder hartfalen die een hartoperatie 
ondergingen. Pathofysiologie is een onderdeel van het (bio)medisch onderzoek dat tracht 
te begrijpen hoe ziekten ontstaan en hoe het lichaam zich daaraan aanpast. Het doel van 
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evalueren in de mens, waarbij klepchirurgie gebruikt werd als een gepland model van I/R. 
Dit model geeft de mogelijkheid om bloedmonsters te verzamelen uit de arteria radialis (een 
slagader in de pols) en de sinus coronarius (een grote ader die het bloed uit de hartspier 
verzamelt en naar de rechter boezem voert) op het moment van reperfusie. Reperfusie na 
een hartoperatie treedt op zodra de chirurg de aortaklem verwijderd heeft aan het einde van 
de operatie. Een aortaklem is noodzakelijk voor het stilleggen en openen van het hart. Door 
bepaalde mediatoren te vergelijken in het slagaderlijk en aderlijk bloed kan de vrijlating van 
I/R markers specifiek uit het hart gemeten worden. 
Allereerst werd schade als gevolg van reactieve zuurstof- en stikstofverbindingen na I/R 
in detail bestudeerd aangezien preklinische studies laten zien dat deze radicalen belangrijke 
initiatoren zijn van I/R schade, zoals beschreven in Hoofdstuk 3.3-5 Zoals verwacht, trad er 
redox stress op tijdens reperfusie welke werd aangetoond middels de activatie van Nrf2, 
de hoofdregulator van de antioxidant stress reactie. Opvallend was dat de gegenereerde 
reactieve zuurstof- en stikstofverbindingen niet tot schade leiden in de mens na I/R. Geen 
van de schade markers – malondialdehyde, 15(S)-8-iso-prostaglandine F2α, nitriet en nitraat 
– werd namelijk door het hart vrijgelaten na myocardiale reperfusie. Orgaanspecificiteit 
werd uitgesloten door ook metingen over de nier te verrichten. De resultaten waren voor 
beide condities zeer consistent en er werd geen vrijlating van oxidatieve schade markers 
geobserveerd. Deze resultaten suggereren een efficiënt endogeen antioxidant systeem in 
de mens en geven ook een verklaring voor de beperkte effectiviteit van antioxidant therapie 
bij humane I/R tot op heden.6
In Hoofdstuk 4 wordt de activatie van het complement systeem na hartklepchirurgie 
geëvalueerd. Dit systeem omvat een groot aantal eiwitten die deel uitmaken van het 
afweersysteem. Het complement systeem werd bestudeerd aangezien klinische studies zeer 
kleine en inconsistente effecten van anti-complement therapie tonen in tegenstelling tot 
preklinische studies.7-9 Onze bevindingen toonden aan dat endomyocardiale afzettingen van 
C3d en C5b-9 reeds aanwezig waren in de vroeg ischemische biopten. Bovendien was dit 
meer uitgesproken bij patiënten met hartfalen in vergelijking tot patiënten zonder hartfalen. 
Deze afzettingen kunnen mogelijk gerelateerd worden aan het syndroom van hartfalen, 
aangezien deze al aanwezig waren op het moment dat de operatie nog maar kortdurend 
bezig was. Opvallend was dat het hart, zowel van patiënten met als zonder hartfalen, geen 
C5a of sC5b-9 vrij maakte gedurende de reperfusie fase. De bovenstaande resultaten 
suggereren dat de bijdrage van complement activatie aan I/R schade in de mens misschien 
wel minder is dan algemeen gedacht. Dit zou ook verklaren waarom anti-complement 
therapie tot op heden bij de mens minimale en inconsistente effecten heeft laten zien. 
Een mogelijke rol van bloedplaatjes en endotheelcel activatie werd bestudeerd in 
de Hoofdstukken 5 en 6. Endotheel is de bedekkende laag cellen die de binnenkant van 
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betrokkenheid van bloedplaatjes bij I/R schade van het menselijke hart niet. De activatie 
van bloedplaatjes was beperkt met name als gevolg van hart-longmachine gerelateerde 
verdunning van het bloed. Bovendien bleven geactiveerde plaatjes achter in het circuit 
van de hart-longmachine. Endotheelcel activatie mediatoren werden geanalyseerd in 
patiënten met en zonder vasoplegie na hartchirurgie. In onze studie werd aangetoond dat 
patiënten die vasoplegie ontwikkelden al voor de operatie hogere waarden van P-selectine 
en van Willebrand Factor propeptide hadden. Dit duidt op een systemische laaggradige 
endotheelcel activatie die al aanwezig is voor de hartoperatie. 
In Hoofdstuk 7 werd de inflammatoire reactie bij patiënten met en zonder hartfalen 
bestudeerd, na het stilleggen van het hart en de daaropvolgende reperfusie. Falende 
harten tonen een andere en meer uitgesproken inflammatoire respons na reperfusie dan 
harten van patiënten zonder hartfalen. Dit kan geassocieerd worden met de systemische 
complicaties zoals beschreven in Hoofdstuk 2. Deze reactie kan verklaard worden door 
degranulatie van preoperatief geïnfiltreerde inflammatoire cellen in het hartweefsel van 
falende harten. Direct na reperfusie werden diverse cytokines en chemokines – eiwitten 
die immuunreacties reguleren – door het hart vrijgelaten. Desondanks blijft het de vraag of 
deze reactie gunstig is en of deze noodzakelijk is voor herstel van het weefsel, of dat deze 
respons ongunstig is en weefselschade verergerd. Tot op heden hebben anti-inflammatoire 
medicamenten, zoals corticosteroiden, niet geleid tot verbeterde klinische uitkomsten.10-12 
De rol van galectine-3, een marker van inflammatie en fibrose van het hart, werd 
beschreven in Hoofdstuk 8 in relatie tot linker kamer reverse remodeling (afname van 
linker kamer hypertrofie en -dilatatie) na herstel van de mitralisklep bij patiënten met niet-
ischemisch en ischemisch hartfalen. Resultaten tonen aan dat lage preoperatieve waarden 
van deze marker geassocieerd zijn met linker kamer reverse remodeling 6 maanden na 
de operatie. Derhalve kan het meten van galectine-3 voor de operatie bruikbaar zijn om 
patiënten te identificeren die zullen reageren op de additionele (chirurgische) therapie met 
als doel reverse remodeling te bereiken.
Translatie van de resultaten van de bovengenoemde pathofysiologische mechanismen 
naar praktische toepassing is essentieel om de gezondheid van patiënten met hartfalen 
te bevorderen. Derhalve werd toediening van sevoflurane, een anti-inflammatoir 
anestheticum, rechtstreeks in het hart (intramyocardiaal) in detail bestudeerd in Hoofdstuk 
9. Eerdere klinische studies hebben contrasterende resultaten laten zien na systemische 
toediening van sevoflurane.13-16 Dit kan wijzen op het feit dat er sprake is van een dosis-
respons relatie, wat vraagtekens oproept over de concentratie van sevoflurane in het hart 
na systemische toediening. Onze studie toont aan dat na intramyocardiale toediening 
van sevoflurane tijdens mitraalklepchirurgie de systemische pro-inflammatoire reactie na 
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risico patiënten, die relatief complexe klepchirurgie ondergaan, lijkt niet te resulteren in 
minder hartschade. We kunnen niet uitsluiten dat in meer extreme condities sevoflurane 
wel deze cardioprotectieve effecten heeft. Ook in deze studie blijft het de vraag of de 
vermindering van de pro-inflammatoire respons gunstig en noodzakelijk is voor herstel van 
het weefsel, of dat deze respons ongunstig is en weefselschade verergert.
In het laatste hoofdstuk van dit proefschrift, Hoofdstuk 10, werd de rol van interleukine 
(IL)-9 bij nier I/R schade beschreven. Klinische resultaten tonen aan dat nieren van 
overleden donoren bij een niertransplantatie een substantiële hoeveelheid IL-9 vrijlaten op 
het moment van reperfusie. Dit IL-9 bleek opgeslagen te liggen in niertubuli. Preklinische 
resultaten tonen daarentegen aan dat remming van IL-9 nierschade verergert. IL-9 kan 
daarom een regulerende rol spelen bij klinische nier I/R schade, maar kan ook een initiële 
trigger zijn voor beperking van schade. Er werd gebruik gemaakt van een muismodel van 
nier I/R aangezien weefselschade als gevolg van I/R meer homogeen was in dit model 
in vergelijking met een hartmodel. Bovendien was de uitleesparameter van nierschade 
makkelijk te evalueren middels creatinine waarden. 
Conclusie
Dé uitdaging van dit proefschrift was te evalueren of het hart na reperfusie effecten elders 
in het lichaam induceert, die bijdragen aan sterfte en complicaties na hartchirurgie. Pre-
existente processen, zoals afzettingen van complement en influx van inflammatoire cellen 
in het hart, werden geïdentificeerd bij patiënten met hartfalen. Deze veranderingen op hun 
beurt veranderden de reactie van het hart na reperfusie. Bovendien voorspelde een pre-
existente laaggradige endotheelcel activatie het ontstaan van vasoplegie na hartchirurgie. 
Er werd geen bewijs gevonden voor oxidatieve schade na reperfusie in tegenstelling tot 
de huidige theorie. Tot slot resulteerde de beïnvloeding van de inflammatoire respons 
middels sevoflurane inderdaad in een vermindering van pro-inflammatoire markers, maar 
werden er geen cardioprotectieve effecten geobserveerd. Een stapsgewijze benadering 
voor verder onderzoek van preklinisch naar klinisch onderzoek en vice versa is essentieel 
om de vooruitgangen in de pathofysiologische wetenschap te kunnen integreren in klinische 
studies. 
Toekomstperspectieven 
Pre-existente mechanismen lijken een grotere bijdrage te leveren aan de verschillende 
respons op reperfusie van het hart bij patiënten met hartfalen dan fundamenteel 
verschillende processen tussen mensen met en zonder hartfalen. Sterfte en complicaties 
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dysregulatie geassocieerd met het syndroom van hartfalen. Diverse vragen zijn nog altijd 
onbeantwoord en nieuwe vragen ontstaan dagelijks. Ondanks continue vooruitgang wat 
betreft het ontrafelen van de onderliggende pathofysiologische mechanismen van I/R van 
het hart bij patiënten met hartfalen, tonen behandelingen tot op heden geen gunstige 
effecten of moeten nog bestudeerd worden in klinische studies zoals beschreven in de 
introductie van dit proefschrift. 
Hoewel het buiten het bestek van dit proefschrift valt, blijft het gezegde ‘voorkomen is 
beter dan genezen’ toepasbaar op bijna alle patiënten met hartfalen. Primaire preventie 
zou nog steeds de meest simpele en veilige oplossing zijn. Door verbeteringen in secundaire 
en tertiaire preventie na een hartinfarct en de diagnose van hartfalen zelf, is er een gestage 
groei van patiënten met hartfalen die een gevorderd stadium van de ziekte bereiken. 
Zoals beschreven in dit proefschrift zijn pre-existente processen aanwezig bij patiënten 
met eindstadium hartfalen. Hartchirurgie bij deze patiënten kan gemakkelijk leiden tot 
dysregulatie van hun strak gereguleerde homeostase. Derhalve zouden interventies gericht 
moeten zijn op de optimalisatie van deze pre-existente processen, wat mogelijk kan leiden 
tot verbeterde uitkomsten na hartchirurgie. Te denken valt hierbij aan neurohumorale 
reacties, inflammatoire netwerken en reactiviteit van het vasculaire systeem (bloedvaten), 
welke hieronder nader worden toegelicht. 
Als hartfalen gediagnosticeerd is en chirurgische indicaties gesteld zijn, dan kan 
het gunstig zijn om hartchirurgie in een vroeg stadium van de ziekte te verrichten. 
Neurohumorale reacties – gericht op het behoud van arteriële / veneuze druk en toename 
van het bloedvolume – zijn minder prominent aanwezig in vroege stadia van de ziekte. 
Deze neurohumorale mechanismen zijn tot op zekere hoogte compensatoir, maar kunnen 
ook het syndroom van hartfalen verergeren door toename in voor- en nabelasting van de 
hartkamers. Dit leidt uiteindelijk tot verhoogde drukken in het longvaatbed en oedeem. 
Vermeldenswaardig is dat het moment van chirurgie nog nooit gerelateerd is aan de 
neurohumorale status van patiënten. In een studie van Schenk et al. is wel aangetoond dat 
er een verbetering in neuroendocriene activiteit werd gezien een jaar na reconstructie van 
de linker kamer in patiënten met hartfalen.17 
Zoals beschreven in Hoofdstuk 7 hebben patiënten met pre-existent hartfalen een 
verschillende en meer uitgesproken inflammatoire respons van het hart na reperfusie 
dan patiënten zonder hartfalen. In onze studie werden alleen circulerende inflammatoire 
mediatoren en inflammatoire cellen in het hartweefsel bestudeerd. Analyse naar 
inflammatoire netwerken in hartweefsel van voor en na reperfusie bij patiënten met pre-
existent hartfalen zou extra informatie op kunnen leveren. Gezien de diverse oorzaken van 
hartfalen is het waarschijnlijk niet juist te verwachten dat er één algemeen inflammatoir 
netwerk is. Het ontrafelen van de complexiteit van deze netwerken is cruciaal voor 
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Bovendien hebben preklinische studies laten zien dat diverse subtypen van inflammatoire 
cellen zowel pro-inflammatoire als matrix-degraderende effecten kunnen bewerkstelligen 
of juist pro-angiogenetische en herstellende effecten hebben in hartinfarct modellen.20-22 
Dit heeft tot gevolg dat toekomstige anti-inflammatoire strategieën de verwoestende 
effecten van de inflammatoire respons zouden moeten reduceren, maar daarnaast zouden 
ze ook de gunstige functies moeten behouden die het risico op hartfalen na een hartinfarct 
verminderen.19 
Een andere belangrijke observatie in de dagelijkse praktijk is (therapieresistente) 
vasoplegie, wat meest waarschijnlijk gerelateerd is aan de prominente inflammatoire reacties 
postoperatief. Dit syndroom wordt het meest gezien bij patiënten met pre-existent hartfalen 
en wordt gekenmerkt door lage bloeddruk, metabole acidose en een extreem lage perifere 
vaatweerstand. Opvallend is dat dit tegengesteld is aan de dagelijkse klinische praktijk 
waarin patiënten met eindstadium hartfalen profiteren van medicamenteuze behandeling 
die de perifere vaatweerstand juist verlaagd. Bij patiënten met hartfalen is de reactiviteit 
van het vasculaire systeem soms permanent veranderd. Patiënten met hartfalen tonen een 
andere vasoreactiviteit op exogene (adrenerge) stimuli, die verklaard kunnen worden als 
gevolg van chronische endogene adrenerge stimulatie en het naar beneden bijstellen of het 
verminderd gevoelig worden van vasculaire adrenerge receptoren.23,24 Anders uitgelegd is 
er sprake van een chronisch verhoogde stimulatie van sympathische zenuwvezels door het 
lichaam zelf, met verhoogde productie van adrenaline en noradrenaline tot gevolg. Dit leidt 
weer tot minder of het minder gevoelig zijn van die receptoren in de bloedvaten. Patiënten 
met chronisch hartfalen hebben over het algemeen meer ondersteuning met inotropica en 
vasopressiva nodig na hartchirurgie ter ondersteuning van de hemodynamiek dan patiënten 
zonder hartfalen.25 Ondanks medicamenteuze adrenerge stimulatie is het behoud van een 
adequate bloeddruk vaak problematisch tijdens de vroege postoperatieve fase. Deze respons 
kan verklaard worden doordat de cardiac output onvoldoende verhoogd kan worden 
om aan de behoeften van het vasculaire systeem tegemoet te komen tijdens vasoplegie. 
Langdurige lage bloeddruk en de bijbehorende verminderde doorbloeding leiden tot eind-
orgaan dysfunctie, een van de belangrijkste complicaties in deze patiëntenpopulatie na 
hartchirurgie.26 Gedetailleerd begrip van de vasculaire reactiviteit na hartchirurgie zou tot 
therapeutische opties of preventieve strategieën kunnen leiden. Deze zouden op hun beurt 
weer tot veiligere chirurgische interventies en verbeteringen in uitkomsten kunnen leiden 
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AbbReVIAtIonS
6MWT   six-Minute Walk Test
15(S)-8-iso-PGF2α  15(S)-8-iso-prostaglandin F2α 
Ab   Antibody
ACE   Angiotensin Converting Enzyme
ADP   Adenosine Diphosphate
AF   Atrial Fibrillation
Ang-2   Angiopoietin-2
ANOVA   One-way between-groups Analysis of Variance
AoX   Aortic cross-clamping
APACHE   Acute Physiology and Chronic Health Evaluation
ARB   Angiotensin Receptor Blocker
ARDS   Acute Respiratory Distress Syndrome
ARE   Antioxidant Responsive Element
AT-I/II   Angiotensin I/II
ATP   Adenosine Triphosphate
AUC   Area Under the Curve
BDD   Brain-Dead Donor
Beta-TG   Beta-Thromboglobulin
BM   Basement Membrane
BN   Band Necrosis
CABG   Coronary Artery Bypass Grafting
CAD   Coronary Artery Disease
CCL   Chemokine Ligand
CD   Cluster of Differentiation 
CDD   Cardiac-Dead Donor
CIT   Cold Ischemia Time
CK   Creatine Kinase
CO   Cardiac Output
COPD   Chronic Obstructive Pulmonary Disease
COX   Cyclooxygenase
CPB   Cardiopulmonary Bypass
CRP   C-Reactive Protein
C-RP   Collagen-Related Peptide
CRT   Cardiac Resynchronization Therapy
cTnT   cardiac Troponin T
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DD   Deceased Donor
DNA   Deoxyribonucleic Acid
EDTA   Ethylenediaminetetraacetic Acid
EF   Ejection Fraction
eGFR   estimated Glomerular Filtration Rate
ELISA   Enzyme-Linked Immunosorbent Assay
EROA   Effective Regurgitation Orifice Area
FACS   Fluorescence-Activated Cell Sorting
FMR   Functional Mitral Regurgitation
G-CSF   Granulocyte Colony-Stimulating Factor 
GAPDH   Glyceraldehyde Phosphate Dehydrogenase
GC-MS   Gas Chromatography-Mass Spectrometry
GC-MS/MS  Gas Chromatography-Tandem Mass Spectrometry
GSH   Glutathione
GSTA2   Glutathione S-transferase A2
HF   Heart Failure
HMOX-1   Heme Oxygenase-1
HLA   Human Leucocyte Antigen
HTK   Histidine-Tryptophan-Ketoglutarate
I/R   Ischemia/Reperfusion
ICD   Implantable Cardioverter Defibrillator
ICU   Intensive Care Unit
IHF   Ischemic Heart Failure
IL   Interleukin
IP-10   Interferon-inducible Protein-10 
LAVI   Left Atrial Volume Index
LD   Living Donor
LV   Left Ventricle/Ventricular
LVEDP   Left Ventricular End-Diastolic Pressure
LVEDV   Left Ventricular End-Diastolic Volume
LVEF   Left Ventricular Ejection Fraction
LVESV   Left Ventricular End-Systolic Volume
MCP-1   Monocyte Chemoattractant Protein-1
MDA   Malondialdehyde
MFI   Median Fluorescence Intensity
MI   Myocardial Infarction
MMP   Matrix Metallopeptidase 
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MVP   Mitral Valve Annuloplasty
MODS   Multiple Organ Dysfunction Syndrome
mPTP   mitochondrial Permeability Transition Pore
MR   Mitral Regurgitation
NADPH   Nicotinamide Adenine Dinucleotide Phosphate
NF-κB   Nuclear Factor-κB
NHF   Non-Heart Failure
NIHF   Non-Ischemic Heart Failure
NQO-1   NAD(P)H Quinone Oxidoreductase
Nrf2   Nuclear factor (erythroid-derived 2)-related factor 2 
NT-proBNP  N-Terminal pro-Brain Natriuretic Peptide
NYHA   New York Heart Association
OPG   Osteoprotegerin 
PAS   Periodic Acid-Schiff
Pcr   Phosphocreatine
PCWP   Pulmonary Capillary Wedge Pressure
PDGF   Platelet-Derived Growth Factor
PGE2   Prostaglandin E2
PTCA   Percutaneous Transluminal Coronary Angioplasty
QoL   Quality of Life
RAAS   Renin-Angiotensin-Aldosterone System
RANTES   Regulated upon Activation, Normal T-cell Expressed and Secreted
RMA   Restrictive Mitral Annuloplasty
ROC   Receiver Operating Characteristic
RONS   Reactive Oxygen and Nitrogen Species
R Vol   Regurgitant Volume
SD   Standard Deviation
SEM   Standard Error of the Mean
SIRS   Systemic Inflammatory Response Syndrome
SNS   Sympathetic Nervous System
SPAP   Systolic Pulmonary Artery Pressure
SOD   Superoxide Dismutase
TBARS   Thiobarbituric Acid-Reactive Substances
TNF   Tumor Necrosis Factor
TRAP    Thrombin Receptor-Activating Peptide
TVP   Tricuspid Valve Annuloplasty
VEGF   Vascular Endothelial Growth Factor
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vWF   von Willebrand Factor
vWFpp   von Willebrand Factor propeptide
WIT   Warm Ischemia Time
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